Novel imidazopyrimidinyl and imidazopyri dinyl derivatives

ABSTRACT

Provided herein are compounds of the formula (I):  
                 
 
     as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by execssive CRF expression. These include, for example: affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer&#39;s disease, Huntington&#39;s disease, Parkinson&#39;s disease, amyotrophic lateral sclerosis, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia.

FIELD OF THE INVENTION

[0001] The invention presented herein is directed to novelimidazopyrimidinyl and imidazopyridinyl derivatives, and to their use asCRF antagonists in the treatment of a variety of neurological andpsychiatric disorders.

BACKGROUND OF THE INVENTION

[0002] Corticotropin releasing factor (herein referred to as CRF), a 41amino acid peptide, is the primary physiological regulator ofproopiomelanocortin (POMC)—derived peptide secretion from the anteriorpituitary gland [J. Rivier et al., Proc. Nat. Acad. Sci. (USA) 80:4851(1983); W. Vale et al., Science 213:1394 (1981)]. In addition to itsendocrine role at the pituitary gland, immunohistochemical localizationof CRF has demonstrated that the hormone has a broad extrahypothalamicdistribution in the central nervous system and produces a wide spectrumof autonomic, electrophysiological and behavioral effects consistentwith a neurotransmitter or neuromodulator role in the brain [W. Vale etal., Rec. Prog. Horm. Res. 39:245 (1983); G. F. Koob, Persp. Behav. Med.2:39 (1985); E. B. De Souza et al., J. Neurosci. 5:3189 (1985)]. Thereis also evidence that CRF plays a significant role in integrating theresponse of the immune system to physiological, psychological, andimmunological stressors [J. E. Blalock, Physiological Reviews 69:1(1989); J. E. Morley, Life Sci. 41:527 (1987)].

[0003] Clinical data provides evidence that CRF has a role inpsychiatric disorders and neurological diseases including depression,anxiety-related disorders and feeding disorders. A role for CRF has alsobeen postulated in the etiology and pathophysiology of Alzheimer'sdisease, Parkinson's disease, Huntington's disease, progressivesupranuclear palsy and amyotrophic lateral sclerosis, as they relate tothe dysfunction of CRF neurons in the central nervous system [for reviewsee E. B. De Souza, Hosp. Practice 23:59 (1988)].

[0004] In affective disorder, or major depression, the concentration ofCRF is significantly increased in the cerebral spinal fluid (CSF) ofdrug-free individuals [C. B. Nemeroff et al., Science 226:1342- (1984);C. M. Banki et al., Am. J. Psychiatry 144:873 (1987); R.D. France etal., Biol. Psychiatry 28:86 (1988); M. Arato et al., Biol Psychiatry25:355 (1989)]. Furthermore, the density of CRF receptors issignificantly decreased in the frontal cortex of suicide victims,consistent with a hypersecretion of CRF [C. B. Nemeroff et al., Arch.Gen. Psychiatry 45:577 (1988)]. In addition, there is a bluntedadrenocorticotropin (ACTH) response to CRF (i.v. administered) observedin depressed patients [P. W. Gold et al., Am J. Psychiatry 141:619(1984); F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984); P. W.Gold et al., New Eng. J. Med. 314:1129 (1986)]. Preclinical studies inrats and non-human primates provide additional support for thehypothesis that hypersecretion of CRF may be involved in the symptomsseen in human depression [R. M. Sapolsky, Arch. Gen. Psychiatry 46:1047(1989)]. There is preliminary evidence that tricyclic antidepressantscan alter CRF levels and thus modulate the numbers of CRF receptors inthe brain [Grigoriadis et al., Neuropsychopharmacology 2:53 (1989)].

[0005] Furthermore, CRF has been postulated to have a role in theetiology of anxiety-related disorders, and is known to produceanxiogenic effects in animals. Moreover, interactions betweenbenzodiazepine/non-benzodiazepine anxiolytics and CRF have beendemonstrated in a variety of behavioral anxiety models [D. R. Britton etal., Life Sci. 31:363 (1982); C. W. Berridge and A. J. Dunn Regul.Peptides 16:83 (1986)]. Preliminary studies using the putative CRFreceptor antagonist α-helical ovine CRF (9-41) in a variety ofbehavioral paradigms demonstrate that the antagonist produces“anxiolytic-like” effects that are qualitatively similar to thebenzodiazepines [C. W. Berridge and A. J. Dunn Horm. Behav. 21:393(1987), Brain Research Reviews 15:71 (1990)].

[0006] Neurochemical, endocrine and receptor binding studies have alldemonstrated interactions between CRF and benzodiazepine anxiolytics,providing further evidence for the involvement of CRF in thesedisorders. Chlordiazepoxide attenuates the “anxiogenic” effects of CRFin both the conflict test [K. T. Britton et al., Psychopharmacology86:170 (1985); K. T. Britton et al., Psychopharmacology 94:306 (1988)]and in the acoustic startle test [N. R. Swerdlow et al.,Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptorantagonist (Ro15-1788), which was without behavioral activity alone inthe operant conflict test, reversed the effects of CRF in adose-dependent manner while the benzodiazepine inverse agonist (FG7142)enhanced the actions of CRF [K. T. Britton et al., Psychopharmacology94:306 (1988)].

[0007] It has been further postulated that CRF has a role inimmunological, cardiovascular or heart-related diseases such ashypertension, tachycardia and congestive heart failure, stroke,osteoporosis, premature birth, psychosocial dwarfism, stress-inducedfever, ulcer, diarrhea, post-operative ileus and colonichypersensitivity associated with psychopathological disturbance andstress.

[0008] The mechanisms and sites of action through which the standardanxiolytics and antidepressants produce their therapeutic effects remainto be elucidated. It has been hypothesized however, that they areinvolved in the suppression of the CRF hypersecretion that is observedin these disorders. Of particular interest is that preliminary studiesexamining the effects of a CRF receptor antagonist (alpha helicalCRF9-41) in a variety of behavioral paradigms have demonstrated that theCRF antagonist produces “anxiolytic-like” effects qualitatively similarto the benzodiazepines [for review see G. F. Koob and K. T. Britton, In:Corticotropin-Releasing Factor: Basic and Clinical Studies of aNeuropeptide, E. B. De Souza and C. B. Nemeroff eds., CRC Press p221(1990)].

[0009] DuPont Merck PCT application US94/11050 describes corticotropinreleasing factor antagonist compounds, and their use in treatingpsychiatric disorders and neurological diseases; however, said compoundsdo not have the same structures as do the compounds provided herein.Other compounds reported to have activity as corticotropin releasingfactors are disclosed in WO 95/33750, WO 95/34563 and WO 95/33727; thesecompounds also do not have the structures of the compounds providedherein.

SUMMARY OF THE INVENTION

[0010] This invention provides compounds of the formula (I)

[0011] as well as stereoisomers and pharmaceutically acceptable saltsthereof.

[0012] Preferably, A is N and B is CH, A is CH and B is N, or A and Bare each N. D is preferably phenyl or 3-pyridyl. Each of these rings issubstituted with 1-2 haloalkoxy groups, such substitution being at anyavailable position of the ring. Most preferably, the haloalkoxysubstitution is at least on the carbon atom of ring D which is furthestaway on the ring from the carbon by which the ring is attached to theimidazopyridine or imidazopyrimidine ring (e.g., at the 4 position ofthe phenyl ring where ring D is phenyl). The haloalkoxy group is C₁₋₄haloalkoxy, preferably —OCHF₂ or —OCF₃, and most preferably, —OCHF₂.

[0013] Most preferably, ring D has at least one substitution in additionto the single haloalkoxy substituent, said substitution being at anyavailable position on the ring. Most preferably, said additionalsubstitution is on that carbon atom of ring D which is adjacent to thecarbon atom of ring D that is the point of attachment of ring D to theimidazopyridine or imidazopyrimidine ring (e.g., at the 2 position ofthe phenyl ring wherein ring D is phenyl); said additional substituentis preferably Cl or CH₃. Optionally, Ring D may also have a thirdsubstitution, said substitution being at any of the available positionson the ring.

[0014] Preferably, R² is CH₃ or C₂H₅, R³ is H or CH₃, X is CH₂ or O, andR¹ is 2-butyl, 2-pentyl, 2-hexyl, 2-heptyl, 3-pentyl, 3-hexyl, 3-heptyl,1-methoxy-3-pentyl, 4-heptyl, 1-cyclopropyl-1-ethyl,1-cyclopropyl-1-propyl, 1-cyclopropyl-1-butyl,1-cyclopropyl-3-methoxy-1-propyl, 1-cyclobutyl-1-ethyl,1-cyclobutyl-1-propyl, 1-cyclobutyl-1-butyl,1-cyclobutyl-3-methoxy-1-propyl, 1-cyclopentyl-1-ethyl,1-cyclopentyl-1-propyl, 1-cyclopentyl-1-butyl,1-cyclopentyl-3-methoxy-1-propyl, alpha-cyclopropylbenzyl,1-phenyl-2-butyn-1-yl, 1-cyclopropyl-2-butyn-1-yl ordicyclopropylmethyl.

[0015] Also provided herein are compositions containing the compound ofthis invention, particularly pharmaceutical compositions comprising apharmaceutically acceptable carrier and a therapeutically effectiveamount of the compound. Said compositions are useful, for example, inthe alleviation of disorders the treatment of which can be effected orfacilitated by antagonizing CRF. Such disorders include, withoutlimitation: affective disorder, anxiety, depression, headache, irritablebowel syndrome, post-traumatic stress disorder, immune suppression,Huntington's disease, Parkinson's disease, progressive supranuclearpalsy, amyotrophic lateral sclerosis, Alzheimer's disease,gastrointestinal diseases, anorexia nervosa or other feeding disorders,drug addiction, drug or alcohol withdrawal symptoms, inflammatorydiseases, cardiovascular or heart-related diseases, fertility problems,human immunodeficiency virus infections, hemorrhagic stress, obesity,infertility, head and spinal cord traumas, epilepsy, stroke, ulcers,amyotrophic lateral sclerosis and hypoglycemia.

DETAILED DESCRIPTION OF THE INVENTION

[0016] This invention provides certain compounds, as well asstereoisomers thereof. Accordingly, compounds provided herein can haveone or more asymmetric centers or planes, and all chiral (enantiomericand diastereomeric) and racemic forms of the compounds are included inthe present invention. Many geometric isomers of olefins, C═N doublebonds, and the like can also be present in the compounds, and all suchstable isomers are contemplated in the present invention. Compounds areisolated in either the racemic form, or in the optically pure form, forexample, by resolution of the racemic form.

[0017] Pharmaceutically acceptable salts of compounds of this inventionare also provided herein. The phrase “pharmaceutically acceptable” isemployed to refer to those compounds, materials, compositions, and/ordosage forms which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of human beings and animalswithout excessive toxicity, irritation, allergic response, or otherproblem or complication, commensurate with a reasonable benefit/riskratio. “Pharmaceutically acceptable salts” refer to derivatives of thedisclosed compounds wherein the parent compound is modified by makingacid or base salts thereof. Examples of pharmaceutically acceptablesalts include, but are not limited to, mineral or organic acid salts ofbasic residues such as amines, or alkali or organic salts of acidicresidues such as carboxylic acids. Pharmaceutically acceptable saltsinclude the conventional non-toxic salts or the quaternary ammoniumsalts of the parent compound formed, for example, from non-toxicinorganic or organic acids. Such conventional nontoxic salts includethose derived from inorganic acids such as hydrochloric, hydrobromic,sulfuric, sulfamic, phosphoric, nitric and the like; and the saltsprepared from organic acids such as acetic, propionic, succinic,glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic,maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic,sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic,ethane disulfonic, oxalic, isethionic, and the like.

[0018] Pharmaceutically acceptable salt forms of compounds providedherein are synthesized from the parent compound which contains a basicor acidic moiety by conventional chemical methods. Generally, such saltsare, for example, prepared by reacting the free acid or base forms ofthese compounds with a stoichiometric amount of the appropriate base oracid in water or in an organic solvent, or in a mixture of the two;generally, nonaqueous media like ether, ethyl acetate, ethanol,isopropanol, or acetonitrile are preferred. Lists of suitable salts arefound in Remington's Pharmaceutical Sciences, 17th ed., Mack PublishingCompany, Easton, Pa., 1985, p. 1418, the disclosure of which is herebyincorporated by reference.

[0019] In the compounds of this invention, “alkyl”, means saturatedhydrocarbon chains, branched or unbranched, having the specified numberof carbon atoms. “Alkenyl” means hydrocarbon chains of either a straightor branched configuration and one or more unsaturated carbon-carbonbonds which may occur in any stable point along the chain, such asethenyl, propenyl, and the like. “Alkynyl” means hydrocarbon chains ofeither a straight or branched configuration and one or more triplecarbon-carbon bonds which may occur in any stable point along the chain,such as ethynyl, propynyl and the like. “Alkoxy” means an alkyl group ofindicated number of carbon atoms attached through an oxygen bridge.“Cycloalkyl” means saturated ring groups, including mono-, bi- orpolycyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, and so forth. “Halo” or “halogen” means fluoro, chloro,bromo, and iodo. “Haloalkyl” means both branched and straight-chainalkyls having the specified number of carbon atoms, substituted with 1or more halogen. “Haloalkoxy” means an alkoxy group substituted by atleast one halogen atom.

[0020] “Substituted” means that one or more hydrogen on the designatedatom is replaced with a selection from the indicated group, providedthat the designated atom's normal valency is not exceeded, and that thesubstitution results in a stable compound. “Unsubstituted” atoms bearall of the hydrogen atoms dictated by their valency. When a substituentis keto, then 2 hydrogens on the atom are replaced. Combinations ofsubstituents and/or variables are permissible only if such combinationsresult in stable compounds; by “stable compound” or “stable structure”is meant a compound that is sufficiently robust to survive isolation toa useful degree of purity from a reaction mixture, and formulation intoan efficacious therapeutic agent.

[0021] Compounds provided herein are of the formula I:

[0022] wherein A is N or C—R⁷ and B is N or C—R⁸, provided that at leastone of A and B is N. R⁷ and R⁸ are each independently selected from H,C₁₋₄ alkyl, C₃₋₈ cycloalkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄alkylsulfinyl, C₁₋₄ alkylsulfonyl, amino, C₁₋₄ alkylamino, C₂₋₈dialkylamino, phenyl and phenyl substituted by 1-3 groups selected fromC₁₋₇ alkyl, C₃₋₈ cycloalkyl, halogen, nitro, C₁₋₄ alkoxy, C₁₋₄ alkylthioand C₂₋₈ dialkylamino. In preferred embodiments of this invention, A isN and B is C—R⁸, A is C—R⁸ and B is N, or A and B are both N; where B isC—R⁸, it is most preferably CH.

[0023] D is an aryl ring or a heteroaryl ring, aryl rings being6-carbon, substituted or unsubstituted aromatic rings, or multiplecondensed, substituted or unsubstituted 6-carbon rings, and heteroarylrings being substituted or unsubstituted 5-10 membered mono or bicyclicaromatic rings containing from one to three heteroatoms selected fromthe group consisting of O, N or S. Aryl ring D is selected herein fromphenyl, naphthyl, indanyl and indenyl. Heteroaryl ring D is selectedherein from pyridyl, pyrimidyl, triazinyl, furanyl, quinolinyl,isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl,oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl,isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2,3-dihydrobenzofuranyl,2,3-dihydrobenzothienyl, the S-oxide of 2,3-dihydrobenzothienyl, theS,S-dioxide of 2,3-dihydrobenzothienyl, indolinyl,benzoxazolin-2-one-yl, benzodioxolanyl, and benzodioxanyl. Mostpreferably, ring D is either a phenyl ring or a 3-pyridyl ring.

[0024] Ring D herein is substituted by a C₁₋₄ alkoxy group, saidsubstitution being at any of the available positions on the ring. Mostpreferably, where there is a single haloalkoxy substitution of ring D,the substitution is on the carbon atom of ring D which is furthest awayon the ring from the carbon atom of ring D by which the ring is attachedto the imidazopyridine or imidazopyrimidine ring (e.g., at the 4position of the phenyl ring where ring D is phenyl). Alternatively,where there are multiple haloalkoxy substitutions of ring D, one of suchsubstituents is preferably located on said carbon atom. The haloalkoxygroup is C₁₋₄ haloalkoxy, preferably —OCHF₂ or —OCF₃, and mostpreferably, —OCHF₂.

[0025] Ring member atoms unoccupied by a haloalkoxy group can beunsubstituted or, optionally, substituted with 1-3 additional moieties;preferably at least one ring member in addition to the atom substitutedwith haloalkoxy is also substituted. Most preferably, the first of saidadditional substitutions is on the carbon atom adjacent to the carbon ofring D which is the point by which the ring is attached to theimidazopyridine or imidazopyrimidine ring (e.g., at the 2 position ofthe phenyl ring wherein ring D is phenyl). Such additional substituentsare preferably selected independently from C₁₋₆ alkyl, C₃₋₆ cycloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, halogen, C₁₋₄ haloalkyl, OH, C₁₋₄ alkoxy,(C₁₋₄ alkoxy)-C₁₋₄ alkoxy, CN, SH, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl,C₁₋₄ alkylsulfonyl, CR¹⁷, CO2R¹⁷ and NR¹⁷R¹⁹. R¹⁷, R¹⁸ and R¹⁹ areindependently selected at each occurrence thereof H, C₁₋₆ alkyl, C₃₋₁₀cycloalkyl or C₄₋₁₆ cycloalkylalkyl.

[0026] Optionally, Ring D may also have a third substitution, or asecond substitution in addition to the haloalkoxy substituent, saidadditional substitution being at any of the available positions on thering. Preferably, said additional substitution is on a carbon atombetween: (1) the carbon atom to which the haloalkoxy is preferablyattached (e.g., the 4 position of the phenyl ring when ring D is phenyl)and, (2) the point of attachment of ring D to the imidazopyridine orimidazopyrimidine rings, and is also preferably further along the ringthan is the haloalkoxy substituent (e.g., at the 5 or 6 position of thephenyl ring where ring D is phenyl). More preferably, the additionalsubstitution is also on a carbon atom adjacent to the preferredhaloalkoxy location (e.g., at the 5 position of the phenyl ring wherering D is phenyl).

[0027] Accordingly, ring D's most preferred herein have the followingstructures:

[0028] R¹ is selected from H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,C₃₋₈ cycloalkyl, C₄₋₁₂ cycloalkylalkyl and (C₁₋₄ alkoxy)-C₁₋₄ alkyl,each of these being optionally substituted with 1 to 3 substituentsselected independently from C₁₋₆ alkyl, C3-6 cycloalkyl, C₄₋₈cycloalkyl, C₄₋₈ cycloalkyl comprising a ring-member oxygen, aryl,heteroaryl, heterocyclyl, halogen, C₁₋₄ haloalkyl, cyano, —OR¹³,—S(O)R¹⁴, —COR¹³, —CO₂R¹³, —NR₁₅COR¹³, N(COR¹³)₂, —NR¹⁵CONR¹³R¹⁶,—NR¹⁵CO₂R¹⁴, —NR¹³R¹⁶, —CONR¹³R¹⁶ and the cyclic groups morpholinyl,1-piperidinyl, 1-piperazinyl and 1-piperazinyl having an N4 substitutedwith methyl, acetyl or methylsulfonyl. R¹³ and R¹⁶ are selectedindependently at each occurrence thereof from H, C₁₋₄ alkyl, C₁₋₄haloalkyl, C₂₋₈ alkoxyalkyl, C₃₋₆ cycloalkyl, C₄₋₁₂ cycloalkylalkyl,aryl, (aryl)C₁₋₄ alkyl, heteroaryl and (heteroaryl)-C₁₋₄ alkyl. R¹⁴ isselected from C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₈ alkoxyalkyl, C₃₋₆cycloalkyl, C₄₋₁₂ cycloalkylalkyl, aryl, (aryl)C₁₋₄ alkyl, heteroaryland (heteroaryl)C₁₋₄ alkyl. R¹⁵ is selected independently from H, C₁₋₄alkyl, C₃₋₇ cycloalkyl, C₄₋₁₂ cycloalkylalkyl and benzyl (optionallysubstituted with 1-3 groups chosen from C₁₋₄ alkyl, halogen, nitro, C₁₋₄alkoxy, or dimethylamino) and m is equal to 0, 1, or 2.

[0029] Preferably, R¹ is C₁₋₇ alkyl, C₅₋₇ cycloalkyl, or C₂₋₇ alkynyl,and R¹ is substituted with C₃₋₅ cycloalkyl, C₁₋₂ alkoxy, phenyl orphenyl substituted with 1-3 CN, C₁₋₃ alkoxy, or C₁₋₃ alkyl groups. Mostpreferably, R¹ is 2-butyl, 2-pentyl, 2-hexyl, 2-heptyl, 3-pentyl,3-hexyl, 3-heptyl, 1-methoxy-3-pentyl, 4-heptyl, 1-cyclopropyl-1-ethyl,1-cyclopropyl-1-propyl, 1-cyclopropyl-1-butyl,1-cyclopropyl-3-methoxy-1-propyl, 1-cyclobutyl-1-ethyl,1-dihydrobenzothienyl, cyclobutyl-1-propyl, 1-cyclobutyl-1-butyl,1-cyclobutyl-3-methoxy-1-propyl, 1-cyclopentyl-1-ethyl,1-cyclopentyl-1-propyl, 1-cyclopentyl-1-butyl,1-cyclopentyl-3-methoxy-1-propyl, alpha-cyclopropylbenzyl,1-phenyl-2-butyn-1-yl, 1-cyclopropyl-2-butyn-1-yl ordicyclopropylmethyl.

[0030] X is CH—R⁹, N—R¹⁰, O, S(O)_(n) or a bond, wherein R⁹ and R¹⁰ areeach independently H, C₁₋₄ alkyl or C₃₋₈ cycloalkyl and n is equal to 0,2 or 3. Most preferably, X os O or CH—R⁹, wherein R⁹ is H.

[0031] R² is C₁₋₄ alkyl or C₃₋₈ cycloalkyl, each optionally substitutedwith 1-3 substituents selected from hydroxy, halo and C₁₋₄ alkoxy, orwhere X is a bond, R² is optionally also cyano. Most preferably, R² isCH₃ or C₂H₅.

[0032] R³ is selected from H, C₁₋₄ alkyl, C₃₋₈ cycloalkyl, C₁₋₄ alkoxy,C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, amino, C₁₋₄alkylamino, C₂₋₈ dialkylamino, phenyl and phenyl substituted by 1-3groups selected from C₁₋₇ alkyl, C₃₋₈ cycloalkyl, halogen, nitro, C₁₋₄alkoxy, C₁₋₄ alkylthio and C₂₋₈ dialkylamino. Most preferably, R³ is Hor CH₃.

[0033] Accordingly, compounds are provided having the followingstructures:

[0034] Preferably: R¹ is 2-butyl, 2-pentyl, 2-hexyl, 2-heptyl, 3-pentyl,3-hexyl, 3-heptyl, 1-methoxy-3-pentyl, 4-heptyl, 1-cyclopropyl-1-ethyl,1-cyclopropyl-1-propyl, 1-cyclopropyl-1-butyl,1-cyclopropyl-3-methoxy-1-propyl, 1-cyclobutyl-1-ethyl,1-cyclobutyl-1-propyl, 1-cyclobutyl-1-butyl,1-cyclobutyl-3-methoxy-1-propyl, 1-cyclopentyl-1-ethyl,1-cyclopentyl-1-propyl, 1-cyclopentyl-1-butyl,1-cyclopentyl-3-methoxy-1-propyl, alpha-cyclopropylbenzyl,1-phenyl-2-butyn-1-yl, 1-cyclopropyl-2-butyn-1-yl ordicyclopropylmethyl; R² is CH₃ or C₂H₅; R³ is H or CH₃; X is CH₂ or O; Ais N; B is N or CH; and, D is phenyl or 3-pyridyl. Preferred compoundsof this invention include compounds with any combination of the abovedescribed substituents at the various positions.

[0035] Particularly preferred compounds provided herein are those havingthe following structure, with the substituents being given in the tablefollowing thereafter. TABLE A

R^(1(a)) X R² R³ R^(aryl) R^(aryl2) R^(aryl3) A CH₂ CH₃ H Cl CF₃ H B CH₂CH₃ H Cl CF₃ H C CH₂ CH₃ H Cl CF₃ H D CH₂ CH₃ H Cl CF₃ H E CH₂ CH₃ H ClCF₃ H F CH₂ CH₃ H Cl CF₃ H G CH₂ CH₃ H Cl CF₃ H H CH₂ CH₃ H Cl CF₃ H ICH₂ CH₃ H Cl CF₃ H J CH₂ CH₃ H Cl CF₃ H K CH₂ CH₃ H Cl CF₃ H L CH₂ CH₃ HCl CF₃ H N CH₂ CH₃ H Cl CF₃ H N CH₂ CH₃ H Cl CF₃ H O CH₂ CH₃ H Cl CF₃ HP CH₂ CH₃ H Cl CF₃ H Q CH₂ CH₃ H Cl CF₃ H R CH₂ CH₃ H Cl CF₃ H S CH₂ CH₃H Cl CF₃ H T CH₂ CH₃ H Cl CF₃ H U CH₂ CH₃ H Cl CF₃ H V CH₂ CH₃ H Cl CF₃H W CH₂ CH₃ H Cl CF₃ H X CH₂ CH₃ H Cl CF₃ H Y CH₂ CH₃ H Cl CF₃ H A O CH₃H Cl CF₃ H B O CH₃ H Cl CF₃ H C O CH₃ H Cl CF₃ H D O CH₃ H Cl CF₃ H E OCH₃ H Cl CF₃ H F O CH₃ H Cl CF₃ H G O CH₃ H Cl CF₃ H H O CH₃ H Cl CF₃ HI O CH₃ H Cl CF₃ H J O CH₃ H Cl CF₃ H K O CH₃ H Cl CF₃ H L O CH₃ H ClCF₃ H M O CH₃ H Cl CF₃ H N O CH₃ H Cl CF₃ H O O CH₃ H Cl CF₃ H P O CH₃ HCl CF₃ H Q O CH₃ H Cl CF₃ H R O CH₃ H Cl CF₃ H S O CH₃ H Cl CF₃ H T OCH₃ H Cl CF₃ H U O CH₃ H Cl CF₃ H V O CH₃ H Cl CF₃ H W O CH₃ H Cl CF₃ HX O CH₃ H Cl CF₃ H Y O CH₃ H Cl CF₃ H A O C₂H₅ H Cl CF₃ H B O C₂H₅ H ClCF₃ H C O C₂H₅ H Cl CF₃ H D O C₂H₅ H Cl CF₃ H E O C₂H₅ H Cl CF₃ H F OC₂H₅ H Cl CF₃ H G O C₂H₅ H Cl CF₃ H H O C₂H₅ H Cl CF₃ H I O C₂H₅ H ClCF₃ H J O C₂H₅ H Cl CF₃ H K O C₂H₅ H Cl CF₃ H L O C₂H₅ H Cl CF₃ H M OC₂H₅ H Cl CF₃ H N O C₂H₅ H Cl CF₃ H O O C₂H₅ H Cl CF₃ H P O C₂H₅ H ClCF₃ H Q O C₂H₅ H Cl CF₃ H R O C₂H₅ H Cl CF₃ H S O C₂H₅ H Cl CF₃ H T OC₂H₅ H Cl CF₃ H U O C₂H₅ H Cl CF₃ H V O C₂H₅ H Cl CF₃ H W O C₂H₅ H ClCF₃ H X O C₂H₅ H Cl CF₃ H Y O C₂H₅ H Cl CF₃ H A CH₂ CH₃ CH₃ Cl CF₃ H BCH₂ CH₃ CH₃ Cl CF₃ H C CH₂ CH₃ CH₃ Cl CF₃ H D CH₂ CH₃ CH₃ Cl CF₃ H E CH₂CH₃ CH₃ Cl CF₃ H F CH₂ CH₃ CH₃ Cl CF₃ H G CH₂ CH₃ CH₃ Cl CF₃ H H CH₂ CH₃CH₃ Cl CF₃ H I CH₂ CH₃ CH₃ Cl CF₃ H J CH₂ CH₃ CH₃ Cl CF₃ H K CH₂ CH₃ CH₃Cl CF₃ H L CH₂ CH₃ CH₃ Cl CF₃ H M CH₂ CH₃ CH₃ Cl CF₃ H N CH₂ CH₃ CH₃ ClCF₃ H O CH₂ CH₃ CH₃ Cl CF₃ H P CH₂ CH₃ CH₃ Cl CF₃ H Q CH₂ CH₃ CH₃ Cl CF₃H R CH₂ CH₃ CH₃ Cl CF₃ H S CH₂ CH₃ CH₃ Cl CF₃ H T CH₂ CH₃ CH₃ Cl CF₃ H UCH₂ CH₃ CH₃ Cl CF₃ H V CH₂ CH₃ CH₃ Cl CF₃ H W CH₂ CH₃ CH₃ Cl CF₃ H X CH₂CH₃ CH₃ Cl CF₃ H Y CH₂ CH₃ CH₃ Cl CF₃ H A CH₂ CH₃ H CH₃ CF₃ H B CH₂ CH₃H CH₃ CF₃ H C CH₂ CH₃ H CH₃ CF₃ H D CH₂ CH₃ H CH₃ CF₃ H E CH₂ CH₃ H CH₃CF₃ H F CH₂ CH₃ H CH₃ CF₃ H G CH₂ CH₃ H CH₃ CF₃ H H CH₂ CH₃ H CH₃ CF₃ HI CH₂ CH₃ H CH₃ CF₃ H J CH₂ CH₃ H CH₃ CF₃ H K CH₂ CH₃ H CH₃ CF₃ H L CH₂CH₃ H CH₃ CF₃ H M CH₂ CH₃ H CH₃ CF₃ H N CH₂ CH₃ H CH₃ CF₃ H O CH₂ CH₃ HCH₃ CF₃ H P CH₂ CH₃ H CH₃ CF₃ H Q CH₂ CH₃ H CH₃ CF₃ H R CH₂ CH₃ H CH₃CF₃ H S CH₂ CH₃ H CH₃ CF₃ H T CH₂ CH₃ H CH₃ CF₃ H U CH₂ CH₃ H CH₃ CF₃ HV CH₂ CH₃ H CH₃ CF₃ H W CH₂ CH₃ H CH₃ CF₃ H X CH₂ CH₃ H CH₃ CF₃ H Y CH₂CH₃ H CH₃ CF₃ H A O CH₃ H CH₃ CF₃ H B O CH₃ H CH₃ CF₃ H C O CH₃ H CH₃CF₃ H D O CH₃ H CH₃ CF₃ H E O CH₃ H CH₃ CF₃ H F O CH₃ H CH₃ CF₃ H G OCH₃ H CH₃ CF₃ H H O CH₃ H CH₃ CF₃ H I O CH₃ H CH₃ CF₃ H J O CH₃ H CH₃CF₃ H K O CH₃ H CH₃ CF₃ H L O CH₃ H CH₃ CF₃ H H O CH₃ H CH₃ CF₃ H N OCH₃ H CH₃ CF₃ H O O CH₃ H CH₃ CF₃ H P O CH₃ H CH₃ CF₃ H Q O CH₃ H CH₃CF₃ H R O CH₃ H CH₃ CF₃ H S O CH₃ H CH₃ CF₃ H T O CH₃ H CH₃ CF₃ H U OCH₃ H CH₃ CF₃ H V O CH₃ H CH₃ CF₃ H W O CH₃ H CH₃ CF₃ H X O CH₃ H CH₃CF₃ H Y O CH₃ H CH₃ CF₃ H A O C₂H₅ H CH₃ CF₃ H B O C₂H₅ H CH₃ CF₃ H C OC₂H₅ H CH₃ CF₃ H D O C₂H₅ H CH₃ CF₃ H E O C₂H₅ H CH₃ CF₃ H F O C₂H₅ HCH₃ CF₃ H G O C₂H₅ H CH₃ CF₃ H H O C₂H₅ H CH₃ CF₃ H I O C₂H₅ H CH₃ CF₃ HJ O C₂H₅ H CH₃ CF₃ H K O C₂H₅ H CH₃ CF₃ H L O C₂H₅ H CH₃ CF₃ H H O C₂H₅H CH₃ CF₃ H N O C₂H₅ H CH₃ CF₃ H O O C₂H₅ H CH₃ CF₃ H P O C₂H₅ H CH₃ CF₃H Q O C₂H₅ H CH₃ CF₃ H R O C₂H₅ H CH₃ CF₃ H S O C₂H₅ H CH₃ CF₃ H T OC₂H₅ H CH₃ CF₃ H U O C₂H₅ H CH₃ CF₃ H V O C₂H₅ H CH₃ CF₃ H W O C₂H₅ HCH₃ CF₃ H X O C₂H₅ H CH₃ CF₃ H Y O C₂H₅ H CH₃ CF₃ H A CH₂ CH₃ CH₃ CH₃CF₃ H B CH₂ CH₃ CH₃ CH₃ CF₃ H O CH₂ CH₃ CH₃ CH₃ CF₃ H D CH₂ CH₃ CH₃ CH₃CF₃ H E CH₂ CH₃ CH₃ CH₃ CF₃ H F CH₂ CH₃ CH₃ CH₃ CF₃ H G CH₂ CH₃ CH₃ CH₃CF₃ H H CH₂ CH₃ CH₃ CH₃ CF₃ H I CH₂ CH₃ CH₃ CH₃ CF₃ H J CH₂ CH₃ CH₃ CH₃CF₃ H K CH₂ CH₃ CH₃ CH₃ CF₃ H L CH₂ CH₃ CH₃ CH₃ CF₃ H M CH₂ CH₃ CH₃ CH₃CF₃ H N CH₂ CH₃ CH₃ CH₃ CF₃ H O CH₂ CH₃ CH₃ CH₃ CF₃ H P CH₂ CH₃ CH₃ CH₃CF₃ H Q CH₂ CH₃ CH₃ CH₃ CF₃ H R CH₂ CH₃ CH₃ CH₃ CF₃ H S CH₂ CH₃ CH₃ CH₃CF₃ H T CH₂ CH₃ CH₃ CH₃ CF₃ H U CH₂ CH₃ CH₃ CH₃ CF₃ H V CH₂ CH₃ CH₃ CH₃CF₃ R W CH₂ CH₃ CH₃ CH₃ CF₃ H X CH₂ CH₃ CH₃ CH₃ CF₃ H Y CH₂ CH₃ CH₃ CH₃CF₃ H A CH₂ CH₃ H Cl CHF₂ H B CH₂ CH₃ H Cl CHF₂ H C CH₂ CH₃ H Cl CHF₂ HD CH₂ CH₃ H Cl CHF₂ H E CH₂ CH₃ H Cl CHF₂ H F CH₂ CH₃ H Cl CHF₂ H G CH₂CH₃ H Cl CHF₂ H H CH₂ CH₃ H Cl CHF₂ H I CH₂ CH₃ H Cl CHF₂ H J CH₂ CH₃ HCl CHF₂ H K CH₂ CH₃ H Cl CHF₂ H L CH₂ CH₃ H Cl CHF₂ H M CH₂ CH₃ H ClCHF₂ H N CH₂ CH₃ H Cl CHF₂ H O CH₂ CH₃ H Cl CHF₂ H P CH₂ CH₃ H Cl CHF₂ HQ CH₂ CH₃ H Cl CHF₂ H R CH₂ CH₃ H Cl CHF₂ H S CH₂ CH₃ H Cl CHF₂ H T CH₂CH₃ H Cl CHF₂ R U CH₂ CH₃ H Cl CHF₂ H V CH₂ CH₃ H Cl CHF₂ H W CH₂ CH₃ HCl CHF₂ R X CH₂ CH₃ H Cl CHF₂ H Y CH₂ CH₃ H Cl CHF₂ H A O CH₃ H Cl CHF₂H B O CH₃ H Cl CHF₂ H C O CH₃ H Cl CHF₂ H D O CH₃ H Cl CHF₂ H E O CH₃ HCl CHF₂ H F O CH₃ H Cl CHF₂ H G O CH₃ H Cl CHF₂ H H O CH₃ H Cl CHF₂ H IO CH₃ H Cl CHF₂ H J O CH₃ H Cl CHF₂ H K O CH₃ H Cl CHF₂ H L O CH₃ H ClCHF₂ H M O CH₃ H Cl CHF₂ H N O CH₃ H Cl CHF₂ H O O CH₃ H Cl CHF₂ H P OCH₃ H Cl CHF₂ H Q O CH₃ H Cl CHF₂ H R O CH₃ H Cl CHF₂ H S O CH₃ H ClCHF₂ H T O CH₃ H Cl CHF₂ H U O CH₃ H Cl CHF₂ H V O CH₃ H Cl CHF₂ H W OCH₃ H Cl CHF₂ H X O CH₃ H Cl CHF₂ H Y O CH₃ H Cl CHF₂ H A O C₂H₅ H ClCHF₂ H B O C₂H₅ H Cl CHF₂ H C O C₂H₅ H Cl CHF₂ H D O C₂H₅ H Cl CHF₂ H EO C₂H₅ H Cl CHF₂ H F O C₂H₅ H Cl CHF₂ H G O C₂H₅ H Cl CHF₂ H H O C₂H₅ HCl CHF₂ H I O C₂H₅ H Cl CHF₂ H J O C₂H₅ H Cl CHF₂ H K O C₂H₅ H Cl CHF₂ HL O C₂H₅ H Cl CHF₂ H M O C₂H₅ H Cl CHF₂ H N O C₂H₅ H Cl CHF₂ H O O C₂H₅H Cl CHF₂ H P O C₂H₅ H Cl CHF₂ H Q O C₂H₅ H Cl CHF₂ H R O C₂H₅ H Cl CHF₂H S O C₂H₅ H Cl CHF₂ H T O C₂H₅ H Cl CHF₂ H U O C₂H₅ H Cl CHF₂ H V OC₂H₅ H Cl CHF₂ H W O C₂H₅ H Cl CHF₂ H X O C₂H₅ H Cl CHF₂ H Y O C₂H₅ H ClCHF₂ H A CH₂ CH₃ CH₃ Cl CHF₂ H B CH₂ CH₃ CH₃ Cl CHF₂ H C CH₂ CH₃ CH₃ ClCHF₂ H D CH₂ CH₃ CH₃ Cl CHF₂ H E CH₂ CH₃ CH₃ Cl CHF₂ H F CH₂ CH₃ CH₃ ClCHF₂ H G CH₂ CH₃ CH₃ Cl CHF₂ H H CH₂ CH₃ CH₃ Cl CHF₂ H I CH₂ CH₃ CH₃ ClCHF₂ H J CH₂ CH₃ CH₃ Cl CHF₂ H K CH₂ CH₃ CH₃ Cl CHF₂ H L CH₂ CH₃ CH₃ ClCHF₂ H M CH₂ CH₃ CH₃ Cl CHF₂ H N CH₂ CH₃ CH₃ Cl CHF₂ H O CH₂ CH₃ CH₃ ClCHF₂ H P CH₂ CH₃ CH₃ Cl CHF₂ H Q CH₂ CH₃ CH₃ Cl CHF₂ H R CH₂ CH₃ CH₃ ClCHF₂ H S CH₂ CH₃ CH₃ Cl CHF₂ H T CH₂ CH₃ CH₃ Cl CHF₂ H U CH₂ CH₃ CH₃ ClCHF₂ H V CH₂ CH₃ CH₃ Cl CHF₂ H W CH₂ CH₃ CH₃ Cl CHF₂ H X CH₂ CH₃ CH₃ ClCHF₂ H Y CH₂ CH₃ CH₃ Cl CHF₂ H A CH₂ CH₃ H CH₃ CHF₂ H B CH₂ CH₃ H CH₃CHF₂ H O CH₂ CH₃ H CH₃ CHF₂ H D CH₂ CH₃ H CH₃ CHF₂ H E CH₂ CH₃ H CH₃CHF₂ H F CH₂ CH₃ H CH₃ CHF₂ H G CH₂ CH₃ H CH₃ CHF₂ H H CH₂ CH₃ H CH₃CHF₂ H I CH₂ CH₃ H CH₃ CHF₂ H J CH₂ CH₃ H CH₃ CHF₂ H K CH₂ CH₃ H CH₃CHF₂ H L CH₂ CH₃ H CH₃ CHF₂ H M CH₂ CH₃ H CH₃ CHF₂ H N CH₂ CH₃ H CH₃CHF₂ H O CH₂ CH₃ H CH₃ CHF₂ H P CH₂ CH₃ H CH₃ CHF₂ H Q CH₂ CH₃ H CH₃CHF₂ H R CH₂ CH₃ H CH₃ CHF₂ H S CH₂ CH₃ H CH₃ CHF₂ H T CH₂ CH₃ H CH₃CHF₂ H U CH₂ CH₃ H CH₃ CHF₂ H V CH₂ CH₃ H CH₃ CHF₂ H W CH₂ CH₃ H CH₃CHF₂ H X CH₂ CH₃ H CH₃ CHF₂ H Y CH₂ CH₃ H CH₃ CHF₂ H A O CH₃ H CH₃ CHF₂H B O CH₃ H CH₃ CHF₂ H C O CH₃ H CH₃ CHF₂ H D O CH₃ H CH₃ CHF₂ H E O CH₃H CH₃ CHF₂ H F O CH₃ H CH₃ CHF₂ H G O CH₃ H CH₃ CHF₂ H H O CH₃ H CH₃CHF₂ H I O CH₃ H CH₃ CHF₂ H J O CH₃ H CH₃ CHF₂ H K O CH₃ H CH₃ CHF₂ H LO CH₃ H CH₃ CHF₂ H N O CH₃ H CH₃ CHF₂ H N O CH₃ H CH₃ CHF₂ H O O CH₃ HCH₃ CHF₂ H P O CH₃ H CH₃ CHF₂ H Q O CH₃ H CH₃ CHF₂ H R O CH₃ H CH₃ CHF₂H S O CH₃ H CH₃ CHF₂ H T O CH₃ H CH₃ CHF₂ H U O CH₃ H CH₃ CHF₂ H V O CH₃H CH₃ CHF₂ H W O CH₃ H CH₃ CHF₂ H X O CH₃ H CH₃ CHF₂ H Y O CH₃ H CH₃CHF₂ H A O C₂H₅ H CH₃ CHF₂ H B O C₂H₅ H CH₃ CHF₂ H C O C₂H₅ H CH₃ CHF₂ HD O C₂H₅ H CH₃ CHF₂ H E O C₂H₅ H CH₃ CHF₂ H F O C₂H₅ H CH₃ CHF₂ H G OC₂H₅ H CH₃ CHF₂ H H O C₂H₅ H CH₃ CHF₂ H I O C₂H₅ H CH₃ CHF₂ H J O C₂H₅ HCH₃ CHF₂ H K O C₂H₅ H CH₃ CHF₂ H L O C₂H₅ H CH₃ CHF₂ H M O C₂H₅ H CH₃CHF₂ H N O C₂H₅ H CH₃ CHF₂ H O O C₂H₅ H CH₃ CHF₂ H P O C₂H₅ H CH₃ CHF₂ HQ O C₂H₅ H CH₃ CHF₂ H R O C₂H₅ H CH₃ CHF₂ H S O C₂H₅ H CH₃ CHF₂ H T OC₂H₅ H CH₃ CHF₂ H U O C₂H₅ H CH₃ CHF₂ H V O C₂H₅ H CH₃ CHF₂ H W O C₂H₅ HCH₃ CHF₂ H X O C₂H₅ H CH₃ CHF₂ H Y O C₂H₅ H CH₃ CHF₂ H A CH₂ CH₃ CH₃ CH₃CHF₂ H B CH₂ CH₃ CH₃ CH₃ CHF₂ H C CH₂ CH₃ CH₃ CH₃ CHF₂ H D CH₂ CH₃ CH₃CH₃ CHF₂ H E CH₂ CH₃ CH₃ CH₃ CHF₂ H F CH₂ CH₃ CH₃ CH₃ CHF₂ H G CH₂ CH₃CH₃ CH₃ CHF₂ H H CH₂ CH₃ CH₃ CH₃ CHF₂ H I CH₂ CH₃ CH₃ CH₃ CHF₂ H J CH₂CH₃ CH₃ CH₃ CHF₂ H K CH₂ CH₃ CH₃ CH₃ CHF₂ H L CH₂ CH₃ CH₃ CH₃ CHF₂ H NCH₂ CH₃ CH₃ CH₃ CHF₂ H N CH₂ CH₃ CH₃ CH₃ CHF₂ H O CH₂ CH₃ CH₃ CH₃ CHF₂ HP CH₂ CH₃ CH₃ CH₃ CHF₂ H Q CH₂ CH₃ CH₃ CH₃ CHF₂ H R CH₂ CH₃ CH₃ CH₃ CHF₂H S CH₂ CH₃ CH₃ CH₃ CHF₂ H T CH₂ CH₃ CH₃ CH₃ CHF₂ H U CH₂ CH₃ CH₃ CH₃CHF₂ H V CH₂ CH₃ CH₃ CH₃ CHF₂ H W CH₂ CH₃ CH₃ CH₃ CHF₂ H X CH₂ CH₃ CH₃CH₃ CHF₂ H Y CH₂ CH₃ CH₃ CH₃ CHF₂ H A CH₂ CH₃ H Cl CF₃ CH₃ B CH₂ CH₃ HCl CF₃ CH₃ C CH₂ CH₃ H Cl CF₃ CH₃ D CH₂ CH₃ H Cl CF₃ CH₃ E CH₂ CH₃ H ClCF₃ CH₃ F CH₂ CH₃ H Cl CF₃ CH₃ G CH₂ CH₃ H Cl CF₃ CH₃ H CH₂ CH₃ H Cl CF₃CH₃ I CH₂ CH₃ H Cl CF₃ CH₃ J CH₂ CH₃ H Cl CF₃ CH₃ K CH₂ CH₃ H Cl CF₃ CH₃L CH₂ CH₃ H Cl CF₃ CH₃ M CH₂ CH₃ H Cl CF₃ CH₃ N CH₂ CH₃ H Cl CF₃ CH₃ OCH₂ CH₃ H Cl CF₃ CH₃ P CH₂ CH₃ H Cl CF₃ CH₃ Q CH₂ CH₃ H Cl CF₃ CH₃ R CH₂CH₃ H Cl CF₃ CH₃ S CH₂ CH₃ H Cl CF₃ CH₃ T CH₂ CH₃ H Cl CF₃ CH₃ U CH₂ CH₃H Cl CF₃ CH₃ V CH₂ CH₃ H Cl CF₃ CH₃ W CH₂ CH₃ H Cl CF₃ CH₃ X CH₂ CH₃ HCl CF₃ CH₃ Y CH₂ CH₃ H Cl CF₃ CH₃ A O CH₃ H Cl CF₃ CH₃ B O CH₃ H Cl CF₃CH₃ C O CH₃ H Cl CF₃ CH₃ D O CH₃ H Cl CF₃ CH₃ E O CH₃ H Cl CF₃ CH₃ F OCH₃ H Cl CF₃ CH₃ G O CH₃ H Cl CF₃ CH₃ H O CH₃ H Cl CF₃ CH₃ I O CH₃ H ClCF₃ CH₃ J O CH₃ H Cl CF₃ CH₃ K O CH₃ H Cl CF₃ CH₃ L O CH₃ H Cl CF₃ CH₃ MO CH₃ H Cl CF₃ CH₃ N O CH₃ H Cl CF₃ CH₃ O O CH₃ H Cl CF₃ CH₃ P O CH₃ HCl CF₃ CH₃ Q O CH₃ H Cl CF₃ CH₃ R O CH₃ H Cl CF₃ CH₃ S O CH₃ H Cl CF₃CH₃ T O CH₃ H Cl CF₃ CH₃ U O CH₃ H Cl CF₃ CH₃ V O CH₃ H Cl CF₃ CH₃ W OCH₃ H Cl CF₃ CH₃ X O CH₃ H Cl CF₃ CH₃ Y O CH₃ H Cl CF₃ CH₃ A O C₂H₅ H ClCF₃ CH₃ B O C₂H₅ H Cl CF₃ CH₃ C O C₂H₅ H Cl CF₃ CH₃ D O C₂H₅ H Cl CF₃CH₃ E O C₂H₅ H Cl CF₃ CH₃ F O C₂H₅ H Cl CF₃ CH₃ G O C₂H₅ H Cl CF₃ CH₃ HO C₂H₅ H Cl CF₃ CH₃ I O C₂H₅ H Cl CF₃ CH₃ J O C₂H₅ H Cl CF₃ CH₃ K O C₂H₅H Cl CF₃ CH₃ L O C₂H₅ H Cl CF₃ CH₃ M O C₂H₅ H Cl CF₃ CH₃ N O C₂H₅ H ClCF₃ CH₃ O O C₂H₅ H Cl CF₃ CH₃ P O C₂H₅ H Cl CF₃ CH₃ Q O C₂H₅ H Cl CF₃CH₃ R O C₂H₅ H Cl CF₃ CH₃ S O C₂H₅ H Cl CF₃ CH₃ T O C₂H₅ H Cl CF₃ CH₃ UO C₂H₅ H Cl CF₃ CH₃ V O C₂H₅ H Cl CF₃ CH₃ W O C₂H₅ H Cl CF₃ CH₃ X O C₂H₅H Cl CF₃ CH₃ Y O C₂H₅ H Cl CF₃ CH₃ A CH₂ CH₃ CH₃ Cl CF₃ CH₃ B CH₂ CH₃CH₃ Cl CF₃ CH₃ C CH₂ CH₃ CH₃ Cl CF₃ CH₃ D CH₂ CH₃ CH₃ Cl CF₃ CH₃ E CH₂CH₃ CH₃ Cl CF₃ CH₃ F CH₂ CH₃ CH₃ Cl CF₃ CH₃ G CH₂ CH₃ CH₃ Cl CF₃ CH₃ HCH₂ CH₃ CH₃ Cl CF₃ CH₃ I CH₂ CH₃ CH₃ Cl CF₃ CH₃ J CH₂ CH₃ CH₃ Cl CF₃ CH₃K CH₂ CH₃ CH₃ Cl CF₃ CH₃ L CH₂ CH₃ CH₃ Cl CF₃ CH₃ M CH₂ CH₃ CH₃ Cl CF₃CH₃ N CH₂ CH₃ CH₃ Cl CF₃ CH₃ O CH₂ CH₃ CH₃ Cl CF₃ CH₃ P CH₂ CH₃ CH₃ ClCF₃ CH₃ Q CH₂ CH₃ CH₃ Cl CF₃ CH₃ R CH₂ CH₃ CH₃ Cl CF₃ CH₃ S CH₂ CH₃ CH₃Cl CF₃ CH₃ T CH₂ CH₃ CH₃ Cl CF₃ CH₃ U CH₂ CH₃ CH₃ Cl CF₃ CH₃ V CH₂ CH₃CH₃ Cl CF₃ CH₃ W CH₂ CH₃ CH₃ Cl CF₃ CH₃ X CH₂ CH₃ CH₃ Cl CF₃ CH₃ Y CH₂CH₃ CH₃ Cl CF₃ CH₃ A CH₂ CH₃ H CH₃ CF₃ CH₃ B CH₂ CH₃ H CH₃ CF₃ CH₃ C CH₂CH₃ H CH₃ CF₃ CH₃ D CH₂ CH₃ H CH₃ CF₃ CH₃ E CH₂ CH₃ H CH₃ CF₃ CH₃ F CH₂CH₃ H CH₃ CF₃ CH₃ G CH₂ CH₃ H CH₃ CF₃ CH₃ H CH₂ CH₃ H CH₃ CF₃ CH₃ I CH₂CH₃ H CH₃ CF₃ CH₃ J CH₂ CH₃ H CH₃ CF₃ CH₃ K CH₂ CH₃ H CH₃ CF₃ CH₃ L CH₂CH₃ H CH₃ CF₃ CH₃ M CH₂ CH₃ H CH₃ CF₃ CH₃ N CH₂ CH₃ H CH₃ CF₃ CH₃ O CH₂CH₃ H CH₃ CF₃ CH₃ P CH₂ CH₃ H CH₃ CF₃ CH₃ Q CH₂ CH₃ H CH₃ CF₃ CH₃ R CH₂CH₃ H CH₃ CF₃ CH₃ S CH₂ CH₃ H CH₃ CF₃ CH₃ T CH₂ CH₃ H CH₃ CF₃ CH₃ U CH₂CH₃ H CH₃ CF₃ CH₃ V CH₂ CH₃ H CH₃ CF₃ CH₃ W CH₂ CH₃ H CH₃ CF₃ CH₃ X CH₂CH₃ H CH₃ CF₃ CH₃ Y CH₂ CH₃ H CH₃ CF₃ CH₃ A O CH₃ H CH₃ CF₃ CH₃ B O CH₃H CH₃ CF₃ CH₃ C O CH₃ H CH₃ CF₃ CH₃ D O CH₃ H CH₃ CF₃ CH₃ E O CH₃ H CH₃CF₃ CH₃ F O CH₃ H CH₃ CF₃ CH₃ G O CH₃ H CH₃ CF₃ CH₃ H O CH₃ H CH₃ CF₃CH₃ I O CH₃ H CH₃ CF₃ CH₃ J O CH₃ H CH₃ CF₃ CH₃ K O CH₃ H CH₃ CF₃ CH₃ LO CH₃ H CH₃ CF₃ CH₃ M O CH₃ H CH₃ CF₃ CH₃ N O CH₃ H CH₃ CF₃ CH₃ O O CH₃H CH₃ CF₃ CH₃ P O CH₃ H CH₃ CF₃ CH₃ Q O CH₃ H CH₃ CF₃ CH₃ R O CH₃ H CH₃CF₃ CH₃ S O CH₃ H CH₃ CF₃ CH₃ T O CH₃ H CH₃ CF₃ CH₃ U O CH₃ H CH₃ CF₃CH₃ V O CH₃ H CH₃ CF₃ CH₃ W O CH₃ H CH₃ CF₃ CH₃ X O CH₃ H CH₃ CF₃ CH₃ YO CH₃ H CH₃ CF₃ CH₃ A O C₂H₅ H CH₃ CF₃ CH₃ B O C₂H₅ H CH₃ CF₃ CH₃ C OC₂H₅ H CH₃ CF₃ CH₃ D O C₂H₅ H CH₃ CF₃ CH₃ E O C₂H₅ H CH₃ CF₃ CH₃ F OC₂H₅ H CH₃ CF₃ CH₃ G O C₂H₅ H CH₃ CF₃ CH₃ H O C₂H₅ H CH₃ CF₃ CH₃ I OC₂H₅ H CH₃ CF₃ CH₃ J O C₂H₅ H CH₃ CF₃ CH₃ K O C₂H₅ H CH₃ CF₃ CH₃ L OC₂H₅ H CH₃ CF₃ CH₃ M O C₂H₅ H CH₃ CF₃ CH₃ N O C₂H₅ H CH₃ CF₃ CH₃ O OC₂H₅ H CH₃ CF₃ CH₃ P O C₂H₅ H CH₃ CF₃ CH₃ Q O C₂H₅ H CH₃ CF₃ CH₃ R OC₂H₅ H CH₃ CF₃ CH₃ S O C₂H₅ H CH₃ CF₃ CH₃ T O C₂H₅ H CH₃ CF₃ CH₃ U OC₂H₅ H CH₃ CF₃ CH₃ V O C₂H₅ H CH₃ CF₃ CH₃ W O C₂H₅ H CH₃ CF₃ CH₃ X OC₂H₅ H CH₃ CF₃ CH₃ Y O C₂H₅ H CH₃ CF₃ CH₃ A CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ BCH₂ CH₃ CH₃ CH₃ CF₃ CH₃ O CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ D CH₂ CH₃ CH₃ CH₃ CF₃CH₃ E CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ F CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ G CH₂ CH₃ CH₃CH₃ CF₃ CH₃ H CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ I CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ J CH₂CH₃ CH₃ CH₃ CF₃ CH₃ K CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ L CH₂ CH₃ CH₃ CH₃ CF₃ CH₃M CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ N CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ O CH₂ CH₃ CH₃ CH₃CF₃ CH₃ P CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ Q CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ R CH₂ CH₃CH₃ CH₃ CF₃ CH₃ S CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ T CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ UCH₂ CH₃ CH₃ CH₃ CF₃ CH₃ V CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ W CH₂ CH₃ CH₃ CH₃ CF₃CH₃ X CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ Y CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ A CH₂ CH₃ H ClCHF₂ CH₃ B CH₂ CH₃ H Cl CHF₂ CH₃ O CH₂ CH₃ H Cl CHF₂ CH₃ D CH₂ CH₃ H ClCHF₂ CH₃ E CH₂ CH₃ H Cl CHF₂ CH₃ F CH₂ CH₃ H Cl CHF₂ CH₃ G CH₂ CH₃ H ClCHF₂ CH₃ H CH₂ CH₃ H Cl CHF₂ CH₃ I CH₂ CH₃ H Cl CHF₂ CH₃ J CH₂ CH₃ H ClCHF₂ CH₃ K CH₂ CH₃ H Cl CHF₂ CH₃ L CH₂ CH₃ H Cl CHF₂ CH₃ M CH₂ CH₃ H ClCHF₂ CH₃ N CH₂ CH₃ H Cl CHF₂ CH₃ O CH₂ CH₃ H Cl CHF₂ CH₃ P CH₂ CH₃ H ClCHF₂ CH₃ Q CH₂ CH₃ H Cl CHF₂ CH₃ R CH₂ CH₃ H Cl CHF₂ CH₃ S CH₂ CH₃ H ClCHF₂ CH₃ T CH₂ CH₃ H Cl CHF₂ CH₃ U CH₂ CH₃ H Cl CHF₂ CH₃ V CH₂ CH₃ H ClCHF₂ CH₃ W CH₂ CH₃ H Cl CHF₂ CH₃ X CH₂ CH₃ H Cl CHF₂ CH₃ Y CH₂ CH₃ H ClCHF₂ CH₃ A O CH₃ H Cl CHF₂ CH₃ B O CH₃ H Cl CHF₂ CH₃ C O CH₃ H Cl CHF₂CH₃ D O CH₃ H Cl CHF₂ CH₃ E O CH₃ H Cl CHF₂ CH₃ F O CH₃ H Cl CHF₂ CH₃ GO CH₃ H Cl CHF₂ CH₃ H O CH₃ H Cl CHF₂ CH₃ I O CH₃ H Cl CHF₂ CH₃ J O CH₃H Cl CHF₂ CH₃ K O CH₃ H Cl CHF₂ CH₃ L O CH₃ H Cl CHF₂ CH₃ M O CH₃ H ClCHF₂ CH₃ N O CH₃ H Cl CHF₂ CH₃ O O CH₃ H Cl CHF₂ CH₃ P O CH₃ H Cl CHF₂CH₃ Q O CH₃ H Cl CHF₂ CH₃ R O CH₃ H Cl CHF₂ CH₃ S O CH₃ H Cl CHF₂ CH₃ TO CH₃ H Cl CHF₂ CH₃ U O CH₃ H Cl CHF₂ CH₃ V O CH₃ H Cl CHF₂ CH₃ W O CH₃H Cl CHF₂ CH₃ X O CH₃ H Cl CHF₂ CH₃ Y O CH₃ H Cl CHF₂ CH₃ A O C₂H₅ H ClCHF₂ CH₃ B O C₂H₅ H Cl CHF₂ CH₃ C O C₂H₅ H Cl CHF₂ CH₃ D O C₂H₅ H ClCHF₂ CH₃ E O C₂H₅ H Cl CHF₂ CH₃ F O C₂H₅ H Cl CHF₂ CH₃ G O C₂H₅ H ClCHF₂ CH₃ H O C₂H₅ H Cl CHF₂ CH₃ I O C₂H₅ H Cl CHF₂ CH₃ J O C₂H₅ H ClCHF₂ CH₃ K O C₂H₅ H Cl CHF₂ CH₃ L O C₂H₅ H Cl CHF₂ CH₃ M O C₂H₅ H ClCHF₂ CH₃ N O C₂H₅ H Cl CHF₂ CH₃ O O C₂H₅ H Cl CHF₂ CH₃ P O C₂H₅ H ClCHF₂ CH₃ Q O C₂H₅ H Cl CHF₂ CH₃ R O C₂H₅ H Cl CHF₂ CH₃ S O C₂H₅ H ClCHF₂ CH₃ T O C₂H₅ H Cl CHF₂ CH₃ U O C₂H₅ H Cl CHF₂ CH₃ V O C₂H₅ H ClCHF₂ CH₃ W O C₂H₅ H Cl CHF₂ CH₃ X O C₂H₅ H Cl CHF₂ CH₃ Y O C₂H₅ H ClCHF₂ CH₃ A CH₂ CH₃ CH₃ Cl CHF₂ CH₃ B CH₂ CH₃ CH₃ Cl CHF₂ CH₃ C CH₂ CH₃CH₃ Cl CHF₂ CH₃ D CH₂ CH₃ CH₃ Cl CHF₂ CH₃ E CH₂ CH₃ CH₃ Cl CHF₂ CH₃ FCH₂ CH₃ CH₃ Cl CHF₂ CH₃ G CH₂ CH₃ CH₃ Cl CHF₂ CH₃ H CH₂ CH₃ CH₃ Cl CHF₂CH₃ I CH₂ CH₃ CH₃ Cl CHF₂ CH₃ J CH₂ CH₃ CH₃ Cl CHF₂ CH₃ K CH₂ CH₃ CH₃ ClCHF₂ CH₃ L CH₂ CH₃ CH₃ Cl CHF₂ CH₃ M CH₂ CH₃ CH₃ Cl CHF₂ CH₃ N CH₂ CH₃CH₃ Cl CHF₂ CH₃ O CH₂ CH₃ CH₃ Cl CHF₂ CH₃ P CH₂ CH₃ CH₃ Cl CHF₂ CH₃ QCH₂ CH₃ CH₃ Cl CHF₂ CH₃ R CH₂ CH₃ CH₃ Cl CHF₂ CH₃ S CH₂ CH₃ CH₃ Cl CHF₂CH₃ T CH₂ CH₃ CH₃ Cl CHF₂ CH₃ U CH₂ CH₃ CH₃ Cl CHF₂ CH₃ V CH₂ CH₃ CH₃ ClCHF₂ CH₃ W CH₂ CH₃ CH₃ Cl CHF₂ CH₃ X CH₂ CH₃ CH₃ Cl CHF₂ CH₃ Y CH₂ CH₃CH₃ Cl CHF₂ CH₃ A CH₂ CH₃ H CH₃ CHF₂ CH₃ B CH₂ CH₃ H CH₃ CHF₂ CH₃ C CH₂CH₃ H CH₃ CHF₂ CH₃ D CH₂ CH₃ H CH₃ CHF₂ CH₃ E CH₂ CH₃ H CH₃ CHF₂ CH₃ FCH₂ CH₃ H CH₃ CHF₂ CH₃ G CH₂ CH₃ H CH₃ CHF₂ CH₃ H CH₂ CH₃ H CH₃ CHF₂ CH₃I CH₂ CH₃ H CH₃ CHF₂ CH₃ J CH₂ CH₃ H CH₃ CHF₂ CH₃ K CH₂ CH₃ H CH₃ CHF₂CH₃ L CH₂ CH₃ H CH₃ CHF₂ CH₃ M CH₂ CH₃ H CH₃ CHF₂ CH₃ N CH₂ CH₃ H CH₃CHF₂ CH₃ O CH₂ CH₃ H CH₃ CHF₂ CH₃ P CH₂ CH₃ H CH₃ CHF₂ CH₃ Q CH₂ CH₃ HCH₃ CHF₂ CH₃ R CH₂ CH₃ H CH₃ CHF₂ CH₃ S CH₂ CH₃ H CH₃ CHF₂ CH₃ T CH₂ CH₃H CH₃ CHF₂ CH₃ U CH₂ CH₃ H CH₃ CHF₂ CH₃ V CH₂ CH₃ H CH₃ CHF₂ CH₃ W CH₂CH₃ H CH₃ CHF₂ CH₃ X CH₂ CH₃ H CH₃ CHF₂ CH₃ Y CH₂ CH₃ H CH₃ CHF₂ CH₃ A OCH₃ H CH₃ CHF₂ CH₃ B O CH₃ H CH₃ CHF₂ CH₃ C O CH₃ H CH₃ CHF₂ CH₃ D O CH₃H CH₃ CHF₂ CH₃ E O CH₃ H CH₃ CHF₂ CH₃ F O CH₃ H CH₃ CHF₂ CH₃ G O CH₃ HCH₃ CHF₂ CH₃ H O CH₃ H CH₃ CHF₂ CH₃ I O CH₃ H CH₃ CHF₂ CH₃ J O CH₃ H CH₃CHF₂ CH₃ K O CH₃ H CH₃ CHF₂ CH₃ L O CH₃ H CH₃ CHF₂ CH₃ M O CH₃ H CH₃CHF₂ CH₃ N O CH₃ H CH₃ CHF₂ CH₃ O O CH₃ H CH₃ CHF₂ CH₃ P O CH₃ H CH₃CHF₂ CH₃ Q O CH₃ H CH₃ CHF₂ CH₃ R O CH₃ H CH₃ CHF₂ CH₃ S O CH₃ H CH₃CHF₂ CH₃ T O CH₃ H CH₃ CHF₂ CH₃ U O CH₃ H CH₃ CHF₂ CH₃ V O CH₃ H CH₃CHF₂ CH₃ W O CH₃ H CH₃ CHF₂ CH₃ X O CH₃ H CH₃ CHF₂ CH₃ Y O CH₃ H CH₃CHF₂ CH₃ A O C₂H₅ H CH₃ CHF₂ CH₃ B O C₂H₅ H CH₃ CHF₂ CH₃ C O C₂H₅ H CH₃CHF₂ CH₃ D O C₂H₅ H CH₃ CHF₂ CH₃ E O C₂H₅ H CH₃ CHF₂ CH₃ F O C₂H₅ H CH₃CHF₂ CH₃ G O C₂H₅ H CH₃ CHF₂ CH₃ H O C₂H₅ H CH₃ CHF₂ CH₃ I O C₂H₅ H CH₃CHF₂ CH₃ J O C₂H₅ H CH₃ CHF₂ CH₃ K O C₂H₅ H CH₃ CHF₂ CH₃ L O C₂H₅ H CH₃CHF₂ CH₃ M O C₂H₅ H CH₃ CHF₂ CH₃ N O C₂H₅ H CH₃ CHF₂ CH₃ O O C₂H₅ H CH₃CHF₂ CH₃ P O C₂H₅ H CH₃ CHF₂ CH₃ Q O C₂H₅ H CH₃ CHF₂ CH₃ R O C₂H₅ H CH₃CHF₂ CH₃ S O C₂H₅ H CH₃ CHF₂ CH₃ T O C₂H₅ H CH₃ CHF₂ CH₃ U O C₂H₅ H CH₃CHF₂ CH₃ V O C₂H₅ H CH₃ CHF₂ CH₃ W O C₂H₅ H CH₃ CHF₂ CH₃ X O C₂H₅ H CH₃CHF₂ CH₃ Y O C₂H₅ H CH₃ CHF₂ CH₃ A CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ B CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ C CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ D CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ ECH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ F CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ G CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ H CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ I CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ J CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ K CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ L CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ MCH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ N CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ O CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ P CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Q CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ R CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ S CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ T CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ UCH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ V CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ W CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ X CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Y CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Z CH₂ CH₃H Cl CF₃ H Z O CH₃ H Cl CF₃ H Z O C₂H₅ H Cl CF₃ H Z CH₂ CH₃ H CH₃ CF₃ HZ O CH₃ H CH₃ CF₃ H Z O C₂H₅ H CH₃ CF₃ H Z CH₂ CH₃ H Cl CHF₂ H Z O CH₃ HCl CHF₂ H Z O C₂H₅ H Cl CHF₂ H Z CH₂ CH₃ H CH₃ CHF₂ H Z O CH₃ H CH₃ CHF₂H Z O C₂H₅ H CH₃ CHF₂ H AA CH₂ CH₃ H Cl CHF₂ H EB CH₂ CH₃ H Cl CHF₂ H NO CH₃ H H CHF₂ H # Q = 1-cyclobutyl-3-methoxy-1-propyl; R =1-cyclopentyl-1-ethyl; S = 1-cyclopentyl-1-propyl; T =1-cyclopentyl-1-butyl; U = 1-cyclopentyl-3-methoxy-1-propyl; V =?-cyclopropylbenzyl; W = 1-phenyl-2-butyn-1-yl; X =1-cyclopropyl-2-butyn-1-yl; Y = dicyclopropylmethyl; Z = 2-hexyn-3-yl;AA = cyclopentyl; BB = 1-cyclopropyl-2-propyl.

[0036] Particular compounds provided herein also include those of thefollowing structure, with the substituents thereof being set forth inthe table. TABLE B

R^(1(a)) X R² R³ R^(aryl) R^(aryl2) R^(aryl3) A CH₂ CH₃ H Cl CF₃ H B CH₂CH₃ H Cl CF₃ H C CH₂ CH₃ H Cl CF₃ H D CH₂ CH₃ H Cl CF₃ H E CH₂ CH₃ H ClCF₃ H F CH₂ CH₃ H Cl CF₃ H G CH₂ CH₃ H Cl CF₃ H H CH₂ CH₃ H Cl CF₃ H ICH₂ CH₃ H Cl CF₃ H J CH₂ CH₃ H Cl CF₃ H K CH₂ CH₃ H Cl CF₃ H L CH₂ CH₃ HCl CF₃ H M CH₂ CH₃ H Cl CF₃ H N CH₂ CH₃ H Cl CF₃ H O CH₂ CH₃ H Cl CF₃ HP CH₂ CH₃ H Cl CF₃ H Q CH₂ CH₃ H Cl CF₃ H R CH₂ CH₃ H Cl CF₃ H S CH₂ CH₃H Cl CF₃ H T CH₂ CH₃ H Cl CF₃ H U CH₂ CH₃ H Cl CF₃ H V CH₂ CH₃ H Cl CF₃H W CH₂ CH₃ H Cl CF₃ H X CH₂ CH₃ H Cl CF₃ H Y CH₂ CH₃ H Cl CF₃ H A O CH₃H Cl CF₃ H B O CH₃ H Cl CF₃ H C O CH₃ H Cl CF₃ H D O CH₃ H Cl CF₃ H E OCH₃ H Cl CF₃ H F O CH₃ H Cl CF₃ H G O CH₃ H Cl CF₃ H H O CH₃ H Cl CF₃ HI O CH₃ H Cl CF₃ H J O CH₃ H Cl CF₃ H K O CH₃ H Cl CF₃ H L O CH₃ H ClCF₃ H N O CH₃ H Cl CF₃ H N O CH₃ H Cl CF₃ H O O CH₃ H Cl CF₃ H P O CH₃ HCl CF₃ H Q O CH₃ H Cl CF₃ H R O CH₃ H Cl CF₃ H S O CH₃ H Cl CF₃ H T OCH₃ H Cl CF₃ H U O CH₃ H Cl CF₃ H V O CH₃ H Cl CF₃ H W O CH₃ H Cl CF₃ HX O CH₃ H Cl CF₃ H Y O CH₃ H Cl CF₃ H A O C₂H₅ H Cl CF₃ H B O C₂H₅ H ClCF₃ H C O C₂H₅ H Cl CF₃ H D O C₂H₅ H Cl CF₃ H E O C₂H₅ H Cl CF₃ H F OC₂H₅ H Cl CF₃ H G O C₂H₅ H Cl CF₃ H H O C₂H₅ H Cl CF₃ H I O C₂H₅ H ClCF₃ H J O C₂H₅ H Cl CF₃ H K O C₂H₅ H Cl CF₃ H L O C₂H₅ H Cl CF₃ H M OC₂H₅ H Cl CF₃ H N O C₂H₅ H Cl CF₃ H O O C₂H₅ H Cl CF₃ H P O C₂H₅ H ClCF₃ H Q O C₂H₅ H Cl CF₃ H R O C₂H₅ H Cl CF₃ H S O C₂H₅ H Cl CF₃ H T OC₂H₅ H Cl CF₃ H U O C₂H₅ H Cl CF₃ H V O C₂H₅ H Cl CF₃ H W O C₂H₅ H ClCF₃ H X O C₂H₅ H Cl CF₃ H Y O C₂H₅ H Cl CF₃ H A CH₂ CH₃ CH₃ Cl CF₃ H BCH₂ CH₃ CH₃ Cl CF₃ H C CH₂ CH₃ CH₃ Cl CF₃ H D CH₂ CH₃ CH₃ Cl CF₃ H E CH₂CH₃ CH₃ Cl CF₃ H F CH₂ CH₃ CH₃ Cl CF₃ H G CH₂ CH₃ CH₃ Cl CF₃ H H CH₂ CH₃CH₃ Cl CF₃ H I CH₂ CH₃ CH₃ Cl CF₃ H J CH₂ CH₃ CH₃ Cl CF₃ H K CH₂ CH₃ CH₃Cl CF₃ H L CH₂ CH₃ CH₃ Cl CF₃ H M CH₂ CH₃ CH₃ Cl CF₃ H N CH₂ CH₃ CH₃ ClCF₃ H O CH₂ CH₃ CH₃ Cl CF₃ H P CH₂ CH₃ CH₃ Cl CF₃ H Q CH₂ CH₃ CH₃ Cl CF₃H R CH₂ CH₃ CH₃ Cl CF₃ H S CH₂ CH₃ CH₃ Cl CF₃ H T CH₂ CH₃ CH₃ Cl CF₃ H UCH₂ CH₃ CH₃ Cl CF₃ H V CH₂ CH₃ CH₃ Cl CF₃ H W CH₂ CH₃ CH₃ Cl CF₃ H X CH₂CH₃ CH₃ Cl CF₃ H Y CH₂ CH₃ CH₃ Cl CF₃ H A CH₂ CH₃ H CH₃ CF₃ H B CH₂ CH₃H CH₃ CF₃ H C CH₂ CH₃ H CH₃ CF₃ H D CH₂ CH₃ H CH₃ CF₃ H E CH₂ CH₃ H CH₃CF₃ H F CH₂ CH₃ H CH₃ CF₃ H G CH₂ CH₃ H CH₃ CF₃ H H CH₂ CH₃ H CH₃ CF₃ HI CH₂ CH₃ H CH₃ CF₃ H J CH₂ CH₃ H CH₃ CF₃ H K CH₂ CH₃ H CH₃ CF₃ H L CH₂CH₃ H CH₃ CF₃ H M CH₂ CH₃ H CH₃ CF₃ H N CH₂ CH₃ H CH₃ CF₃ H O CH₂ CH₃ HCH₃ CF₃ H P CH₂ CH₃ H CH₃ CF₃ H Q CH₂ CH₃ H CH₃ CF₃ H R CH₂ CH₃ H CH₃CF₃ H S CH₂ CH₃ H CH₃ CF₃ H T CH₂ CH₃ H CH₃ CF₃ H U CH₂ CH₃ H CH₃ CF₃ HV CH₂ CH₃ H CH₃ CF₃ H W CH₂ CH₃ H CH₃ CF₃ H X CH₂ CH₃ H CH₃ CF₃ H A OCH₃ H CH₃ CF₃ H B O CH₃ H CH₃ CF₃ H C O CH₃ H CH₃ CF₃ H D O CH₃ H CH₃CF₃ H E O CH₃ H CH₃ CF₃ H F O CH₃ H CH₃ CF₃ H G O CH₃ H CH₃ CF₃ H H OCH₃ H CH₃ CF₃ H I O CH₃ H CH₃ CF₃ H J O CH₃ H CH₃ CF₃ H K O CH₃ H CH₃CF₃ H L O CH₃ H CH₃ CF₃ H M O CH₃ H CH₃ CF₃ H N O CH₃ H CH₃ CF₃ H O OCH₃ H CH₃ CF₃ H P O CH₃ H CH₃ CF₃ H Q O CH₃ H CH₃ CF₃ H R O CH₃ H CH₃CF₃ H S O CH₃ H CH₃ CF₃ H T O CH₃ H CH₃ CF₃ H U O CH₃ H CH₃ CF₃ H V OCH₃ H CH₃ CF₃ H W O CH₃ H CH₃ CF₃ H X O CH₃ H CH₃ CF₃ H Y O CH₃ H CH₃CF₃ H A O C₂H₅ H CH₃ CF₃ H B O C₂H₅ H CH₃ CF₃ H C O C₂H₅ H CH₃ CF₃ H D OC₂H₅ H CH₃ CF₃ H E O C₂H₅ H CH₃ CF₃ H F O C₂H₅ H CH₃ CF₃ H G O C₂H₅ HCH₃ CF₃ H H O C₂H₅ H CH₃ CF₃ H I O C₂H₅ H CH₃ CF₃ H J O C₂H₅ H CH₃ CF₃ HK O C₂H₅ H CH₃ CF₃ H L O C₂H₅ H CH₃ CF₃ H M O C₂H₅ H CH₃ CF₃ H N O C₂H₅H CH₃ CF₃ H o O C₂H₅ H CH₃ CF₃ H P O C₂H₅ H CH₃ CF₃ H Q O C₂H₅ H CH₃ CF₃H R O C₂H₅ H CH₃ CF₃ H S O C₂H₅ H CH₃ CF₃ H T O C₂H₅ H CH₃ CF₃ H U OC₂H₅ H CH₃ CF₃ H V O C₂H₅ H CH₃ CF₃ H W O C₂H₅ H CH₃ CF₃ H X O C₂H₅ HCH₃ CF₃ H Y O C₂H₅ H CH₃ CF₃ H A CH₂ CH₃ CH₃ CH₃ CF₃ H B CH₂ CH₃ CH₃ CH₃CF₃ H C CH₂ CH₃ CH₃ CH₃ CF₃ H D CH₂ CH₃ CH₃ CH₃ CF₃ H E CH₂ CH₃ CH₃ CH₃CF₃ H F CH₂ CH₃ CH₃ CH₃ CF₃ H G CH₂ CH₃ CH₃ CH₃ CF₃ H H CH₂ CH₃ CH₃ CH₃CF₃ H I CH₂ CH₃ CH₃ CH₃ CF₃ H J CH₂ CH₃ CH₃ CH₃ CF₃ H K CH₂ CH₃ CH₃ CH₃CF₃ H L CH₂ CH₃ CH₃ CH₃ CF₃ H H CH₂ CH₃ CH₃ CH₃ CF₃ H N CH₂ CH₃ CH₃ CH₃CF₃ H O CH₂ CH₃ CH₃ CH₃ CF₃ H P CH₂ CH₃ CH₃ CH₃ CF₃ H Q CH₂ CH₃ CH₃ CH₃CF₃ H R CH₂ CH₃ CH₃ CH₃ CF₃ H S CH₂ CH₃ CH₃ CH₃ CF₃ H T CH₂ CH₃ CH₃ CH₃CF₃ H U CH₂ CH₃ CH₃ CH₃ CF₃ H V CH₂ CH₃ CH₃ CH₃ CF₃ H W CH₂ CH₃ CH₃ CH₃CF₃ H X CH₂ CH₃ CH₃ CH₃ CF₃ H Y CH₂ CH₃ CH₃ CH₃ CF₃ H A CH₂ CH₃ H ClCHF₂ H B CH₂ CH₃ H Cl CHF₂ H C CH₂ CH₃ H Cl CHF₂ H D CH₂ CH₃ H Cl CHF₂ HE CH₂ CH₃ H Cl CHF₂ H F CH₂ CH₃ H Cl CHF₂ H G CH₂ CH₃ H Cl CHF₂ H H CH₂CH₃ H Cl CHF₂ H I CH₂ CH₃ H Cl CHF₂ H J CH₂ CH₃ H Cl CHF₂ H K CH₂ CH₃ HCl CHF₂ H L CH₂ CH₃ H Cl CHF₂ H M CH₂ CH₃ H Cl CHF₂ H N CH₂ CH₃ H ClCHF₂ H O CH₂ CH₃ H Cl CHF₂ H P CH₂ CH₃ H Cl CHF₂ H Q CH₂ CH₃ H Cl CHF₂ HR CH₂ CH₃ H Cl CHF₂ H S CH₂ CH₃ H Cl CHF₂ H T CH₂ CH₃ H Cl CHF₂ H U CH₂CH₃ H Cl CHF₂ H V CH₂ CH₃ H Cl CHF₂ H W CH₂ CH₃ H Cl CHF₂ H X CH₂ CH₃ HCl CHF₂ H Y CH₂ CH₃ H Cl CHF₂ H A O CH₃ H Cl CHF₂ H B O CH₃ H Cl CHF₂ HC O CH₃ H Cl CHF₂ H D O CH₃ H Cl CHF₂ H E O CH₃ H Cl CHF₂ H F O CH₃ H ClCHF₂ H G O CH₃ H Cl CHF₂ H H O CH₃ H Cl CHF₂ H I O CH₃ H Cl CHF₂ H J OCH₃ H Cl CHF₂ H K O CH₃ H Cl CHF₂ H L O CH₃ H Cl CHF₂ H M O CH₃ H ClCHF₂ H N O CH₃ H Cl CHF₂ H O O CH₃ H Cl CHF₂ H P O CH₃ H Cl CHF₂ H Q OCH₃ H Cl CHF₂ H R O CH₃ H Cl CHF₂ H S O CH₃ H Cl CHF₂ H T O CH₃ H ClCHF₂ H U O CH₃ H Cl CHF₂ H V O CH₃ H Cl CHF₂ H W O CH₃ H Cl CHF₂ H X OCH₃ H Cl CHF₂ H Y O CH₃ H Cl CHF₂ H A O C₂H₅ H Cl CHF₂ H B O C₂H₅ H ClCHF₂ H C O C₂H₅ H Cl CHF₂ H D O C₂H₅ H Cl CHF₂ H E O C₂H₅ H Cl CHF₂ H FO C₂H₅ H Cl CHF₂ H G O C₂H₅ H Cl CHF₂ H H O C₂H₅ H Cl CHF₂ H I O C₂H₅ HCl CHF₂ H J O C₂H₅ H Cl CHF₂ H K O C₂H₅ H Cl CHF₂ H L O C₂H₅ H Cl CHF₂ HM O C₂H₅ H Cl CHF₂ H N O C₂H₅ H Cl CHF₂ H O O C₂H₅ H Cl CHF₂ H P O C₂H₅H Cl CHF₂ H Q O C₂H₅ H Cl CHF₂ H R O C₂H₅ H Cl CHF₂ H S O C₂H₅ H Cl CHF₂H T O C₂H₅ H Cl CHF₂ H U O C₂H₅ H Cl CHF₂ H V O C₂H₅ H Cl CHF₂ H W OC₂H₅ H Cl CHF₂ H X O C₂H₅ H Cl CHF₂ H Y O C₂H₅ H Cl CHF₂ H A CH₂ CH₃ CH₃Cl CHF₂ H B CH₂ CH₃ CH₃ Cl CHF₂ H C CH₂ CH₃ CH₃ Cl CHF₂ H D CH₂ CH₃ CH₃Cl CHF₂ H E CH₂ CH₃ CH₃ Cl CHF₂ H F CH₂ CH₃ CH₃ Cl CHF₂ H G CH₂ CH₃ CH₃Cl CHF₂ H H CH₂ CH₃ CH₃ Cl CHF₂ H I CH₂ CH₃ CH₃ Cl CHF₂ H J CH₂ CH₃ CH₃Cl CHF₂ H K CH₂ CH₃ CH₃ Cl CHF₂ H L CH₂ CH₃ CH₃ Cl CHF₂ H M CH₂ CH₃ CH₃Cl CHF₂ H N CH₂ CH₃ CH₃ Cl CHF₂ H O CH₂ CH₃ CH₃ Cl CHF₂ H P CH₂ CH₃ CH₃Cl CHF₂ H Q CH₂ CH₃ CH₃ Cl CHF₂ H H CH₂ CH₃ CH₃ Cl CHF₂ H S CH₂ CH₃ CH₃Cl CHF₂ H T CH₂ CH₃ CH₃ Cl CHF₂ H U CH₂ CH₃ CH₃ Cl CHF₂ H V CH₂ CH₃ CH₃Cl CHF₂ H W CH₂ CH₃ CH₃ Cl CHF₂ H X CH₂ CH₃ CH₃ Cl CHF₂ H Y CH₂ CH₃ CH₃Cl CHF₂ H A CH₂ CH₃ H CH₃ CHF₂ H B CH₂ CH₃ H CH₃ CHF₂ H C CH₂ CH₃ H CH₃CHF₂ H D CH₂ CH₃ H CH₃ CHF₂ H E CH₂ CH₃ H CH₃ CHF₂ H F CH₂ CH₃ H CH₃CHF₂ H G CH₂ CH₃ H CH₃ CHF₂ H H CH₂ CH₃ H CH₃ CHF₂ H I CH₂ CH₃ H CH₃CHF₂ H J CH₂ CH₃ H CH₃ CHF₂ H K CH₂ CH₃ H CH₃ CHF₂ H L CH₂ CH₃ H CH₃CHF₂ H M CH₂ CH₃ H CH₃ CHF₂ H N CH₂ CH₃ H CH₃ CHF₂ H O CH₂ CH₃ H CH₃CHF₂ R P CH₂ CH₃ H CH₃ CHF₂ H Q CH₂ CH₃ H CH₃ CHF₂ H R CH₂ CH₃ H CH₃CHF₂ H S CH₂ CH₃ H CH₃ CHF₂ H T CH₂ CH₃ H CH₃ CHF₂ R U CH₂ CH₃ H CH₃CHF₂ H V CH₂ CH₃ H CH₃ CHF₂ H W CH₂ CH₃ H CH₃ CHF₂ R X CH₂ CH₃ H CH₃CHF₂ H Y CH₂ CH₃ H CH₃ CHF₂ H A O CH₃ H CH₃ CHF₂ H B O CH₃ H CH₃ CHF₂ RC O CH₃ H CH₃ CHF₂ H D O CH₃ H CH₃ CHF₂ R F O CH₃ H CH₃ CHF₂ R F O CH₃ HCH₃ CHF₂ H G O CH₃ H CH₃ CHF₂ H H O CH₃ H CH₃ CHF₂ H I O CH₃ H CH₃ CHF₂H J O CH₃ H CH₃ CHF₂ H K O CH₃ H CH₃ CHF₂ H L O CH₃ H CH₃ CHF₂ H M O CH₃H CH₃ CHF₂ H N O CH₃ H CH₃ CHF₂ H O O CH₃ H CH₃ CHF₂ H P O CH₃ H CH₃CHF₂ H Q O CH₃ H CH₃ CHF₂ H R O CH₃ H CH₃ CHF₂ H S O CH₃ H CH₃ CHF₂ H TO CH₃ H CH₃ CHF₂ H U O CH₃ H CH₃ CHF₂ H V O CH₃ H CH₃ CHF₂ H W O CH₃ HCH₃ CHF₂ H X O CH₃ H CH₃ CHF₂ H Y O CH₃ H CH₃ CHF₂ H A O C₂H₅ H CH₃ CHF₂H B O C₂H₅ H CH₃ CHF₂ H C O C₂H₅ H CH₃ CHF₂ H D O C₂H₅ H CH₃ CHF₂ H E OC₂H₅ H CH₃ CHF₂ H F O C₂H₅ H CH₃ CHF₂ H G O C₂H₅ H CH₃ CHF₂ H H O C₂H₅ HCH₃ CHF₂ H I O C₂H₅ H CH₃ CHF₂ H J O C₂H₅ H CH₃ CHF₂ H K O C₂H₅ H CH₃CHF₂ H L O C₂H₅ H CH₃ CHF₂ H M O C₂H₅ H CH₃ CHF₂ H N O C₂H₅ H CH₃ CHF₂ HO O C₂H₅ H CH₃ CHF₂ H P O C₂H₅ H CH₃ CHF₂ H Q O C₂H₅ H CH₃ CHF₂ H R OC₂H₅ H CH₃ CHF₂ H S O C₂H₅ H CH₃ CHF₂ H T O C₂H₅ H CH₃ CHF₂ H U O C₂H₅ HCH₃ CHF₂ H V O C₂H₅ H CH₃ CHF₂ H W O C₂H₅ H CH₃ CHF₂ H X O C₂H₅ H CH₃CHF₂ H Y O C₂H₅ H CH₃ CHF₂ H A CH₂ CH₃ CH₃ CH₃ CHF₂ H B CH₂ CH₃ CH₃ CH₃CHF₂ H C CH₂ CH₃ CH₃ CH₃ CHF₂ H D CH₂ CH₃ CH₃ CH₃ CHF₂ H E CH₂ CH₃ CH₃CH₃ CHF₂ H F CH₂ CH₃ CH₃ CH₃ CHF₂ H G CH₂ CH₃ CH₃ CH₃ CHF₂ H H CH₂ CH₃CH₃ CH₃ CHF₂ H I CH₂ CH₃ CH₃ CH₃ CHF₂ H J CH₂ CH₃ CH₃ CH₃ CHF₂ H K CH₂CH₃ CH₃ CH₃ CHF₂ H L CH₂ CH₃ CH₃ CH₃ CHF₂ H M CH₂ CH₃ CH₃ CH₃ CHF₂ H NCH₂ CH₃ CH₃ CH₃ CHF₂ H O CH₂ CH₃ CH₃ CH₃ CHF₂ H P CH₂ CH₃ CH₃ CH₃ CHF₂ HQ CH₂ CH₃ CH₃ CH₃ CHF₂ H R CH₂ CH₃ CH₃ CH₃ CHF₂ H S CH₂ CH₃ CH₃ CH₃ CHF₂H T CH₂ CH₃ CH₃ CH₃ CHF₂ H U CH₂ CH₃ CH₃ CH₃ CHF₂ H V CH₂ CH₃ CH₃ CH₃CHF₂ H W CH₂ CH₃ CH₃ CH₃ CHF₂ H X CH₂ CH₃ CH₃ CH₃ CHF₂ H Y CH₂ CH₃ CH₃CH₃ CHF₂ H A CH₂ CH₃ H Cl CF₃ CH₃ B CH₂ CH₃ H Cl CF₃ CH₃ C CH₂ CH₃ H ClCF₃ CH₃ D CH₂ CH₃ H Cl CF₃ CH₃ E CH₂ CH₃ H Cl CF₃ CH₃ F CH₂ CH₃ H Cl CF₃CH₃ G CH₂ CH₃ H Cl CF₃ CH₃ H CH₂ CH₃ H Cl CF₃ CH₃ I CH₂ CH₃ H Cl CF₃ CH₃J CH₂ CH₃ H Cl CF₃ CH₃ K CH₂ CH₃ H Cl CF₃ CH₃ L CH₂ CH₃ H Cl CF₃ CH₃ MCH₂ CH₃ H Cl CF₃ CH₃ N CH₂ CH₃ H Cl CF₃ CH₃ O CH₂ CH₃ H Cl CF₃ CH₃ P CH₂CH₃ H Cl CF₃ CH₃ Q CH₂ CH₃ H Cl CF₃ CH₃ R CH₂ CH₃ H Cl CF₃ CH₃ S CH₂ CH₃H Cl CF₃ CH₃ T CH₂ CH₃ H Cl CF₃ CH₃ U CH₂ CH₃ H Cl CF₃ CH₃ V CH₂ CH₃ HCl CF₃ CH₃ W CH₂ CH₃ H Cl CF₃ CH₃ X CH₂ CH₃ H Cl CF₃ CH₃ Y CH₂ CH₃ H ClCF₃ CH₃ A O CH₃ H Cl CF₃ CH₃ B O CH₃ H Cl CF₃ CH₃ C O CH₃ H Cl CF₃ CH₃ DO CH₃ H Cl CF₃ CH₃ E O CH₃ H Cl CF₃ CH₃ F O CH₃ H Cl CF₃ CH₃ G O CH₃ HCl CF₃ CH₃ H O CH₃ H Cl CF₃ CH₃ I O CH₃ H Cl CF₃ CH₃ J O CH₃ H Cl CF₃CH₃ K O CH₃ H Cl CF₃ CH₃ L O CH₃ H Cl CF₃ CH₃ M O CH₃ H Cl CF₃ CH₃ N OCH₃ H Cl CF₃ CH₃ O O CH₃ H Cl CF₃ CH₃ P O CH₃ H Cl CF₃ CH₃ Q O CH₃ H ClCF₃ CH₃ R O CH₃ H Cl CF₃ CH₃ S O CH₃ H Cl CF₃ CH₃ T O CH₃ H Cl CF₃ CH₃ UO CH₃ H Cl CF₃ CH₃ V O CH₃ H Cl CF₃ CH₃ W O CH₃ H Cl CF₃ CH₃ X O CH₃ HCl CF₃ CH₃ Y O CH₃ H Cl CF₃ CH₃ A O C₂H₅ H Cl CF₃ CH₃ B O C₂H₅ H Cl CF₃CH₃ C O C₂H₅ H Cl CF₃ CH₃ D O C₂H₅ H Cl CF₃ CH₃ E O C₂H₅ H Cl CF₃ CH₃ FO C₂H₅ H Cl CF₃ CH₃ G O C₂H₅ H Cl CF₃ CH₃ H O C₂H₅ H Cl CF₃ CH₃ I O C₂H₅H Cl CF₃ CH₃ J O C₂H₅ H Cl CF₃ CH₃ K O C₂H₅ H Cl CF₃ CH₃ L O C₂H₅ H ClCF₃ CH₃ M O C₂H₅ H Cl CF₃ CH₃ N O C₂H₅ H Cl CF₃ CH₃ O O C₂H₅ H Cl CF₃CH₃ P O C₂H₅ H Cl CF₃ CH₃ Q O C₂H₅ H Cl CF₃ CH₃ R O C₂H₅ H Cl CF₃ CH₃ SO C₂H₅ H Cl CF₃ CH₃ T O C₂H₅ H Cl CF₃ CH₃ U O C₂H₅ H Cl CF₃ CH₃ V O C₂H₅H Cl CF₃ CH₃ W O C₂H₅ H Cl CF₃ CH₃ X O C₂H₅ H Cl CF₃ CH₃ Y O C₂H₅ H ClCF₃ CH₃ A CH₂ CH₃ CH₃ Cl CF₃ CH₃ B CH₂ CH₃ CH₃ Cl CF₃ CH₃ C CH₂ CH₃ CH₃Cl CF₃ CH₃ D CH₂ CH₃ CH₃ Cl CF₃ CH₃ E CH₂ CH₃ CH₃ Cl CF₃ CH₃ F CH₂ CH₃CH₃ Cl CF₃ CH₃ G CH₂ CH₃ CH₃ Cl CF₃ CH₃ H CH₂ CH₃ CH₃ Cl CF₃ CH₃ I CH₂CH₃ CH₃ Cl CF₃ CH₃ J CH₂ CH₃ CH₃ Cl CF₃ CH₃ K CH₂ CH₃ CH₃ Cl CF₃ CH₃ LCH₂ CH₃ CH₃ Cl CF₃ CH₃ M CH₂ CH₃ CH₃ Cl CF₃ CH₃ N CH₂ CH₃ CH₃ Cl CF₃ CH₃O CH₂ CH₃ CH₃ Cl CF₃ CH₃ P CH₂ CH₃ CH₃ Cl CF₃ CH₃ Q CH₂ CH₃ CH₃ Cl CF₃CH₃ R CH₂ CH₃ CH₃ Cl CF₃ CH₃ S CH₂ CH₃ CH₃ Cl CF₃ CH₃ T CH₂ CH₃ CH₃ ClCF₃ CH₃ U CH₂ CH₃ CH₃ Cl CF₃ CH₃ V CH₂ CH₃ CH₃ Cl CF₃ CH₃ W CH₂ CH₃ CH₃Cl CF₃ CH₃ X CH₂ CH₃ CH₃ Cl CF₃ CH₃ Y CH₂ CH₃ CH₃ Cl CF₃ CH₃ A CH₂ CH₃ HCH₃ CF₃ CH₃ B CH₂ CH₃ H CH₃ CF₃ CH₃ C CH₂ CH₃ H CH₃ CF₃ CH₃ D CH₂ CH₃ HCH₃ CF₃ CH₃ E CH₂ CH₃ H CH₃ CF₃ CH₃ F CH₂ CH₃ H CH₃ CF₃ CH₃ G CH₂ CH₃ HCH₃ CF₃ CH₃ H CH₂ CH₃ H CH₃ CF₃ CH₃ I CH₂ CH₃ H CH₃ CF₃ CH₃ J CH₂ CH₃ HCH₃ CF₃ CH₃ K CH₂ CH₃ H CH₃ CF₃ CH₃ L CH₂ CH₃ H CH₃ CF₃ CH₃ M CH₂ CH₃ HCH₃ CF₃ CH₃ N CH₂ CH₃ H CH₃ CF₃ CH₃ O CH₂ CH₃ H CH₃ CF₃ CH₃ P CH₂ CH₃ HCH₃ CF₃ CH₃ Q CH₂ CH₃ H CH₃ CF₃ CH₃ R CH₂ CH₃ H CH₃ CF₃ CH₃ S CH₂ CH₃ HCH₃ CF₃ CH₃ T CH₂ CH₃ H CH₃ CF₃ CH₃ U CH₂ CH₃ H CH₃ CF₃ CH₃ V CH₂ CH₃ HCH₃ CF₃ CH₃ W CH₂ CH₃ H CH₃ CF₃ CH₃ X CH₂ CH₃ H CH₃ CF₃ CH₃ Y CH₂ CH₃ HCH₃ CF₃ CH₃ A O CH₃ H CH₃ CF₃ CH₃ B O CH₃ H CH₃ CF₃ CH₃ C O CH₃ H CH₃CF₃ CH₃ D O CH₃ H CH₃ CF₃ CH₃ E O CH₃ H CH₃ CF₃ CH₃ F O CH₃ H CH₃ CF₃CH₃ G O CH₃ H CH₃ CF₃ CH₃ H O CH₃ H CH₃ CF₃ CH₃ I O CH₃ H CH₃ CF₃ CH₃ JO CH₃ H CH₃ CF₃ CH₃ K O CH₃ H CH₃ CF₃ CH₃ L O CH₃ H CH₃ CF₃ CH₃ M O CH₃H CH₃ CF₃ CH₃ N O CH₃ H CH₃ CF₃ CH₃ O O CH₃ H CH₃ CF₃ CH₃ P O CH₃ H CH₃CF₃ CH₃ Q O CH₃ H CH₃ CF₃ CH₃ R O CH₃ H CH₃ CF₃ CH₃ S O CH₃ H CH₃ CF₃CH₃ T O CH₃ H CH₃ CF₃ CH₃ U O CH₃ H CH₃ CF₃ CH₃ V O CH₃ H CH₃ CF₃ CH₃ WO CH₃ H CH₃ CF₃ CH₃ X O CH₃ H CH₃ CF₃ CH₃ Y O CH₃ H CH₃ CF₃ CH₃ A O C₂H₅H CH₃ CF₃ CH₃ B O C₂H₅ H CH₃ CF₃ CH₃ C O C₂H₅ H CH₃ CF₃ CH₃ D O C₂H₅ HCH₃ CF₃ CH₃ E O C₂H₅ H CH₃ CF₃ CH₃ F O C₂H₅ H CH₃ CF₃ CH₃ G O C₂H₅ H CH₃CF₃ CH₃ H O C₂H₅ H CH₃ CF₃ CH₃ I O C₂H₅ H CH₃ CF₃ CH₃ J O C₂H₅ H CH₃ CF₃CH₃ K O C₂H₅ H CH₃ CF₃ CH₃ L O C₂H₅ H CH₃ CF₃ CH₃ M O C₂H₅ H CH₃ CF₃ CH₃N O C₂H₅ H CH₃ CF₃ CH₃ O O C₂H₅ H CH₃ CF₃ CH₃ P O C₂H₅ H CH₃ CF₃ CH₃ Q OC₂H₅ H CH₃ CF₃ CH₃ R O C₂H₅ H CH₃ CF₃ CH₃ S O C₂H₅ H CH₃ CF₃ CH₃ T OC₂H₅ H CH₃ CF₃ CH₃ U O C₂H₅ H CH₃ CF₃ CH₃ V O C₂H₅ H CH₃ CF₃ CH₃ W OC₂H₅ H CH₃ CF₃ CH₃ X O C₂H₅ H CH₃ CF₃ CH₃ Y O C₂H₅ H CH₃ CF₃ CH₃ A CH₂CH₃ CH₃ CH₃ CF₃ CH₃ B CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ C CH₂ CH₃ CH₃ CH₃ CF₃ CH₃D CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ E CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ F CH₂ CH₃ CH₃ CH₃CF₃ CH₃ G CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ H CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ I CH₂ CH₃CH₃ CH₃ CF₃ CH₃ J CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ K CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ LCH₂ CH₃ CH₃ CH₃ CF₃ CH₃ M CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ N CH₂ CH₃ CH₃ CH₃ CF₃CH₃ O CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ P CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ Q CH₂ CH₃ CH₃CH₃ CF₃ CH₃ R CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ S CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ T CH₂CH₃ CH₃ CH₃ CF₃ CH₃ U CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ V CH₂ CH₃ CH₃ CH₃ CF₃ CH₃W CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ X CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ Y CH₂ CH₃ CH₃ CH₃CF₃ CH₃ A CH₂ CH₃ H Cl CHF₂ CH₃ B CH₂ CH₃ H Cl CHF₂ CH₃ C CH₂ CH₃ H ClCHF₂ CH₃ D CH₂ CH₃ H Cl CHF₂ CH₃ E CH₂ CH₃ H Cl CHF₂ CH₃ F CH₂ CH₃ H ClCHF₂ CH₃ G CH₂ CH₃ H Cl CHF₂ CH₃ H CH₂ CH₃ H Cl CHF₂ CH₃ I CH₂ CH₃ H ClCHF₂ CH₃ J CH₂ CH₃ H Cl CHF₂ CH₃ K CH₂ CH₃ H Cl CHF₂ CH₃ L CH₂ CH₃ H ClCHF₂ CH₃ M CH₂ CH₃ H Cl CHF₂ CH₃ N CH₂ CH₃ H Cl CHF₂ CH₃ O CH₂ CH₃ H ClCHF₂ CH₃ P CH₂ CH₃ H Cl CHF₂ CH₃ Q CH₂ CH₃ H Cl CHF₂ CH₃ R CH₂ CH₃ H ClCHF₂ CH₃ S CH₂ CH₃ H Cl CHF₂ CH₃ T CH₂ CH₃ H Cl CHF₂ CH₃ U CH₂ CH₃ H ClCHF₂ CH₃ V CH₂ CH₃ H Cl CHF₂ CH₃ W CH₂ CH₃ H Cl CHF₂ CH₃ X CH₂ CH₃ H ClCHF₂ CH₃ Y CH₂ CH₃ H Cl CHF₂ CH₃ A O CH₃ H Cl CHF₂ CH₃ B O CH₃ H Cl CHF₂CH₃ C O CH₃ H Cl CHF₂ CH₃ D O CH₃ H Cl CHF₂ CH₃ E O CH₃ H Cl CHF₂ CH₃ FO CH₃ H Cl CHF₂ CH₃ G O CH₃ H Cl CHF₂ CH₃ H O CH₃ H Cl CHF₂ CH₃ I O CH₃H Cl CHF₂ CH₃ J O CH₃ H Cl CHF₂ CH₃ K O CH₃ H Cl CHF₂ CH₃ L O CH₃ H ClCHF₂ CH₃ M O CH₃ H Cl CHF₂ CH₃ N O CH₃ H Cl CHF₂ CH₃ O O CH₃ H Cl CHF₂CH₃ P O CH₃ H Cl CHF₂ CH₃ Q O CH₃ H Cl CHF₂ CH₃ R O CH₃ H Cl CHF₂ CH₃ SO CH₃ H Cl CHF₂ CH₃ T O CH₃ H Cl CHF₂ CH₃ U O CH₃ H Cl CHF₂ CH₃ V O CH₃H Cl CHF₂ CH₃ W O CH₃ H Cl CHF₂ CH₃ X O CH₃ H Cl CHF₂ CH₃ Y O CH₃ H ClCHF₂ CH₃ A O C₂H₅ H Cl CHF₂ CH₃ B O C₂H₅ H Cl CHF₂ CH₃ C O C₂H₅ H ClCHF₂ CH₃ D O C₂H₅ H Cl CHF₂ CH₃ E O C₂H₅ H Cl CHF₂ CH₃ F O C₂H₅ H ClCHF₂ CH₃ G O C₂H₅ H Cl CHF₂ CH₃ H O C₂H₅ H Cl CHF₂ CH₃ I O C₂H₅ H ClCHF₂ CH₃ J O C₂H₅ H Cl CHF₂ CH₃ K O C₂H₅ H Cl CHF₂ CH₃ L O C₂H₅ H ClCHF₂ CH₃ M O C₂H₅ H Cl CHF₂ CH₃ N O C₂H₅ H Cl CHF₂ CH₃ O O C₂H₅ H ClCHF₂ CH₃ P O C₂H₅ H Cl CHF₂ CH₃ Q O C₂H₅ H Cl CHF₂ CH₃ R O C₂H₅ H ClCHF₂ CH₃ S O C₂H₅ H Cl CHF₂ CH₃ T O C₂H₅ H Cl CHF₂ CH₃ U O C₂H₅ H ClCHF₂ CH₃ V O C₂H₅ H Cl CHF₂ CH₃ W O C₂H₅ H Cl CHF₂ CH₃ X O C₂H₅ H ClCHF₂ CH₃ Y O C₂H₅ H Cl CHF₂ CH₃ A CH₂ CH₃ CH₃ Cl CHF₂ CH₃ B CH₂ CH₃ CH₃Cl CHF₂ CH₃ O CH₂ CH₃ CH₃ Cl CHF₂ CH₃ D CH₂ CH₃ CH₃ Cl CHF₂ CH₃ E CH₂CH₃ CH₃ Cl CHF₂ CH₃ F CH₂ CH₃ CH₃ Cl CHF₂ CH₃ G CH₂ CH₃ CH₃ Cl CHF₂ CH₃H CH₂ CH₃ CH₃ Cl CHF₂ CH₃ I CH₂ CH₃ CH₃ Cl CHF₂ CH₃ J CH₂ CH₃ CH₃ ClCHF₂ CH₃ K CH₂ CH₃ CH₃ Cl CHF₂ CH₃ L CH₂ CH₃ CH₃ Cl CHF₂ CH₃ M CH₂ CH₃CH₃ Cl CHF₂ CH₃ N CH₂ CH₃ CH₃ Cl CHF₂ CH₃ O CH₂ CH₃ CH₃ Cl CHF₂ CH₃ PCH₂ CH₃ CH₃ Cl CHF₂ CH₃ Q CH₂ CH₃ CH₃ Cl CHF₂ CH₃ R CH₂ CH₃ CH₃ Cl CHF₂CH₃ S CH₂ CH₃ CH₃ Cl CHF₂ CH₃ T CH₂ CH₃ CH₃ Cl CHF₂ CH₃ U CH₂ CH₃ CH₃ ClCHF₂ CH₃ V CH₂ CH₃ CH₃ Cl CHF₂ CH₃ W CH₂ CH₃ CH₃ Cl CHF₂ CH₃ X CH₂ CH₃CH₃ Cl CHF₂ CH₃ Y CH₂ CH₃ CH₃ Cl CHF₂ CH₃ A CH₂ CH₃ H CH₃ CHF₂ CH₃ B CH₂CH₃ H CH₃ CHF₂ CH₃ C CH₂ CH₃ H CH₃ CHF₂ CH₃ D CH₂ CH₃ H CH₃ CHF₂ CH₃ ECH₂ CH₃ H CH₃ CHF₂ CH₃ F CH₂ CH₃ H CH₃ CHF₂ CH₃ G CH₂ CH₃ H CH₃ CHF₂ CH₃H CH₂ CH₃ H CH₃ CHF₂ CH₃ I CH₂ CH₃ H CH₃ CHF₂ CH₃ J CH₂ CH₃ H CH₃ CHF₂CH₃ K CH₂ CH₃ H CH₃ CHF₂ CH₃ L CH₂ CH₃ H CH₃ CHF₂ CH₃ M CH₂ CH₃ H CH₃CHF₂ CH₃ N CH₂ CH₃ H CH₃ CHF₂ CH₃ O CH₂ CH₃ H CH₃ CHF₂ CH₃ P CH₂ CH₃ HCH₃ CHF₂ CH₃ Q CH₂ CH₃ H CH₃ CHF₂ CH₃ R CH₂ CH₃ H CH₃ CHF₂ CH₃ S CH₂ CH₃H CH₃ CHF₂ CH₃ T CH₂ CH₃ H CH₃ CHF₂ CH₃ U CH₂ CH₃ H CH₃ CHF₂ CH₃ V CH₂CH₃ H CH₃ CHF₂ CH₃ W CH₂ CH₃ H CH₃ CHF₂ CH₃ X CH₂ CH₃ H CH₃ CHF₂ CH₃ YCH₂ CH₃ H CH₃ CHF₂ CH₃ A O CH₃ H CH₃ CHF₂ CH₃ B O CH₃ H CH₃ CHF₂ CH₃ C OCH₃ H CH₃ CHF₂ CH₃ D O CH₃ H CH₃ CHF₂ CH₃ E O CH₃ H CH₃ CHF₂ CH₃ F O CH₃H CH₃ CHF₂ CH₃ G O CH₃ H CH₃ CHF₂ CH₃ H O CH₃ H CH₃ CHF₂ CH₃ I O CH₃ HCH₃ CHF₂ CH₃ J O CH₃ H CH₃ CHF₂ CH₃ K O CH₃ H CH₃ CHF₂ CH₃ L O CH₃ H CH₃CHF₂ CH₃ M O CH₃ H CH₃ CHF₂ CH₃ N O CH₃ H CH₃ CHF₂ CH₃ O O CH₃ H CH₃CHF₂ CH₃ P O CH₃ H CH₃ CHF₂ CH₃ Q O CH₃ H CH₃ CHF₂ CH₃ R O CH₃ H CH₃CHF₂ CH₃ S O CH₃ H CH₃ CHF₂ CH₃ T O CH₃ H CH₃ CHF₂ CH₃ U O CH₃ H CH₃CHF₂ CH₃ V O CH₃ H CH₃ CHF₂ CH₃ W O CH₃ H CH₃ CHF₂ CH₃ X O CH₃ H CH₃CHF₂ CH₃ Y O CH₃ H CH₃ CHF₂ CH₃ A O C₂H₅ H CH₃ CHF₂ CH₃ B O C₂H₅ H CH₃CHF₂ CH₃ O O C₂H₅ H CH₃ CHF₂ CH₃ D O C₂H₅ H CH₃ CHF₂ CH₃ E O C₂H₅ H CH₃CHF₂ CH₃ F O C₂H₅ H CH₃ CHF₂ CH₃ G O C₂H₅ H CH₃ CHF₂ CH₃ H O C₂H₅ H CH₃CHF₂ CH₃ I O C₂H₅ H CH₃ CHF₂ CH₃ J O C₂H₅ H CH₃ CHF₂ CH₃ K O C₂H₅ H CH₃CHF₂ CH₃ L O C₂H₅ H CH₃ CHF₂ CH₃ M O C₂H₅ H CH₃ CHF₂ CH₃ N O C₂H₅ H CH₃CHF₂ CH₃ O O C₂H₅ H CH₃ CHF₂ CH₃ P O C₂H₅ H CH₃ CHF₂ CH₃ Q O C₂H₅ H CH₃CHF₂ CH₃ R O C₂H₅ H CH₃ CHF₂ CH₃ S O C₂H₅ H CH₃ CHF₂ CH₃ T O C₂H₅ H CH₃CHF₂ CH₃ U O C₂H₅ H CH₃ CHF₂ CH₃ V O C₂H₅ H CH₃ CHF₂ CH₃ W O C₂H₅ H CH₃CHF₂ CH₃ X O C₂H₅ H CH₃ CHF₂ CH₃ Y O C₂H₅ H CH₃ CHF₂ CH₃ A CH₂ CH₃ CH₃CH₃ CHF₂ CH₃ B CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ C CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ D CH₂CH₃ CH₃ CH₃ CHF₂ CH₃ E CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ F CH₂ CH₃ CH₃ CH₃ CHF₂CH₃ G CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ H CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ I CH₂ CH₃ CH₃CH₃ CHF₂ CH₃ J CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ K CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ L CH₂CH₃ CH₃ CH₃ CHF₂ CH₃ M CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ N CH₂ CH₃ CH₃ CH₃ CHF₂CH₃ O CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ P CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Q CH₂ CH₃ CH₃CH₃ CHF₂ CH₃ R CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ S CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ T CH₂CH₃ CH₃ CH₃ CHF₂ CH₃ U CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ V CH₂ CH₃ CH₃ CH₃ CHF₂CH₃ W CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ X CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Y CH₂ CH₃ CH₃CH₃ CHF₂ CH₃

[0037] Particular compounds provided herein further include those havingthe following structure, with the substituents thereof being set forthin Table C, below. TABLE C

R^(1(a)) X R² R³ R^(aryl) R^(aryl2) R^(aryl3) A CH₂ CH₃ H Cl CF₃ H B CH₂CH₃ H Cl CF₃ H C CH₂ CH₃ H Cl CF₃ H D CH₂ CH₃ H Cl CF₃ H E CH₂ CH₃ H ClCF₃ H F CH₂ CH₃ H Cl CF₃ H G CH₂ CH₃ H Cl CF₃ H H CH₂ CH₃ H Cl CF₃ H ICH₂ CH₃ H Cl CF₃ H J CH₂ CH₃ H Cl CF₃ H K CH₂ CH₃ H Cl CF₃ H L CH₂ CH₃ HCl CF₃ H M CH₂ CH₃ H Cl CF₃ H N CH₂ CH₃ H Cl CF₃ H O CH₂ CH₃ H Cl CF₃ HP CH₂ CH₃ H Cl CF₃ H Q CH₂ CH₃ H Cl CF₃ H R CH₂ CH₃ H Cl CF₃ H S CH₂ CH₃H Cl CF₃ H T CH₂ CH₃ H Cl CF₃ H U CH₂ CH₃ H Cl CF₃ H V CH₂ CH₃ H Cl CF₃H W CH₂ CH₃ H Cl CF₃ H X CH₂ CH₃ H Cl CF₃ H Y CH₂ CH₃ H Cl CF₃ H A O CH₃H Cl CF₃ H B O CH₃ H Cl CF₃ H C O CH₃ H Cl CF₃ H D O CH₃ H Cl CF₃ H E OCH₃ H Cl CF₃ H F O CH₃ H Cl CF₃ H G O CH₃ H Cl CF₃ H H O CH₃ H Cl CF₃ HI O CH₃ H Cl CF₃ H J O CH₃ H Cl CF₃ H K O CH₃ H Cl CF₃ H L O CH₃ H ClCF₃ H M O CH₃ H Cl CF₃ H N O CH₃ H Cl CF₃ H O O CH₃ H Cl CF₃ H P O CH₃ HCl CF₃ H Q O CH₃ H Cl CF₃ H R O CH₃ H Cl CF₃ H S O CH₃ H Cl CF₃ H T OCH₃ H Cl CF₃ H U O CH₃ H Cl CF₃ H V O CH₃ H Cl CF₃ H W O CH₃ H Cl CF₃ HX O CH₃ H Cl CF₃ H Y O CH₃ H Cl CF₃ H A O C₂H₅ H Cl CF₃ H B O C₂H₅ H ClCF₃ H C O C₂H₅ H Cl CF₃ H D O C₂H₅ H Cl CF₃ H E O C₂H₅ H Cl CF₃ H F OC₂H₅ H Cl CF₃ H G O C₂H₅ H Cl CF₃ H H O C₂H₅ H Cl CF₃ H I O C₂H₅ H ClCF₃ H J O C₂H₅ H Cl CF₃ H K O C₂H₅ H Cl CF₃ H L O C₂H₅ H Cl CF₃ H M OC₂H₅ H Cl CF₃ H N O C₂H₅ H Cl CF₃ H O O C₂H₅ H Cl CF₃ H P O C₂H₅ H ClCF₃ H Q O C₂H₅ H Cl CF₃ H R O C₂H₅ H Cl CF₃ H S O C₂H₅ H Cl CF₃ H T OC₂H₅ H Cl CF₃ H U O C₂H₅ H Cl CF₃ H V O C₂H₅ H Cl CF₃ H W O C₂H₅ H ClCF₃ H X O C₂H₅ H Cl CF₃ H Y O C₂H₅ H Cl CF₃ H A CH₂ CH₃ CH₃ Cl CF₃ H BCH₂ CH₃ CH₃ Cl CF₃ H C CH₂ CH₃ CH₃ Cl CF₃ H D CH₂ CH₃ CH₃ Cl CF₃ H E CH₂CH₃ CH₃ Cl CF₃ H F CH₂ CH₃ CH₃ Cl CF₃ H G CH₂ CH₃ CH₃ Cl CF₃ H H CH₂ CH₃CH₃ Cl CF₃ H I CH₂ CH₃ CH₃ Cl CF₃ H J CH₂ CH₃ CH₃ Cl CF₃ H K CH₂ CH₃ CH₃Cl CF₃ H L CH₂ CH₃ CH₃ Cl CF₃ H M CH₂ CH₃ CH₃ Cl CF₃ H N CH₂ CH₃ CH₃ ClCF₃ H O CH₂ CH₃ CH₃ Cl CF₃ H P CH₂ CH₃ CH₃ Cl CF₃ H Q CH₂ CH₃ CH₃ Cl CF₃H R CH₂ CH₃ CH₃ Cl CF₃ H S CH₂ CH₃ CH₃ Cl CF₃ H T CH₂ CH₃ CH₃ Cl CF₃ H UCH₂ CH₃ CH₃ Cl CF₃ H V CH₂ CH₃ CH₃ Cl CF₃ H W CH₂ CH₃ CH₃ Cl CF₃ H X CH₂CH₃ CH₃ Cl CF₃ H Y CH₂ CH₃ CH₃ Cl CF₃ H A CH₂ CH₃ H CH₃ CF₃ H B CH₂ CH₃H CH₃ CF₃ H C CH₂ CH₃ H CH₃ CF₃ H D CH₂ CH₃ H CH₃ CF₃ H E CH₂ CH₃ H CH₃CF₃ H F CH₂ CH₃ H CH₃ CF₃ H G CH₂ CH₃ H CH₃ CF₃ H H CH₂ CH₃ H CH₃ CF₃ HI CH₂ CH₃ H CH₃ CF₃ H J CH₂ CH₃ H CH₃ CF₃ H K CH₂ CH₃ H CH₃ CF₃ H L CH₂CH₃ H CH₃ CF₃ H M CH₂ CH₃ H CH₃ CF₃ H N CH₂ CH₃ H CH₃ CF₃ H O CH₂ CH₃ HCH₃ CF₃ H P CH₂ CH₃ H CH₃ CF₃ H Q CH₂ CH₃ H CH₃ CF₃ H R CH₂ CH₃ H CH₃CF₃ H S CH₂ CH₃ H CH₃ CF₃ H T CH₂ CH₃ H CH₃ CF₃ H U CH₂ CH₃ H CH₃ CF₃ HV CH₂ CH₃ H CH₃ CF₃ H W CH₂ CH₃ H CH₃ CF₃ H X CH₂ CH₃ H CH₃ CF₃ H Y CH₂CH₃ H CH₃ CF₃ H A O CH₃ H CH₃ CF₃ H B O CH₃ H CH₃ CF₃ H C O CH₃ H CH₃CF₃ H D O CH₃ H CH₃ CF₃ H E O CH₃ H CH₃ CF₃ H F O CH₃ H CH₃ CF₃ H G OCH₃ H CH₃ CF₃ H H O CH₃ H CH₃ CF₃ H I O CH₃ H CH₃ CF₃ H J O CH₃ H CH₃CF₃ H K O CH₃ H CH₃ CF₃ H L O CH₃ H CH₃ CF₃ H M O CH₃ H CH₃ CF₃ H N OCH₃ H CH₃ CF₃ H O O CH₃ H CH₃ CF₃ H P O CH₃ H CH₃ CF₃ H Q O CH₃ H CH₃CF₃ H R O CH₃ H CH₃ CF₃ H S O CH₃ H CH₃ CF₃ H T O CH₃ H CH₃ CF₃ H U OCH₃ H CH₃ CF₃ H V O CH₃ H CH₃ CF₃ H W O CH₃ H CH₃ CF₃ H X O CH₃ H CH₃CF₃ H Y O CH₃ H CH₃ CF₃ H A O C₂H₅ H CH₃ CF₃ H B O C₂H₅ H CH₃ CF₃ H C OC₂H₅ H CH₃ CF₃ H D O C₂H₅ H CH₃ CF₃ H E O C₂H₅ H CH₃ CF₃ H F O C₂H₅ HCH₃ CF₃ H G O C₂H₅ H CH₃ CF₃ H H O C₂H₅ H CH₃ CF₃ H I O C₂H₅ H CH₃ CF₃ HJ O C₂H₅ H CH₃ CF₃ H K O C₂H₅ H CH₃ CF₃ H L O C₂H₅ H CH₃ CF₃ H M O C₂H₅H CH₃ CF₃ H N O C₂H₅ H CH₃ CF₃ H O O C₂H₅ H CH₃ CF₃ H P O C₂H₅ H CH₃ CF₃H Q O C₂H₅ H CH₃ CF₃ H R O C₂H₅ H CH₃ CF₃ H S O C₂H₅ H CH₃ CF₃ H T OC₂H₅ H CH₃ CF₃ H U O C₂H₅ H CH₃ CF₃ H V O C₂H₅ H CH₃ CF₃ H W O C₂H₅ HCH₃ CF₃ H X O C₂H₅ H CH₃ CF₃ H Y O C₂H₅ H CH₃ CF₃ H A CH₂ CH₃ CH₃ CH₃CF₃ H B CH₂ CH₃ CH₃ CH₃ CF₃ H C CH₂ CH₃ CH₃ CH₃ CF₃ H D CH₂ CH₃ CH₃ CH₃CF₃ H E CH₂ CH₃ CH₃ CH₃ CF₃ H F CH₂ CH₃ CH₃ CH₃ CF₃ H G CH₂ CH₃ CH₃ CH₃CF₃ H H CH₂ CH₃ CH₃ CH₃ CF₃ H I CH₂ CH₃ CH₃ CH₃ CF₃ H J CH₂ CH₃ CH₃ CH₃CF₃ H K CH₂ CH₃ CH₃ CH₃ CF₃ H L CH₂ CH₃ CH₃ CH₃ CF₃ H M CH₂ CH₃ CH₃ CH₃CF₃ H N CH₂ CH₃ CH₃ CH₃ CF₃ H O CH₂ CH₃ CH₃ CH₃ CF₃ H P CH₂ CH₃ CH₃ CH₃CF₃ H Q CH₂ CH₃ CH₃ CH₃ CF₃ H R CH₂ CH₃ CH₃ CH₃ CF₃ H S CH₂ CH₃ CH₃ CH₃CF₃ H T CH₂ CH₃ CH₃ CH₃ CF₃ H U CH₂ CH₃ CH₃ CH₃ CF₃ H V CH₂ CH₃ CH₃ CH₃CF₃ H W CH₂ CH₃ CH₃ CH₃ CF₃ H X CH₂ CH₃ CH₃ CH₃ CF₃ H Y CH₂ CH₃ CH₃ CH₃CF₃ H A CH₂ CH₃ H Cl CHF₂ H B CH₂ CH₃ H Cl CHF₂ H C CH₂ CH₃ H Cl CHF₂ HD CH₂ CH₃ H Cl CHF₂ H E CH₂ CH₃ H Cl CHF₂ H F CH₂ CH₃ H Cl CHF₂ H G CH₂CH₃ H Cl CHF₂ H H CH₂ CH₃ H Cl CHF₂ H I CH₂ CH₃ H Cl CHF₂ H J CH₂ CH₃ HCl CHF₂ H K CH₂ CH₃ H Cl CHF₂ H L CH₂ CH₃ H Cl CHF₂ H M CH₂ CH₃ H ClCHF₂ H N CH₂ CH₃ H Cl CHF₂ H O CH₂ CH₃ H Cl CHF₂ H P CH₂ CH₃ H Cl CHF₂ HQ CH₂ CH₃ H Cl CHF₂ H R CH₂ CH₃ H Cl CHF₂ H S CH₂ CH₃ H Cl CHF₂ H T CH₂CH₃ H Cl CHF₂ H U CH₂ CH₃ H Cl CHF₂ H V CH₂ CH₃ H Cl CHF₂ H W CH₂ CH₃ HCl CHF₂ H X CH₂ CH₃ H Cl CHF₂ H Y CH₂ CH₃ H Cl CHF₂ H A O CH₃ H Cl CHF₂H B O CH₃ H Cl CHF₂ H C O CH₃ H Cl CHF₂ H D O CH₃ H Cl CHF₂ H E O CH₃ HCl CHF₂ H F O CH₃ H Cl CHF₂ H G O CH₃ H Cl CHF₂ H H O CH₃ H Cl CHF₂ H IO CH₃ H Cl CHF₂ H J O CH₃ H Cl CHF₂ H K O CH₃ H Cl CHF₂ H L O CH₃ H ClCHF₂ H M O CH₃ H Cl CHF₂ H N O CH₃ H Cl CHF₂ H O O CH₃ H Cl CHF₂ H P OCH₃ H Cl CHF₂ H Q O CH₃ H Cl CHF₂ H R O CH₃ H Cl CHF₂ H S O CH₃ H ClCHF₂ H T O CH₃ H Cl CHF₂ H U O CH₃ H Cl CHF₂ H V O CH₃ H Cl CHF₂ H W OCH₃ H Cl CHF₂ H X O CH₃ H Cl CHF₂ H Y O CH₃ H Cl CHF₂ H A O C₂H₅ H ClCHF₂ H B O C₂H₅ H Cl CHF₂ H C O C₂H₅ H Cl CHF₂ H D O C₂H₅ H Cl CHF₂ H EO C₂H₅ H Cl CHF₂ H F O C₂H₅ H Cl CHF₂ H G O C₂H₅ H Cl CHF₂ H H O C₂H₅ HCl CHF₂ H I O C₂H₅ H Cl CHF₂ H J O C₂H₅ H Cl CHF₂ H K O C₂H₅ H Cl CHF₂ HL O C₂H₅ H Cl CHF₂ H M O C₂H₅ H Cl CHF₂ H N O C₂H₅ H Cl CHF₂ H O O C₂H₅H Cl CHF₂ H P O C₂H₅ H Cl CHF₂ H Q O C₂H₅ H Cl CHF₂ H R O C₂H₅ H Cl CHF₂H S O C₂H₅ H Cl CHF₂ H T O C₂H₅ H Cl CHF₂ H U O C₂H₅ H Cl CHF₂ H V OC₂H₅ H Cl CHF₂ H W O C₂H₅ H Cl CHF₂ H X O C₂H₅ H Cl CHF₂ H Y O C₂H₅ H ClCHF₂ H A CH₂ CH₃ CH₃ Cl CHF₂ H B CH₂ CH₃ CH₃ Cl CHF₂ H C CH₂ CH₃ CH₃ ClCHF₂ H D CH₂ CH₃ CH₃ Cl CHF₂ H E CH₂ CH₃ CH₃ Cl CHF₂ H F CH₂ CH₃ CH₃ ClCHF₂ H G CH₂ CH₃ CH₃ Cl CHF₂ H H CH₂ CH₃ CH₃ Cl CHF₂ H I CH₂ CH₃ CH₃ ClCHF₂ H J CH₂ CH₃ CH₃ Cl CHF₂ H K CH₂ CH₃ CH₃ Cl CHF₂ H L CH₂ CH₃ CH₃ ClCHF₂ H M CH₂ CH₃ CH₃ Cl CHF₂ H N CH₂ CH₃ CH₃ Cl CHF₂ H O CH₂ CH₃ CH₃ ClCHF₂ H P CH₂ CH₃ CH₃ Cl CHF₂ H Q CH₂ CH₃ CH₃ Cl CHF₂ H R CH₂ CH₃ CH₃ ClCHF₂ H S CH₂ CH₃ CH₃ Cl CHF₂ H T CH₂ CH₃ CH₃ Cl CHF₂ H U CH₂ CH₃ CH₃ ClCHF₂ H V CH₂ CH₃ CH₃ Cl CHF₂ H W CH₂ CH₃ CH₃ Cl CHF₂ H X CH₂ CH₃ CH₃ ClCHF₂ H Y CH₂ CH₃ CH₃ Cl CHF₂ H A CH₂ CH₃ H CH₃ CHF₂ H B CH₂ CH₃ H CH₃CHF₂ H C CH₂ CH₃ H CH₃ CHF₂ H D CH₂ CH₃ H CH₃ CHF₂ H E CH₂ CH₃ H CH₃CHF₂ H F CH₂ CH₃ H CH₃ CHF₂ H G CH₂ CH₃ H CH₃ CHF₂ H H CH₂ CH₃ H CH₃CHF₂ H I CH₂ CH₃ H CH₃ CHF₂ H J CH₂ CH₃ H CH₃ CHF₂ H K CH₂ CH₃ H CH₃CHF₂ H L CH₂ CH₃ H CH₃ CHF₂ H M CH₂ CH₃ H CH₃ CHF₂ H N CH₂ CH₃ H CH₃CHF₂ H O CH₂ CH₃ H CH₃ CHF₂ H P CH₂ CH₃ H CH₃ CHF₂ H Q CH₂ CH₃ H CH₃CHF₂ H R CH₂ CH₃ H CH₃ CHF₂ H S CH₂ CH₃ H CH₃ CHF₂ H T CH₂ CH₃ H CH₃CHF₂ H U CH₂ CH₃ H CH₃ CHF₂ H V CH₂ CH₃ H CH₃ CHF₂ H W CH₂ CH₃ H CH₃CHF₂ H X CH₂ CH₃ H CH₃ CHF₂ H Y CH₂ CH₃ H CH₃ CHF₂ H A O CH₃ H CH₃ CHF₂H B O CH₃ H CH₃ CHF₂ H C O CH₃ H CH₃ CHF₂ H D O CH₃ H CH₃ CHF₂ H E O CH₃H CH₃ CHF₂ H F O CH₃ H CH₃ CHF₂ H G O CH₃ H CH₃ CHF₂ H H O CH₃ H CH₃CHF₂ H I O CH₃ H CH₃ CHF₂ H J O CH₃ H CH₃ CHF₂ H K O CH₃ H CH₃ CHF₂ H LO CH₃ H CH₃ CHF₂ H M O CH₃ H CH₃ CHF₂ H N O CH₃ H CH₃ CHF₂ H O O CH₃ HCH₃ CHF₂ H P O CH₃ H CH₃ CHF₂ H Q O CH₃ H CH₃ CHF₂ H R O CH₃ H CH₃ CHF₂H S O CH₃ H CH₃ CHF₂ H T O CH₃ H CH₃ CHF₂ H U O CH₃ H CH₃ CHF₂ H V O CH₃H CH₃ CHF₂ H W O CH₃ H CH₃ CHF₂ H X O CH₃ H CH₃ CHF₂ H Y O CH₃ H CH₃CHF₂ H A O C₂H₅ H CH₃ CHF₂ H B O C₂H₅ H CH₃ CHF₂ H C O C₂H₅ H CH₃ CHF₂ HD O C₂H₅ H CH₃ CHF₂ H E O C₂H₃ H CH₃ CHF₂ H F O C₂H₅ H CH₃ CHF₂ H G OC₂H₅ H CH₃ CHF₂ H H O C₂H₅ H CH₃ CHF₂ H I O C₂H₅ H CH₃ CHF₂ H J O C₂H₅ HCH₃ CHF₂ H K O C₂H₅ H CH₃ CHF₂ H L O C₂H₅ H CH₃ CHF₂ H M O C₂H₅ H CH₃CHF₂ H N O C₂H₅ H CH₃ CHF₂ H O O C₂H₅ H CH₃ CHF₂ H P O C₂H₅ H CH₃ CHF₂ HQ O C₂H₅ H CH₃ CHF₂ H R O C₂H₅ H CH₃ CHF₂ H S O C₂H₅ H CH₃ CHF₂ H T OC₂H₅ H CH₃ CHF₂ H U O C₂H₅ H CH₃ CHF₂ H V O C₂H₅ H CH₃ CHF₂ H W O C₂H₅ HCH₃ CHF₂ H X O C₂H₅ H CH₃ CHF₂ H Y O C₂H₅ H CH₃ CHF₂ H A CH₂ CH₃ CH₃ CH₃CHF₂ H B CH₂ CH₃ CH₃ CH₃ CHF₂ H C CH₂ CH₃ CH₃ CH₃ CHF₂ H D CH₂ CH₃ CH₃CH₃ CHF₂ H E CH₂ CH₃ CH₃ CH₃ CHF₂ H F CH₂ CH₃ CH₃ CH₃ CHF₂ H G CH₂ CH₃CH₃ CH₃ CHF₂ H H CH₂ CH₃ CH₃ CH₃ CHF₂ H I CH₂ CH₃ CH₃ CH₃ CHF₂ H J CH₂CH₃ CH₃ CH₃ CHF₂ H K CH₂ CH₃ CH₃ CH₃ CHF₂ H L CH₂ CH₃ CH₃ CH₃ CHF₂ H MCH₂ CH₃ CH₃ CH₃ CHF₂ H N CH₂ CH₃ CH₃ CH₃ CHF₂ H O CH₂ CH₃ CH₃ CH₃ CHF₂ HP CH₂ CH₃ CH₃ CH₃ CHF₂ H Q CH₂ CH₃ CH₃ CH₃ CHF₂ H R CH₂ CH₃ CH₃ CH₃ CHF₂H S CH₂ CH₃ CH₃ CH₃ CHF₂ H T CH₂ CH₃ CH₃ CH₃ CHF₂ H U CH₂ CH₃ CH₃ CH₃CHF₂ H V CH₂ CH₃ CH₃ CH₃ CHF₂ H W CH₂ CH₃ CH₃ CH₃ CHF₂ H X CH₂ CH₃ CH₃CH₃ CHF₂ H Y CH₂ CH₃ CH₃ CH₃ CHF₂ H A CH₂ CH₃ H Cl CF₃ CH₃ B CH₂ CH₃ HCl CF₃ CH₃ C CH₂ CH₃ H Cl CF₃ CH₃ D CH₂ CH₃ H Cl CF₃ CH₃ E CH₂ CH₃ H ClCF₃ CH₃ F CH₂ CH₃ H Cl CF₃ CH₃ G CH₂ CH₃ H Cl CF₃ CH₃ H CH₂ CH₃ H Cl CF₃CH₃ I CH₂ CH₃ H Cl CF₃ CH₃ J CH₂ CH₃ H Cl CF₃ CH₃ K CH₂ CH₃ H Cl CF₃ CH₃L CH₂ CH₃ H Cl CF₃ CH₃ M CH₂ CH₃ H Cl CF₃ CH₃ N CH₂ CH₃ H Cl CF₃ CH₃ OCH₂ CH₃ H Cl CF₃ CH₃ P CH₂ CH₃ H Cl CF₃ CH₃ Q CH₂ CH₃ H Cl CF₃ CH₃ R CH₂CH₃ H Cl CF₃ CH₃ S CH₂ CH₃ H Cl CF₃ CH₃ T CH₂ CH₃ H Cl CF₃ CH₃ U CH₂ CH₃H Cl CF₃ CH₃ V CH₂ CH₃ H Cl CF₃ CH₃ W CH₂ CH₃ H Cl CF₃ CH₃ X CH₂ CH₃ HCl CF₃ CH₃ Y CH₂ CH₃ H Cl CF₃ CH₃ A O CH₃ H Cl CF₃ CH₃ B O CH₃ H Cl CF₃CH₃ C O CH₃ H Cl CF₃ CH₃ D O CH₃ H Cl CF₃ CH₃ E O CH₃ H Cl CF₃ CH₃ F OCH₃ H Cl CF₃ CH₃ G O CH₃ H Cl CF₃ CH₃ H O CH₃ H Cl CF₃ CH₃ I O CH₃ H ClCF₃ CH₃ J O CH₃ H Cl CF₃ CH₃ K O CH₃ H Cl CF₃ CH₃ L O CH₃ H Cl CF₃ CH₃ MO CH₃ H Cl CF₃ CH₃ N O CH₃ H Cl CF₃ CH₃ O O CH₃ H Cl CF₃ CH₃ P O CH₃ HCl CF₃ CH₃ Q O CH₃ H Cl CF₃ CH₃ R O CH₃ H Cl CF₃ CH₃ S O CH₃ H Cl CF₃CH₃ T O CH₃ H Cl CF₃ CH₃ U O CH₃ H Cl CF₃ CH₃ V O CH₃ H Cl CF₃ CH₃ W OCH₃ H Cl CF₃ CH₃ X O CH₃ H Cl CF₃ CH₃ Y O CH₃ H Cl CF₃ CH₃ A O C₂H₅ H ClCF₃ CH₃ B O C₂H₅ H Cl CF₃ CH₃ C O C₂H₅ H Cl CF₃ CH₃ D O C₂H₅ H Cl CF₃CH₃ E O C₂H₅ H Cl CF₃ CH₃ F O C₂H₅ H Cl CF₃ CH₃ G O C₂H₅ H Cl CF₃ CH₃ HO C₂H₅ H Cl CF₃ CH₃ I O C₂H₅ H Cl CF₃ CH₃ J O C₂H₅ H Cl CF₃ CH₃ K O C₂H₅H Cl CF₃ CH₃ L O C₂H₅ H Cl CF₃ CH₃ M O C₂H₅ H Cl CF₃ CH₃ N O C₂H₅ H ClCF₃ CH₃ O O C₂H₅ H Cl CF₃ CH₃ P O C₂H₅ H Cl CF₃ CH₃ Q O C₂H₅ H Cl CF₃CH₃ R O C₂H₅ H Cl CF₃ CH₃ S O C₂H₅ H Cl CF₃ CH₃ T O C₂H₅ H Cl CF₃ CH₃ UO C₂H₅ H Cl CF₃ CH₃ V O C₂H₅ H Cl CF₃ CH₃ W O C₂H₅ H Cl CF₃ CH₃ X O C₂H₅H Cl CF₃ CH₃ Y O C₂H₅ H Cl CF₃ CH₃ A CH₂ CH₃ CH₃ Cl CF₃ CH₃ B CH₂ CH₃CH₃ Cl CF₃ CH₃ C CH₂ CH₃ CH₃ Cl CF₃ CH₃ D CH₂ CH₃ CH₃ Cl CF₃ CH₃ E CH₂CH₃ CH₃ Cl CF₃ CH₃ F CH₂ CH₃ CH₃ Cl CF₃ CH₃ G CH₂ CH₃ CH₃ Cl CF₃ CH₃ HCH₂ CH₃ CH₃ Cl CF₃ CH₃ I CH₂ CH₃ CH₃ Cl CF₃ CH₃ J CH₂ CH₃ CH₃ Cl CF₃ CH₃K CH₂ CH₃ CH₃ Cl CF₃ CH₃ L CH₂ CH₃ CH₃ Cl CF₃ CH₃ M CH₂ CH₃ CH₃ Cl CF₃CH₃ N CH₂ CH₃ CH₃ Cl CF₃ CH₃ O CH₂ CH₃ CH₃ Cl CF₃ CH₃ P CH₂ CH₃ CH₃ ClCF₃ CH₃ Q CH₂ CH₃ CH₃ Cl CF₃ CH₃ R CH₂ CH₃ CH₃ Cl CF₃ CH₃ S CH₂ CH₃ CH₃Cl CF₃ CH₃ T CH₂ CH₃ CH₃ Cl CF₃ CH₃ U CH₂ CH₃ CH₃ Cl CF₃ CH₃ V CH₂ CH₃CH₃ Cl CF₃ CH₃ W CH₂ CH₃ CH₃ Cl CF₃ CH₃ X CH₂ CH₃ CH₃ Cl CF₃ CH₃ Y CH₂CH₃ CH₃ Cl CF₃ CH₃ A CH₂ CH₃ H CH₃ CF₃ CH₃ B CH₂ CH₃ H CH₃ CF₃ CH₃ C CH₂CH₃ H CH₃ CF₃ CH₃ D CH₂ CH₃ H CH₃ CF₃ CH₃ E CH₂ CH₃ H CH₃ CF₃ CH₃ F CH₂CH₃ H CH₃ CF₃ CH₃ G CH₂ CH₃ H CH₃ CF₃ CH₃ H CH₂ CH₃ H CH₃ CF₃ CH₃ I CH₂CH₃ H CH₃ CF₃ CH₃ J CH₂ CH₃ H CH₃ CF₃ CH₃ K CH₂ CH₃ H CH₃ CF₃ CH₃ L CH₂CH₃ H CH₃ CF₃ CH₃ M CH₂ CH₃ H CH₃ CF₃ CH₃ N CH₂ CH₃ H CH₃ CF₃ CH₃ O CH₂CH₃ H CH₃ CF₃ CH₃ P CH₂ CH₃ H CH₃ CF₃ CH₃ Q CH₂ CH₃ H CH₃ CF₃ CH₃ R CH₂CH₃ H CH₃ CF₃ CH₃ S CH₂ CH₃ H CH₃ CF₃ CH₃ T CH₂ CH₃ H CH₃ CF₃ CH₃ U CH₂CH₃ H CH₃ CF₃ CH₃ V CH₂ CH₃ H CH₃ CF₃ CH₃ W CH₂ CH₃ H CH₃ CF₃ CH₃ X CH₂CH₃ H CH₃ CF₃ CH₃ Y CH₂ CH₃ H CH₃ CF₃ CH₃ A O CH₃ H CH₃ CF₃ CH₃ B O CH₃H CH₃ CF₃ CH₃ C O CH₃ H CH₃ CF₃ CH₃ D O CH₃ H CH₃ CF₃ CH₃ E O CH₃ H CH₃CF₃ CH₃ F O CH₃ H CH₃ CF₃ CH₃ G O CH₃ H CH₃ CF₃ CH₃ H O CH₃ H CH₃ CF₃CH₃ I O CH₃ H CH₃ CF₃ CH₃ J O CH₃ H CH₃ CF₃ CH₃ K O CH₃ H CH₃ CF₃ CH₃ LO CH₃ H CH₃ CF₃ CH₃ M O CH₃ H CH₃ CF₃ CH₃ N O CH₃ H CH₃ CF₃ CH₃ O O CH₃H CH₃ CF₃ CH₃ P O CH₃ H CH₃ CF₃ CH₃ Q O CH₃ H CH₃ CF₃ CH₃ R O CH₃ H CH₃CF₃ CH₃ S O CH₃ H CH₃ CF₃ CH₃ T O CH₃ H CH₃ CF₃ CH₃ U O CH₃ H CH₃ CF₃CH₃ V O CH₃ H CH₃ CF₃ CH₃ W O CH₃ H CH₃ CF₃ CH₃ X O CH₃ H CH₃ CF₃ CH₃ YO CH₃ H CH₃ CF₃ CH₃ A O C₂H₅ H CH₃ CF₃ CH₃ B O C₂H₅ H CH₃ CF₃ CH₃ C OC₂H₅ H CH₃ CF₃ CH₃ D O C₂H₅ H CH₃ CF₃ CH₃ E O C₂H₅ H CH₃ CF₃ CH₃ F OC₂H₅ H CH₃ CF₃ CH₃ G O C₂H₅ H CH₃ CF₃ CH₃ H O C₂H₅ H CH₃ CF₃ CH₃ I OC₂H₅ H CH₃ CF₃ CH₃ J O C₂H₅ H CH₃ CF₃ CH₃ K O C₂H₅ H CH₃ CF₃ CH₃ L OC₂H₅ H CH₃ CF₃ CH₃ M O C₂H₅ H CH₃ CF₃ CH₃ N O C₂H₅ H CH₃ CF₃ CH₃ O OC₂H₅ H CH₃ CF₃ CH₃ P O C₂H₅ H CH₃ CF₃ CH₃ Q O C₂H₅ H CH₃ CF₃ CH₃ R OC₂H₅ H CH₃ CF₃ CH₃ S O C₂H₅ H CH₃ CF₃ CH₃ T O C₂H₅ H CH₃ CF₃ CH₃ U OC₂H₅ H CH₃ CF₃ CH₃ V O C₂H₅ H CH₃ CF₃ CH₃ W O C₂H₅ H CH₃ CF₃ CH₃ X OC₂H₅ H CH₃ CF₃ CH₃ Y O C₂H₅ H CH₃ CF₃ CH₃ A CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ BCH₂ CH₃ CH₃ CH₃ CF₃ CH₃ C CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ D CH₂ CH₃ CH₃ CH₃ CF₃CH₃ E CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ F CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ G CH₂ CH₃ CH₃CH₃ CF₃ CH₃ H CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ I CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ J CH₂CH₃ CH₃ CH₃ CF₃ CH₃ K CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ L CH₂ CH₃ CH₃ CH₃ CF₃ CH₃M CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ N CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ O CH₂ CH₃ CH₃ CH₃CF₃ CH₃ P CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ Q CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ R CH₂ CH₃CH₃ CH₃ CF₃ CH₃ S CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ T CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ UCH₂ CH₃ CH₃ CH₃ CF₃ CH₃ V CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ W CH₂ CH₃ CH₃ CH₃ CF₃CH₃ X CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ Y CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ A CH₂ CH₃ H ClCHF₂ CH₃ B CH₂ CH₃ H Cl CHF₂ CH₃ C CH₂ CH₃ H Cl CHF₂ CH₃ D CH₂ CH₃ H ClCHF₂ CH₃ E CH₂ CH₃ H Cl CHF₂ CH₃ F CH₂ CH₃ H Cl CHF₂ CH₃ G CH₂ CH₃ H ClCHF₂ CH₃ H CH₂ CH₃ H Cl CHF₂ CH₃ I CH₂ CH₃ H Cl CHF₂ CH₃ J CH₂ CH₃ H ClCHF₂ CH₃ K CH₂ CH₃ H Cl CHF₂ CH₃ L CH₂ CH₃ H Cl CHF₂ CH₃ M CH₂ CH₃ H ClCHF₂ CH₃ N CH₂ CH₃ H Cl CHF₂ CH₃ O CH₂ CH₃ H Cl CHF₂ CH₃ P CH₂ CH₃ H ClCHF₂ CH₃ Q CH₂ CH₃ H Cl CHF₂ CH₃ R CH₂ CH₃ H Cl CHF₂ CH₃ S CH₂ CH₃ H ClCHF₂ CH₃ T CH₂ CH₃ H Cl CHF₂ CH₃ U CH₂ CH₃ H Cl CHF₂ CH₃ V CH₂ CH₃ H ClCHF₂ CH₃ W CH₂ CH₃ H Cl CHF₂ CH₃ X CH₂ CH₃ H Cl CHF₂ CH₃ Y CH₂ CH₃ H ClCHF₂ CH₃ A O CH₃ H Cl CHF₂ CH₃ B O CH₃ H Cl CHF₂ CH₃ C O CH₃ H Cl CHF₂CH₃ D O CH₃ H Cl CHF₂ CH₃ E O CH₃ H Cl CHF₂ CH₃ F O CH₃ H Cl CHF₂ CH₃ GO CH₃ H Cl CHF₂ CH₃ H O CH₃ H Cl CHF₂ CH₃ I O CH₃ H Cl CHF₂ CH₃ J O CH₃H Cl CHF₂ CH₃ K O CH₃ H Cl CHF₂ CH₃ L O CH₃ H Cl CHF₂ CH₃ M O CH₃ H ClCHF₂ CH₃ N O CH₃ H Cl CHF₂ CH₃ O O CH₃ H Cl CHF₂ CH₃ P O CH₃ H Cl CHF₂CH₃ Q O CH₃ H Cl CHF₂ CH₃ R O CH₃ H Cl CHF₂ CH₃ S O CH₃ H Cl CHF₂ CH₃ TO CH₃ H Cl CHF₂ CH₃ U O CH₃ H Cl CHF₂ CH₃ V O CH₃ H Cl CHF₂ CH₃ W O CH₃H Cl CHF₂ CH₃ X O CH₃ H Cl CHF₂ CH₃ Y O CH₃ H Cl CHF₂ CH₃ A O C₂H₅ H ClCHF₂ CH₃ B O C₂H₅ H Cl CHF₂ CH₃ C O C₂H₅ H Cl CHF₂ CH₃ D O C₂H₅ H ClCHF₂ CH₃ E O C₂H₅ H Cl CHF₂ CH₃ F O C₂H₅ H Cl CHF₂ CH₃ G O C₂H₅ H ClCHF₂ CH₃ H O C₂H₅ H Cl CHF₂ CH₃ I O C₂H₅ H Cl CHF₂ CH₃ J O C₂H₅ H ClCHF₂ CH₃ K O C₂H₅ H Cl CHF₂ CH₃ L O C₂H₅ H Cl CHF₂ CH₃ M O C₂H₅ H ClCHF₂ CH₃ N O C₂H₅ H Cl CHF₂ CH₃ O O C₂H₅ H Cl CHF₂ CH₃ P O C₂H₅ H ClCHF₂ CH₃ Q O C₂H₅ H Cl CHF₂ CH₃ R O C₂H₅ H Cl CHF₂ CH₃ S O C₂H₅ H ClCHF₂ CH₃ T O C₂H₅ H Cl CHF₂ CH₃ U O C₂H₅ H Cl CHF₂ CH₃ V O C₂H₅ H ClCHF₂ CH₃ W O C₂H₅ H Cl CHF₂ CH₃ X O C₂H₅ H Cl CHF₂ CH₃ Y O C₂H₅ H ClCHF₂ CH₃ A CH₂ CH₃ CH₃ Cl CHF₂ CH₃ B CH₂ CH₃ CH₃ Cl CHF₂ CH₃ C CH₂ CH₃CH₃ Cl CHF₂ CH₃ D CH₂ CH₃ CH₃ Cl CHF₂ CH₃ E CH₂ CH₃ CH₃ Cl CHF₂ CH₃ FCH₂ CH₃ CH₃ Cl CHF₂ CH₃ G CH₂ CH₃ CH₃ Cl CHF₂ CH₃ H CH₂ CH₃ CH₃ Cl CHF₂CH₃ I CH₂ CH₃ CH₃ Cl CHF₂ CH₃ J CH₂ CH₃ CH₃ Cl CHF₂ CH₃ K CH₂ CH₃ CH₃ ClCHF₂ CH₃ L CH₂ CH₃ CH₃ Cl CHF₂ CH₃ M CH₂ CH₃ CH₃ Cl CHF₂ CH₃ N CH₂ CH₃CH₃ Cl CHF₂ CH₃ O CH₂ CH₃ CH₃ Cl CHF₂ CH₃ P CH₂ CH₃ CH₃ Cl CHF₂ CH₃ QCH₂ CH₃ CH₃ Cl CHF₂ CH₃ R CH₂ CH₃ CH₃ Cl CHF₂ CH₃ S CH₂ CH₃ CH₃ Cl CHF₂CH₃ T CH₂ CH₃ CH₃ Cl CHF₂ CH₃ U CH₂ CH₃ CH₃ Cl CHF₂ CH₃ V CH₂ CH₃ CH₃ ClCHF₂ CH₃ W CH₂ CH₃ CH₃ Cl CHF₂ CH₃ X CH₂ CH₃ CH₃ Cl CHF₂ CH₃ Y CH₂ CH₃CH₃ Cl CHF₂ CH₃ A CH₂ CH₃ H CH₃ CHF₂ CH₃ B CH₂ CH₃ H CH₃ CHF₂ CH₃ C CH₂CH₃ H CH₃ CHF₂ CH₃ D CH₂ CH₃ H CH₃ CHF₂ CH₃ E CH₂ CH₃ H CH₃ CHF₂ CH₃ FCH₂ CH₃ H CH₃ CHF₂ CH₃ G CH₂ CH₃ H CH₃ CHF₂ CH₃ H CH₂ CH₃ H CH₃ CHF₂ CH₃I CH₂ CH₃ H CH₃ CHF₂ CH₃ J CH₂ CH₃ H CH₃ CHF₂ CH₃ K CH₂ CH₃ H CH₃ CHF₂CH₃ L CH₂ CH₃ H CH₃ CHF₂ CH₃ M CH₂ CH₃ H CH₃ CHF₂ CH₃ N CH₂ CH₃ H CH₃CHF₂ CH₃ O CH₂ CH₃ H CH₃ CHF₂ CH₃ P CH₂ CH₃ H CH₃ CHF₂ CH₃ Q CH₂ CH₃ HCH₃ CHF₂ CH₃ R CH₂ CH₃ H CH₃ CHF₂ CH₃ S CH₂ CH₃ H CH₃ CHF₂ CH₃ T CH₂ CH₃H CH₃ CHF₂ CH₃ U CH₂ CH₃ H CH₃ CHF₂ CH₃ V CH₂ CH₃ H CH₃ CHF₂ CH₃ W CH₂CH₃ H CH₃ CHF₂ CH₃ X CH₂ CH₃ H CH₃ CHF₂ CH₃ Y CH₂ CH₃ H CH₃ CHF₂ CH₃ A OCH₃ H CH₃ CHF₂ CH₃ B O CH₃ H CH₃ CHF₂ CH₃ C O CH₃ H CH₃ CHF₂ CH₃ D O CH₃H CH₃ CHF₂ CH₃ E O CH₃ H CH₃ CHF₂ CH₃ F O CH₃ H CH₃ CHF₂ CH₃ G C CH₃ HCH₃ CHF₂ CH₃ H O CH₃ H CH₃ CHF₂ CH₃ I O CH₃ H CH₃ CHF₂ CH₃ J O CH₃ H CH₃CHF₂ CH₃ K O CH₃ H CH₃ CHF₂ CH₃ L O CH₃ H CH₃ CHF₂ CH₃ M O CH₃ H CH₃CHF₂ CH₃ N O CH₃ H CH₃ CHF₂ CH₃ O O CH₃ H CH₃ CHF₂ CH₃ P O CH₃ H CH₃CHF₂ CH₃ Q O CH₃ H CH₃ CHF₂ CH₃ R O CH₃ H CH₃ CHF₂ CH₃ S O CH₃ H CH₃CHF₂ CH₃ T O CH₃ H CH₃ CHF₂ CH₃ U O CH₃ H CH₃ CHF₂ CH₃ V O CH₃ H CH₃CHF₂ CH₃ W O CH₃ H CH₃ CHF₂ CH₃ X O CH₃ H CH₃ CHF₂ CH₃ Y O CH₃ H CH₃CHF₂ CH₃ A O C₂H₅ H CH₃ CHF₂ CH₃ B O C₂H₅ H CH₃ CHF₂ CH₃ C O C₂H₅ H CH₃CHF₂ CH₃ D O C₂H₅ H CH₃ CHF₂ CH₃ E O C₂H₅ H CH₃ CHF₂ CH₃ F O C₂H₅ H CH₃CHF₂ CH₃ G O C₂H₅ H CH₃ CHF₂ CH₃ H O C₂H₅ H CH₃ CHF₂ CH₃ I O C₂H₅ H CH₃CHF₂ CH₃ J O C₂H₅ H CH₃ CHF₂ CH₃ K O C₂H₅ H CH₃ CHF₂ CH₃ L O C₂H₅ H CH₃CHF₂ CH₃ M O C₂H₅ H CH₃ CHF₂ CH₃ N O C₂H₅ H CH₃ CHF₂ CH₃ O O C₂H₅ H CH₃CHF₂ CH₃ P O C₂H₅ H CH₃ CHF₂ CH₃ Q O C₂H₅ H CH₃ CHF₂ CH₃ R O C₂H₅ H CH₃CHF₂ CH₃ S O C₂H₅ H CH₃ CHF₂ CH₃ T O C₂H₅ H CH₃ CHF₂ CH₃ U O C₂H₅ H CH₃CHF₂ CH₃ V O C₂H₅ H CH₃ CHF₂ CH₃ W O C₂H₅ H CH₃ CHF₂ CH₃ X O C₂H₅ H CH₃CHF₂ CH₃ Y O C₂H₅ H CH₃ CHF₂ CH₃ A CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ B CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ C CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ D CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ ECH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ F CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ G CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ H CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ I CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ J CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ K CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ L CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ MCH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ N CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ O CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ P CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Q CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ R CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ S CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ T CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ UCH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ V CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ W CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ X CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Y CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃

[0038] Particular compounds provided herein further include those havingthe following structure, with the substituents thereof being set forthin Table D, below. TABLE D

R^(1(a)) X R² R³ R^(aryl) R^(aryl2) R^(aryl3) A CH₂ CH₃ H Cl CF₃ H B CH₂CH₃ H Cl CF₃ H C CH₂ CH₃ H Cl CF₃ H D CH₂ CH₃ H Cl CF₃ H E CH₂ CH₃ H ClCF₃ H F CH₂ CH₃ H Cl CF₃ H G CH₂ CH₃ H Cl CF₃ H H CH₂ CH₃ H Cl CF₃ H ICH₂ CH₃ H Cl CF₃ H J CH₂ CH₃ H Cl CF₃ H K CH₂ CH₃ H Cl CF₃ H L CH₂ CH₃ HCl CF₃ H M CH₂ CH₃ H Cl CF₃ H N CH₂ CH₃ H Cl CF₃ H O CH₂ CH₃ H Cl CF₃ HP CH₂ CH₃ H Cl CF₃ H Q CH₂ CH₃ H Cl CF₃ H R CH₂ CH₃ H Cl CF₃ H S CH₂ CH₃H Cl CF₃ H T CH₂ CH₃ H Cl CF₃ H U CH₂ CH₃ H Cl CF₃ H V CH₂ CH₃ H Cl CF₃H W CH₂ CH₃ H Cl CF₃ H X CH₂ CH₃ H Cl CF₃ H Y CH₂ CH₃ H Cl CF₃ H A O CH₃H Cl CF₃ H B O CH₃ H Cl CF₃ H C O CH₃ H Cl CF₃ H D O CH₃ H Cl CF₃ H E OCH₃ H Cl CF₃ H F O CH₃ H Cl CF₃ H G O CH₃ H Cl CF₃ H H O CH₃ H Cl CF₃ HI O CH₃ H Cl CF₃ H J O CH₃ H Cl CF₃ H K O CH₃ H Cl CF₃ H L O CH₃ H ClCF₃ H M O CH₃ H Cl CF₃ H N O CH₃ H Cl CF₃ H O O CH₃ H Cl CF₃ H P O CH₃ HCl CF₃ H Q O CH₃ H Cl CF₃ H R O CH₃ H Cl CF₃ H S O CH₃ H Cl CF₃ H T OCH₃ H Cl CF₃ H U O CH₃ H Cl CF₃ H V O CH₃ H Cl CF₃ H W O CH₃ H Cl CF₃ HX O CH₃ H Cl CF₃ H Y O CH₃ H Cl CF₃ H A O C₂H₅ H Cl CF₃ H B O C₂H₅ H ClCF₃ H C O C₂H₅ H Cl CF₃ H D O C₂H₅ H Cl CF₃ H E O C₂H₅ H Cl CF₃ H F OC₂H₅ H Cl CF₃ H G O C₂H₅ H Cl CF₃ H H O C₂H₅ H Cl CF₃ H I O C₂H₅ H ClCF₃ H J O C₂H₅ H Cl CF₃ H K O C₂H₅ H Cl CF₃ H L O C₂H₅ H Cl CF₃ H M OC₂H₅ H Cl CF₃ H N O C₂H₅ H Cl CF₃ H O O C₂H₅ H Cl CF₃ H P O C₂H₅ H ClCF₃ H Q O C₂H₅ H Cl CF₃ H R O C₂H₅ H Cl CF₃ H S O C₂H₅ H Cl CF₃ H T OC₂H₅ H Cl CF₃ H U O C₂H₅ H Cl CF₃ H V O C₂H₅ H Cl CF₃ H W O C₂H₅ H ClCF₃ H X O C₂H₅ H Cl CF₃ H Y O C₂H₅ H Cl CF₃ H A CH₂ CH₃ CH₃ Cl CF₃ H BCH₂ CH₃ CH₃ Cl CF₃ H C CH₂ CH₃ CH₃ Cl CF₃ H D CH₂ CH₃ CH₃ Cl CF₃ H E CH₂CH₃ CH₃ Cl CF₃ H F CH₂ CH₃ CH₃ Cl CF₃ H G CH₂ CH₃ CH₃ Cl CF₃ H H CH₂ CH₃CH₃ Cl CF₃ H I CH₂ CH₃ CH₃ Cl CF₃ H J CH₂ CH₃ CH₃ Cl CF₃ H K CH₂ CH₃ CH₃Cl CF₃ H L CH₂ CH₃ CH₃ Cl CF₃ H M CH₂ CH₃ CH₃ Cl CF₃ H N CH₂ CH₃ CH₃ ClCF₃ H O CH₂ CH₃ CH₃ Cl CF₃ H P CH₂ CH₃ CH₃ Cl CF₃ H Q CH₂ CH₃ CH₃ Cl CF₃H R CH₂ CH₃ CH₃ Cl CF₃ H S CH₂ CH₃ CH₃ Cl CF₃ H T CH₂ CH₃ CH₃ Cl CF₃ H UCH₂ CH₃ CH₃ Cl CF₃ H V CH₂ CH₃ CH₃ Cl CF₃ H W CH₂ CH₃ CH₃ Cl CF₃ H X CH₂CH₃ CH₃ Cl CF₃ H Y CH₂ CH₃ CH₃ Cl CF₃ H A CH₂ CH₃ H CH₃ CF₃ H B CH₂ CH₃H CH₃ CF₃ H C CH₂ CH₃ H CH₃ CF₃ H D CH₂ CH₃ H CH₃ CF₃ H E CH₂ CH₃ H CH₃CF₃ H F CH₂ CH₃ H CH₃ CF₃ H G CH₂ CH₃ H CH₃ CF₃ H H CH₂ CH₃ H CH₃ CF₃ HI CH₂ CH₃ H CH₃ CF₃ H J CH₂ CH₃ H CH₃ CF₃ H K CH₂ CH₃ H CH₃ CF₃ H L CH₂CH₃ H CH₃ CF₃ H M CH₂ CH₃ H CH₃ CF₃ H N CH₂ CH₃ H CH₃ CF₃ H O CH₂ CH₃ HCH₃ CF₃ H P CH₂ CH₃ H CH₃ CF₃ H Q CH₂ CH₃ H CH₃ CF₃ H R CH₂ CH₃ H CH₃CF₃ H S CH₂ CH₃ H CH₃ CF₃ H T CH₂ CH₃ H CH₃ CF₃ H U CH₂ CH₃ H CH₃ CF₃ HV CH₂ CH₃ H CH₃ CF₃ H W CH₂ CH₃ H CH₃ CF₃ H X CH₂ CH₃ H CH₃ CF₃ H Y CH₂CH₃ H CH₃ CF₃ H A O CH₃ H CH₃ CF₃ H B O CH₃ H CH₃ CF₃ H C O CH₃ H CH₃CF₃ H D O CH₃ H CH₃ CF₃ H E O CH₃ H CH₃ CF₃ H F O CH₃ H CH₃ CF₃ H G OCH₃ H CH₃ CF₃ H H O CH₃ H CH₃ CF₃ H I O CH₃ H CH₃ CF₃ H J O CH₃ H CH₃CF₃ H K O CH₃ H CH₃ CF₃ H L O CH₃ H CH₃ CF₃ H M O CH₃ H CH₃ CF₃ H N OCH₃ H CH₃ CF₃ H O O CH₃ H CH₃ CF₃ H P O CH₃ H CH₃ CF₃ H Q O CH₃ H CH₃CF₃ H R O CH₃ H CH₃ CF₃ H S O CH₃ H CH₃ CF₃ H T O CH₃ H CH₃ CF₃ H U OCH₃ H CH₃ CF₃ H V O CH₃ H CH₃ CF₃ H W O CH₃ H CH₃ CF₃ H X O CH₃ H CH₃CF₃ H Y O CH₃ H CH₃ CF₃ H A O C₂H₅ H CH₃ CF₃ H B O C₂H₅ H CH₃ CF₃ H C OC₂H₅ H CH₃ CF₃ H D O C₂H₅ H CH₃ CF₃ H E O C₂H₅ H CH₃ CF₃ H F O C₂H₅ HCH₃ CF₃ H G O C₂H₅ H CH₃ CF₃ H H O C₂H₅ H CH₃ CF₃ H I O C₂H₅ H CH₃ CF₃ HJ O C₂H₅ H CH₃ CF₃ H K O C₂H₅ H CH₃ CF₃ H L O C₂H₅ H CH₃ CF₃ H M O C₂H₅H CH₃ CF₃ H N O C₂H₅ H CH₃ CF₃ H O O C₂H₅ H CH₃ CF₃ H P O C₂H₅ H CH₃ CF₃H Q O C₂H₅ H CH₃ CF₃ H R O C₂H₅ H CH₃ CF₃ H S O C₂H₅ H CH₃ CF₃ H T OC₂H₅ H CH₃ CF₃ H U O C₂H₅ H CH₃ CF₃ H V O C₂H₅ H CH₃ CF₃ H W O C₂H₅ HCH₃ CF₃ H X O C₂H₅ H CH₃ CF₃ H Y O C₂H₅ H CH₃ CF₃ H A CH₂ CH₃ CH₃ CH₃CF₃ H B CH₂ CH₃ CH₃ CH₃ CF₃ H C CH₂ CH₃ CH₃ CH₃ CF₃ H D CH₂ CH₃ CH₃ CH₃CF₃ H E CH₂ CH₃ CH₃ CH₃ CF₃ H F CH₂ CH₃ CH₃ CH₃ CF₃ H G CH₂ CH₃ CH₃ CH₃CF₃ H H CH₂ CH₃ CH₃ CH₃ CF₃ H I CH₂ CH₃ CH₃ CH₃ CF₃ H J CH₂ CH₃ CH₃ CH₃CF₃ H K CH₂ CH₃ CH₃ CH₃ CF₃ H L CH₂ CH₃ CH₃ CH₃ CF₃ H M CH₂ CH₃ CH₃ CH₃CF₃ H N CH₂ CH₃ CH₃ CH₃ CF₃ H O CH₂ CH₃ CH₃ CH₃ CF₃ H P CH₂ CH₃ CH₃ CH₃CF₃ H Q CH₂ CH₃ CH₃ CH₃ CF₃ H R CH₂ CH₃ CH₃ CH₃ CF₃ H S CH₂ CH₃ CH₃ CH₃CF₃ H T CH₂ CH₃ CH₃ CH₃ CF₃ H U CH₂ CH₃ CH₃ CH₃ CF₃ H V CH₂ CH₃ CH₃ CH₃CF₃ H W CH₂ CH₃ CH₃ CH₃ CF₃ H X CH₂ CH₃ CH₃ CH₃ CF₃ H Y CH₂ CH₃ CH₃ CH₃CF₃ H A CH₂ CH₃ H Cl CHF₂ H B CH₂ CH₃ H Cl CHF₂ H C CH₂ CH₃ H Cl CHF₂ HD CH₂ CH₃ H Cl CHF₂ H E CH₂ CH₃ H Cl CHF₂ H F CH₂ CH₃ H Cl CHF₂ H G CH₂CH₃ H Cl CHF₂ H H CH₂ CH₃ H Cl CHF₂ H I CH₂ CH₃ H Cl CHF₂ H J CH₂ CH₃ HCl CHF₂ H K CH₂ CH₃ H Cl CHF₂ H L CH₂ CH₃ H Cl CHF₂ H M CH₂ CH₃ H ClCHF₂ H N CH₂ CH₃ H Cl CHF₂ H O CH₂ CH₃ H Cl CHF₂ H P CH₂ CH₃ H Cl CHF₂ HQ CH₂ CH₃ H Cl CHF₂ H R CH₂ CH₃ H Cl CHF₂ H S CH₂ CH₃ H Cl CHF₂ H T CH₂CH₃ H Cl CHF₂ H U CH₂ CH₃ H Cl CHF₂ H V CH₂ CH₃ H Cl CHF₂ H W CH₂ CH₃ HCl CHF₂ H X CH₂ CH₃ H Cl CHF₂ H Y CH₂ CH₃ H Cl CHF₂ H A O CH₃ H Cl CHF₂H B O CH₃ H Cl CHF₂ H C O CH₃ H Cl CHF₂ H D O CH₃ H Cl CHF₂ H E O CH₃ HCl CHF₂ H F O CH₃ H Cl CHF₂ H G O CH₃ H Cl CHF₂ H H O CH₃ H Cl CHF₂ H IO CH₃ H Cl CHF₂ H J O CH₃ H Cl CHF₂ H K O CH₃ H Cl CHF₂ H L O CH₃ H ClCHF₂ H M O CH₃ H Cl CHF₂ H N O CH₃ H Cl CHF₂ H O O CH₃ H Cl CHF₂ H P OCH₃ H Cl CHF₂ H Q O CH₃ H Cl CHF₂ H R O CH₃ H Cl CHF₂ H S O CH₃ H ClCHF₂ H T O CH₃ H Cl CHF₂ H U O CH₃ H Cl CHF₂ H V O CH₃ H Cl CHF₂ H W OCH₃ H Cl CHF₂ H X O CH₃ H Cl CHF₂ H Y O CH₃ H Cl CHF₂ H A O C₂H₅ H ClCHF₂ H B O C₂H₅ H Cl CHF₂ H C O C₂H₅ H Cl CHF₂ H D O C₂H₅ H Cl CHF₂ H EO C₂H₅ H Cl CHF₂ H F O C₂H₅ H Cl CHF₂ H G O C₂H₅ H Cl CHF₂ H H O C₂H₅ HCl CHF₂ H I O C₂H₅ H Cl CHF₂ H J O C₂H₅ H Cl CHF₂ H K O C₂H₅ H Cl CHF₂ HL O C₂H₅ H Cl CHF₂ H M O C₂H₅ H Cl CHF₂ H N O C₂H₅ H Cl CHF₂ H O O C₂H₅H Cl CHF₂ H P O C₂H₅ H Cl CHF₂ H Q O C₂H₅ H Cl CHF₂ H R O C₂H₅ H Cl CHF₂H S O C₂H₅ H Cl CHF₂ H T O C₂H₅ H Cl CHF₂ H U O C₂H₅ H Cl CHF₂ H V OC₂H₅ H Cl CHF₂ H W O C₂H₅ H Cl CHF₂ H X O C₂H₅ H Cl CHF₂ H Y O C₂H₅ H ClCHF₂ H A CH₂ CH₃ CH₃ Cl CHF₂ H B CH₂ CH₃ CH₃ Cl CHF₂ H C CH₂ CH₃ CH₃ ClCHF₂ H D CH₂ CH₃ CH₃ Cl CHF₂ H E CH₂ CH₃ CH₃ Cl CHF₂ H F CH₂ CH₃ CH₃ ClCHF₂ H G CH₂ CH₃ CH₃ Cl CHF₂ H H CH₂ CH₃ CH₃ Cl CHF₂ H I CH₂ CH₃ CH₃ ClCHF₂ H J CH₂ CH₃ CH₃ Cl CHF₂ H K CH₂ CH₃ CH₃ Cl CHF₂ H L CH₂ CH₃ CH₃ ClCHF₂ H M CH₂ CH₃ CH₃ Cl CHF₂ H N CH₂ CH₃ CH₃ Cl CHF₂ H O CH₂ CH₃ CH₃ ClCHF₂ H P CH₂ CH₃ CH₃ Cl CHF₂ H Q CH₂ CH₃ CH₃ Cl CHF₂ H R CH₂ CH₃ CH₃ ClCHF₂ H S CH₂ CH₃ CH₃ Cl CHF₂ H T CH₂ CH₃ CH₃ Cl CHF₂ H U CH₂ CH₃ CH₃ ClCHF₂ H V CH₂ CH₃ CH₃ Cl CHF₂ H W CH₂ CH₃ CH₃ Cl CHF₂ H X CH₂ CH₃ CH₃ ClCHF₂ H Y CH₂ CH₃ CH₃ Cl CHF₂ H A CH₂ CH₃ H CH₃ CHF₂ H B CH₂ CH₃ H CH₃CHF₂ H C CH₂ CH₃ H CH₃ CHF₂ H D CH₂ CH₃ H CH₃ CHF₂ H E CH₂ CH₃ H CH₃CHF₂ H F CH₂ CH₃ H CH₃ CHF₂ H G CH₂ CH₃ H CH₃ CHF₂ H H CH₂ CH₃ H CH₃CHF₂ H I CH₂ CH₃ H CH₃ CHF₂ H J CH₂ CH₃ H CH₃ CHF₂ H K CH₂ CH₃ H CH₃CHF₂ H L CH₂ CH₃ H CH₃ CHF₂ H M CH₂ CH₃ H CH₃ CHF₂ H N CH₂ CH₃ H CH₃CHF₂ H O CH₂ CH₃ H CH₃ CHF₂ H P CH₂ CH₃ H CH₃ CHF₂ H Q CH₂ CH₃ H CH₃CHF₂ H R CH₂ CH₃ H CH₃ CHF₂ H S CH₂ CH₃ H CH₃ CHF₂ H T CH₂ CH₃ H CH₃CHF₂ H U CH₂ CH₃ H CH₃ CHF₂ H V CH₂ CH₃ H CH₃ CHF₂ H W CH₂ CH₃ H CH₃CHF₂ H X CH₂ CH₃ H CH₃ CHF₂ H Y CH₂ CH₃ H CH₃ CHF₂ H A O CH₃ H CH₃ CHF₂H B O CH₃ H CH₃ CHF₂ H C O CH₃ H CH₃ CHF₂ H D O CH₃ H CH₃ CHF₂ H E O CH₃H CH₃ CHF₂ H F O CH₃ H CH₃ CHF₂ H G O CH₃ H CH₃ CHF₂ H H O CH₃ H CH₃CHF₂ H I O CH₃ H CH₃ CHF₂ H J O CH₃ H CH₃ CHF₂ H K O CH₃ H CH₃ CHF₂ H LO CH₃ H CH₃ CHF₂ H M O CH₃ H CH₃ CHF₂ H N O CH₃ H CH₃ CHF₂ H O O CH₃ HCH₃ CHF₂ H P O CH₃ H CH₃ CHF₂ H Q O CH₃ H CH₃ CHF₂ H R O CH₃ H CH₃ CHF₂H S O CH₃ H CH₃ CHF₂ H T O CH₃ H CH₃ CHF₂ H U O CH₃ H CH₃ CHF₂ H V O CH₃H CH₃ CHF₂ H W O CH₃ H CH₃ CHF₂ H X O CH₃ H CH₃ CHF₂ H Y O CH₃ H CH₃CHF₂ H A O C₂H₅ H CH₃ CHF₂ H B O C₂H₅ H CH₃ CHF₂ H C O C₂H₅ H CH₃ CHF₂ HD O C₂H₅ H CH₃ CHF₂ H E O C₂H₃ H CH₃ CHF₂ H F O C₂H₅ H CH₃ CHF₂ H G OC₂H₅ H CH₃ CHF₂ H H O C₂H₅ H CH₃ CHF₂ H I O C₂H₅ H CH₃ CHF₂ H J O C₂H₅ HCH₃ CHF₂ H K O C₂H₅ H CH₃ CHF₂ H L O C₂H₅ H CH₃ CHF₂ H M O C₂H₅ H CH₃CHF₂ H N O C₂H₅ H CH₃ CHF₂ H O O C₂H₅ H CH₃ CHF₂ H P O C₂H₅ H CH₃ CHF₂ HQ O C₂H₅ H CH₃ CHF₂ H R O C₂H₅ H CH₃ CHF₂ H S O C₂H₅ H CH₃ CHF₂ H T OC₂H₅ H CH₃ CHF₂ H U O C₂H₅ H CH₃ CHF₂ H V O C₂H₅ H CH₃ CHF₂ H W O C₂H₅ HCH₃ CHF₂ H X O C₂H₅ H CH₃ CHF₂ H Y O C₂H₅ H CH₃ CHF₂ H A CH₂ CH₃ CH₃ CH₃CHF₂ H B CH₂ CH₃ CH₃ CH₃ CHF₂ H C CH₂ CH₃ CH₃ CH₃ CHF₂ H D CH₂ CH₃ CH₃CH₃ CHF₂ H E CH₂ CH₃ CH₃ CH₃ CHF₂ H F CH₂ CH₃ CH₃ CH₃ CHF₂ H G CH₂ CH₃CH₃ CH₃ CHF₂ H H CH₂ CH₃ CH₃ CH₃ CHF₂ H I CH₂ CH₃ CH₃ CH₃ CHF₂ H J CH₂CH₃ CH₃ CH₃ CHF₂ H K CH₂ CH₃ CH₃ CH₃ CHF₂ H L CH₂ CH₃ CH₃ CH₃ CHF₂ H MCH₂ CH₃ CH₃ CH₃ CHF₂ H N CH₂ CH₃ CH₃ CH₃ CHF₂ H O CH₂ CH₃ CH₃ CH₃ CHF₂ HP CH₂ CH₃ CH₃ CH₃ CHF₂ H Q CH₂ CH₃ CH₃ CH₃ CHF₂ H R CH₂ CH₃ CH₃ CH₃ CHF₂H S CH₂ CH₃ CH₃ CH₃ CHF₂ H T CH₂ CH₃ CH₃ CH₃ CHF₂ H U CH₂ CH₃ CH₃ CH₃CHF₂ H V CH₂ CH₃ CH₃ CH₃ CHF₂ H W CH₂ CH₃ CH₃ CH₃ CHF₂ H X CH₂ CH₃ CH₃CH₃ CHF₂ H Y CH₂ CH₃ CH₃ CH₃ CHF₂ H A CH₂ CH₃ H Cl CF₃ CH₃ B CH₂ CH₃ HCl CF₃ CH₃ C CH₂ CH₃ H Cl CF₃ CH₃ D CH₂ CH₃ H Cl CF₃ CH₃ E CH₂ CH₃ H ClCF₃ CH₃ F CH₂ CH₃ H Cl CF₃ CH₃ G CH₂ CH₃ H Cl CF₃ CH₃ H CH₂ CH₃ H Cl CF₃CH₃ I CH₂ CH₃ H Cl CF₃ CH₃ J CH₂ CH₃ H Cl CF₃ CH₃ K CH₂ CH₃ H Cl CF₃ CH₃L CH₂ CH₃ H Cl CF₃ CH₃ M CH₂ CH₃ H Cl CF₃ CH₃ N CH₂ CH₃ H Cl CF₃ CH₃ OCH₂ CH₃ H Cl CF₃ CH₃ P CH₂ CH₃ H Cl CF₃ CH₃ Q CH₂ CH₃ H Cl CF₃ CH₃ R CH₂CH₃ H Cl CF₃ CH₃ S CH₂ CH₃ H Cl CF₃ CH₃ T CH₂ CH₃ H Cl CF₃ CH₃ U CH₂ CH₃H Cl CF₃ CH₃ V CH₂ CH₃ H Cl CF₃ CH₃ W CH₂ CH₃ H Cl CF₃ CH₃ X CH₂ CH₃ HCl CF₃ CH₃ Y CH₂ CH₃ H Cl CF₃ CH₃ A O CH₃ H Cl CF₃ CH₃ B O CH₃ H Cl CF₃CH₃ C O CH₃ H Cl CF₃ CH₃ D O CH₃ H Cl CF₃ CH₃ E O CH₃ H Cl CF₃ CH₃ F OCH₃ H Cl CF₃ CH₃ G O CH₃ H Cl CF₃ CH₃ H O CH₃ H Cl CF₃ CH₃ I O CH₃ H ClCF₃ CH₃ J O CH₃ H Cl CF₃ CH₃ K O CH₃ H Cl CF₃ CH₃ L O CH₃ H Cl CF₃ CH₃ MO CH₃ H Cl CF₃ CH₃ N O CH₃ H Cl CF₃ CH₃ O O CH₃ H Cl CF₃ CH₃ P O CH₃ HCl CF₃ CH₃ Q O CH₃ H Cl CF₃ CH₃ R O CH₃ H Cl CF₃ CH₃ S O CH₃ H Cl CF₃CH₃ T O CH₃ H Cl CF₃ CH₃ U O CH₃ H Cl CF₃ CH₃ V O CH₃ H Cl CF₃ CH₃ W OCH₃ H Cl CF₃ CH₃ X O CH₃ H Cl CF₃ CH₃ Y O CH₃ H Cl CF₃ CH₃ A O C₂H₅ H ClCF₃ CH₃ B O C₂H₅ H Cl CF₃ CH₃ C O C₂H₅ H Cl CF₃ CH₃ D O C₂H₅ H Cl CF₃CH₃ E O C₂H₅ H Cl CF₃ CH₃ F O C₂H₅ H Cl CF₃ CH₃ G O C₂H₅ H Cl CF₃ CH₃ HO C₂H₅ H Cl CF₃ CH₃ I O C₂H₅ H Cl CF₃ CH₃ J O C₂H₅ H Cl CF₃ CH₃ K O C₂H₅H Cl CF₃ CH₃ L O C₂H₅ H Cl CF₃ CH₃ M O C₂H₅ H Cl CF₃ CH₃ N O C₂H₅ H ClCF₃ CH₃ O O C₂H₅ H Cl CF₃ CH₃ P O C₂H₅ H Cl CF₃ CH₃ Q O C₂H₅ H Cl CF₃CH₃ R O C₂H₅ H Cl CF₃ CH₃ S O C₂H₅ H Cl CF₃ CH₃ T O C₂H₅ H Cl CF₃ CH₃ UO C₂H₅ H Cl CF₃ CH₃ V O C₂H₅ H Cl CF₃ CH₃ W O C₂H₅ H Cl CF₃ CH₃ X O C₂H₅H Cl CF₃ CH₃ Y O C₂H₅ H Cl CF₃ CH₃ A CH₂ CH₃ CH₃ Cl CF₃ CH₃ B CH₂ CH₃CH₃ Cl CF₃ CH₃ C CH₂ CH₃ CH₃ Cl CF₃ CH₃ D CH₂ CH₃ CH₃ Cl CF₃ CH₃ E CH₂CH₃ CH₃ Cl CF₃ CH₃ F CH₂ CH₃ CH₃ Cl CF₃ CH₃ G CH₂ CH₃ CH₃ Cl CF₃ CH₃ HCH₂ CH₃ CH₃ Cl CF₃ CH₃ I CH₂ CH₃ CH₃ Cl CF₃ CH₃ J CH₂ CH₃ CH₃ Cl CF₃ CH₃K CH₂ CH₃ CH₃ Cl CF₃ CH₃ L CH₂ CH₃ CH₃ Cl CF₃ CH₃ M CH₂ CH₃ CH₃ Cl CF₃CH₃ N CH₂ CH₃ CH₃ Cl CF₃ CH₃ O CH₂ CH₃ CH₃ Cl CF₃ CH₃ P CH₂ CH₃ CH₃ ClCF₃ CH₃ Q CH₂ CH₃ CH₃ Cl CF₃ CH₃ R CH₂ CH₃ CH₃ Cl CF₃ CH₃ S CH₂ CH₃ CH₃Cl CF₃ CH₃ T CH₂ CH₃ CH₃ Cl CF₃ CH₃ U CH₂ CH₃ CH₃ Cl CF₃ CH₃ V CH₂ CH₃CH₃ Cl CF₃ CH₃ W CH₂ CH₃ CH₃ Cl CF₃ CH₃ X CH₂ CH₃ CH₃ Cl CF₃ CH₃ Y CH₂CH₃ CH₃ Cl CF₃ CH₃ A CH₂ CH₃ H CH₃ CF₃ CH₃ B CH₂ CH₃ H CH₃ CF₃ CH₃ C CH₂CH₃ H CH₃ CF₃ CH₃ D CH₂ CH₃ H CH₃ CF₃ CH₃ E CH₂ CH₃ H CH₃ CF₃ CH₃ F CH₂CH₃ H CH₃ CF₃ CH₃ G CH₂ CH₃ H CH₃ CF₃ CH₃ H CH₂ CH₃ H CH₃ CF₃ CH₃ I CH₂CH₃ H CH₃ CF₃ CH₃ J CH₂ CH₃ H CH₃ CF₃ CH₃ K CH₂ CH₃ H CH₃ CF₃ CH₃ L CH₂CH₃ H CH₃ CF₃ CH₃ M CH₂ CH₃ H CH₃ CF₃ CH₃ N CH₂ CH₃ H CH₃ CF₃ CH₃ O CH₂CH₃ H CH₃ CF₃ CH₃ P CH₂ CH₃ H CH₃ CF₃ CH₃ Q CH₂ CH₃ H CH₃ CF₃ CH₃ R CH₂CH₃ H CH₃ CF₃ CH₃ S CH₂ CH₃ H CH₃ CF₃ CH₃ T CH₂ CH₃ H CH₃ CF₃ CH₃ U CH₂CH₃ H CH₃ CF₃ CH₃ V CH₂ CH₃ H CH₃ CF₃ CH₃ W CH₂ CH₃ H CH₃ CF₃ CH₃ X CH₂CH₃ H CH₃ CF₃ CH₃ Y CH₂ CH₃ H CH₃ CF₃ CH₃ A O CH₃ H CH₃ CF₃ CH₃ B O CH₃H CH₃ CF₃ CH₃ C O CH₃ H CH₃ CF₃ CH₃ D O CH₃ H CH₃ CF₃ CH₃ E O CH₃ H CH₃CF₃ CH₃ F O CH₃ H CH₃ CF₃ CH₃ G O CH₃ H CH₃ CF₃ CH₃ H O CH₃ H CH₃ CF₃CH₃ I O CH₃ H CH₃ CF₃ CH₃ J O CH₃ H CH₃ CF₃ CH₃ K O CH₃ H CH₃ CF₃ CH₃ LO CH₃ H CH₃ CF₃ CH₃ M O CH₃ H CH₃ CF₃ CH₃ N O CH₃ H CH₃ CF₃ CH₃ O O CH₃H CH₃ CF₃ CH₃ P O CH₃ H CH₃ CF₃ CH₃ Q O CH₃ H CH₃ CF₃ CH₃ R O CH₃ H CH₃CF₃ CH₃ S O CH₃ H CH₃ CF₃ CH₃ T O CH₃ H CH₃ CF₃ CH₃ U O CH₃ H CH₃ CF₃CH₃ V O CH₃ H CH₃ CF₃ CH₃ W O CH₃ H CH₃ CF₃ CH₃ X O CH₃ H CH₃ CF₃ CH₃ YO CH₃ H CH₃ CF₃ CH₃ A O C₂H₅ H CH₃ CF₃ CH₃ B O C₂H₅ H CH₃ CF₃ CH₃ C OC₂H₅ H CH₃ CF₃ CH₃ D O C₂H₅ H CH₃ CF₃ CH₃ E O C₂H₅ H CH₃ CF₃ CH₃ F OC₂H₅ H CH₃ CF₃ CH₃ G O C₂H₅ H CH₃ CF₃ CH₃ H O C₂H₅ H CH₃ CF₃ CH₃ I OC₂H₅ H CH₃ CF₃ CH₃ J O C₂H₅ H CH₃ CF₃ CH₃ K O C₂H₅ H CH₃ CF₃ CH₃ L OC₂H₅ H CH₃ CF₃ CH₃ M O C₂H₅ H CH₃ CF₃ CH₃ N O C₂H₅ H CH₃ CF₃ CH₃ O OC₂H₅ H CH₃ CF₃ CH₃ P O C₂H₅ H CH₃ CF₃ CH₃ Q O C₂H₅ H CH₃ CF₃ CH₃ R OC₂H₅ H CH₃ CF₃ CH₃ S O C₂H₅ H CH₃ CF₃ CH₃ T O C₂H₅ H CH₃ CF₃ CH₃ U OC₂H₅ H CH₃ CF₃ CH₃ V O C₂H₅ H CH₃ CF₃ CH₃ W O C₂H₅ H CH₃ CF₃ CH₃ X OC₂H₅ H CH₃ CF₃ CH₃ Y O C₂H₅ H CH₃ CF₃ CH₃ A CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ BCH₂ CH₃ CH₃ CH₃ CF₃ CH₃ C CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ D CH₂ CH₃ CH₃ CH₃ CF₃CH₃ E CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ F CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ G CH₂ CH₃ CH₃CH₃ CF₃ CH₃ H CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ I CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ J CH₂CH₃ CH₃ CH₃ CF₃ CH₃ K CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ L CH₂ CH₃ CH₃ CH₃ CF₃ CH₃M CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ N CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ O CH₂ CH₃ CH₃ CH₃CF₃ CH₃ P CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ Q CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ R CH₂ CH₃CH₃ CH₃ CF₃ CH₃ S CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ T CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ UCH₂ CH₃ CH₃ CH₃ CF₃ CH₃ V CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ W CH₂ CH₃ CH₃ CH₃ CF₃CH₃ X CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ Y CH₂ CH₃ CH₃ CH₃ CF₃ CH₃ A CH₂ CH₃ H ClCHF₂ CH₃ B CH₂ CH₃ H Cl CHF₂ CH₃ C CH₂ CH₃ H Cl CHF₂ CH₃ D CH₂ CH₃ H ClCHF₂ CH₃ E CH₂ CH₃ H Cl CHF₂ CH₃ F CH₂ CH₃ H Cl CHF₂ CH₃ G CH₂ CH₃ H ClCHF₂ CH₃ H CH₂ CH₃ H Cl CHF₂ CH₃ I CH₂ CH₃ H Cl CHF₂ CH₃ J CH₂ CH₃ H ClCHF₂ CH₃ K CH₂ CH₃ H Cl CHF₂ CH₃ L CH₂ CH₃ H Cl CHF₂ CH₃ M CH₂ CH₃ H ClCHF₂ CH₃ N CH₂ CH₃ H Cl CHF₂ CH₃ O CH₂ CH₃ H Cl CHF₂ CH₃ P CH₂ CH₃ H ClCHF₂ CH₃ Q CH₂ CH₃ H Cl CHF₂ CH₃ R CH₂ CH₃ H Cl CHF₂ CH₃ S CH₂ CH₃ H ClCHF₂ CH₃ T CH₂ CH₃ H Cl CHF₂ CH₃ U CH₂ CH₃ H Cl CHF₂ CH₃ V CH₂ CH₃ H ClCHF₂ CH₃ W CH₂ CH₃ H Cl CHF₂ CH₃ X CH₂ CH₃ H Cl CHF₂ CH₃ Y CH₂ CH₃ H ClCHF₂ CH₃ A O CH₃ H Cl CHF₂ CH₃ B O CH₃ H Cl CHF₂ CH₃ C O CH₃ H Cl CHF₂CH₃ D O CH₃ H Cl CHF₂ CH₃ E O CH₃ H Cl CHF₂ CH₃ F O CH₃ H Cl CHF₂ CH₃ GO CH₃ H Cl CHF₂ CH₃ H O CH₃ H Cl CHF₂ CH₃ I O CH₃ H Cl CHF₂ CH₃ J O CH₃H Cl CHF₂ CH₃ K O CH₃ H Cl CHF₂ CH₃ L O CH₃ H Cl CHF₂ CH₃ M O CH₃ H ClCHF₂ CH₃ N O CH₃ H Cl CHF₂ CH₃ O O CH₃ H Cl CHF₂ CH₃ P O CH₃ H Cl CHF₂CH₃ Q O CH₃ H Cl CHF₂ CH₃ R O CH₃ H Cl CHF₂ CH₃ S O CH₃ H Cl CHF₂ CH₃ TO CH₃ H Cl CHF₂ CH₃ U O CH₃ H Cl CHF₂ CH₃ V O CH₃ H Cl CHF₂ CH₃ W O CH₃H Cl CHF₂ CH₃ X O CH₃ H Cl CHF₂ CH₃ Y O CH₃ H Cl CHF₂ CH₃ A O C₂H₅ H ClCHF₂ CH₃ B O C₂H₅ H Cl CHF₂ CH₃ C O C₂H₅ H Cl CHF₂ CH₃ D O C₂H₅ H ClCHF₂ CH₃ E O C₂H₅ H Cl CHF₂ CH₃ F O C₂H₅ H Cl CHF₂ CH₃ G O C₂H₅ H ClCHF₂ CH₃ H O C₂H₅ H Cl CHF₂ CH₃ I O C₂H₅ H Cl CHF₂ CH₃ J O C₂H₅ H ClCHF₂ CH₃ K O C₂H₅ H Cl CHF₂ CH₃ L O C₂H₅ H Cl CHF₂ CH₃ M O C₂H₅ H ClCHF₂ CH₃ N O C₂H₅ H Cl CHF₂ CH₃ O O C₂H₅ H Cl CHF₂ CH₃ P O C₂H₅ H ClCHF₂ CH₃ Q O C₂H₅ H Cl CHF₂ CH₃ R O C₂H₅ H Cl CHF₂ CH₃ S O C₂H₅ H ClCHF₂ CH₃ T O C₂H₅ H Cl CHF₂ CH₃ U O C₂H₅ H Cl CHF₂ CH₃ V O C₂H₅ H ClCHF₂ CH₃ W O C₂H₅ H Cl CHF₂ CH₃ X O C₂H₅ H Cl CHF₂ CH₃ Y O C₂H₅ H ClCHF₂ CH₃ A CH₂ CH₃ CH₃ Cl CHF₂ CH₃ B CH₂ CH₃ CH₃ Cl CHF₂ CH₃ C CH₂ CH₃CH₃ Cl CHF₂ CH₃ D CH₂ CH₃ CH₃ Cl CHF₂ CH₃ E CH₂ CH₃ CH₃ Cl CHF₂ CH₃ FCH₂ CH₃ CH₃ Cl CHF₂ CH₃ G CH₂ CH₃ CH₃ Cl CHF₂ CH₃ H CH₂ CH₃ CH₃ Cl CHF₂CH₃ I CH₂ CH₃ CH₃ Cl CHF₂ CH₃ J CH₂ CH₃ CH₃ Cl CHF₂ CH₃ K CH₂ CH₃ CH₃ ClCHF₂ CH₃ L CH₂ CH₃ CH₃ Cl CHF₂ CH₃ M CH₂ CH₃ CH₃ Cl CHF₂ CH₃ N CH₂ CH₃CH₃ Cl CHF₂ CH₃ O CH₂ CH₃ CH₃ Cl CHF₂ CH₃ P CH₂ CH₃ CH₃ Cl CHF₂ CH₃ QCH₂ CH₃ CH₃ Cl CHF₂ CH₃ R CH₂ CH₃ CH₃ Cl CHF₂ CH₃ S CH₂ CH₃ CH₃ Cl CHF₂CH₃ T CH₂ CH₃ CH₃ Cl CHF₂ CH₃ U CH₂ CH₃ CH₃ Cl CHF₂ CH₃ V CH₂ CH₃ CH₃ ClCHF₂ CH₃ W CH₂ CH₃ CH₃ Cl CHF₂ CH₃ X CH₂ CH₃ CH₃ Cl CHF₂ CH₃ Y CH₂ CH₃CH₃ Cl CHF₂ CH₃ A CH₂ CH₃ H CH₃ CHF₂ CH₃ B CH₂ CH₃ H CH₃ CHF₂ CH₃ C CH₂CH₃ H CH₃ CHF₂ CH₃ D CH₂ CH₃ H CH₃ CHF₂ CH₃ E CH₂ CH₃ H CH₃ CHF₂ CH₃ FCH₂ CH₃ H CH₃ CHF₂ CH₃ G CH₂ CH₃ H CH₃ CHF₂ CH₃ H CH₂ CH₃ H CH₃ CHF₂ CH₃I CH₂ CH₃ H CH₃ CHF₂ CH₃ J CH₂ CH₃ H CH₃ CHF₂ CH₃ K CH₂ CH₃ H CH₃ CHF₂CH₃ L CH₂ CH₃ H CH₃ CHF₂ CH₃ N CH₂ CH₃ H CH₃ CHF₂ CH₃ N CH₂ CH₃ H CH₃CHF₂ CH₃ O CH₂ CH₃ H CH₃ CHF₂ CH₃ P CH₂ CH₃ H CH₃ CHF₂ CH₃ Q CH₂ CH₃ HCH₃ CHF₂ CH₃ R CH₂ CH₃ H CH₃ CHF₂ CH₃ S CH₂ CH₃ H CH₃ CHF₂ CH₃ T CH₂ CH₃H CH₃ CHF₂ CH₃ U CH₂ CH₃ H CH₃ CHF₂ CH₃ V CH₂ CH₃ H CH₃ CHF₂ CH₃ W CH₂CH₃ H CH₃ CHF₂ CH₃ X CH₂ CH₃ H CH₃ CHF₂ CH₃ Y CH₂ CH₃ H CH₃ CHF₂ CH₃ A OCH₃ H CH₃ CHF₂ CH₃ B O CH₃ H CH₃ CHF₂ CH₃ C O CH₃ H CH₃ CHF₂ CH₃ D O CH₃H CH₃ CHF₂ CH₃ E O CH₃ H CH₃ CHF₂ CH₃ F O CH₃ H CH₃ CHF₂ CH₃ G C CH₃ HCH₃ CHF₂ CH₃ H O CH₃ H CH₃ CHF₂ CH₃ I O CH₃ H CH₃ CHF₂ CH₃ J O CH₃ H CH₃CHF₂ CH₃ K O CH₃ H CH₃ CHF₂ CH₃ L O CH₃ H CH₃ CHF₂ CH₃ M O CH₃ H CH₃CHF₂ CH₃ N O CH₃ H CH₃ CHF₂ CH₃ O O CH₃ H CH₃ CHF₂ CH₃ P O CH₃ H CH₃CHF₂ CH₃ Q O CH₃ H CH₃ CHF₂ CH₃ R O CH₃ H CH₃ CHF₂ CH₃ S O CH₃ H CH₃CHF₂ CH₃ T O CH₃ H CH₃ CHF₂ CH₃ U O CH₃ H CH₃ CHF₂ CH₃ V O CH₃ H CH₃CHF₂ CH₃ W O CH₃ H CH₃ CHF₂ CH₃ X O CH₃ H CH₃ CHF₂ CH₃ Y O CH₃ H CH₃CHF₂ CH₃ A O C₂H₅ H CH₃ CHF₂ CH₃ B O C₂H₅ H CH₃ CHF₂ CH₃ C O C₂H₅ H CH₃CHF₂ CH₃ D O C₂H₅ H CH₃ CHF₂ CH₃ E O C₂H₅ H CH₃ CHF₂ CH₃ F O C₂H₅ H CH₃CHF₂ CH₃ G O C₂H₅ H CH₃ CHF₂ CH₃ H O C₂H₅ H CH₃ CHF₂ CH₃ I O C₂H₅ H CH₃CHF₂ CH₃ J O C₂H₅ H CH₃ CHF₂ CH₃ K O C₂H₅ H CH₃ CHF₂ CH₃ L O C₂H₅ H CH₃CHF₂ CH₃ M O C₂H₅ H CH₃ CHF₂ CH₃ N O C₂H₅ H CH₃ CHF₂ CH₃ O O C₂H₅ H CH₃CHF₂ CH₃ P O C₂H₅ H CH₃ CHF₂ CH₃ Q O C₂H₅ H CH₃ CHF₂ CH₃ R O C₂H₅ H CH₃CHF₂ CH₃ S O C₂H₅ H CH₃ CHF₂ CH₃ T O C₂H₅ H CH₃ CHF₂ CH₃ U O C₂H₅ H CH₃CHF₂ CH₃ V O C₂H₅ H CH₃ CHF₂ CH₃ W O C₂H₅ H CH₃ CHF₂ CH₃ X O C₂H₅ H CH₃CHF₂ CH₃ Y O C₂H₅ H CH₃ CHF₂ CH₃ A CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ B CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ C CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ D CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ ECH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ F CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ G CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ H CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ I CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ J CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ K CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ L CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ MCH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ N CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ O CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ P CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Q CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ R CH₂ CH₃CH₃ CH₃ CHF₂ CH₃ S CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ T CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ UCH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ V CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ W CH₂ CH₃ CH₃ CH₃CHF₂ CH₃ X CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃ Y CH₂ CH₃ CH₃ CH₃ CHF₂ CH₃

[0039] Compounds of formula (I), including, but not limited to, thepreferred compounds described hereinabove, are prepared by a number ofmeans well known to ordinarily skilled artisans given the teachings ofthis invention. These include the following synthetic routes andschemes, readily understood by those of ordinary skill in the art.

[0040] For example, compounds of formula (I) are prepared by thereaction shown in Scheme 1.

[0041] A compound of formula (II) is, for example, alkylated on theimidazole nitrogen atom with an appropriate reagent. Typical conditionsfor this transformation include treatment of compound (II) with a base,such as sodium hydride, potassium tert-butoxide, sodiumhexamethyldisilazide, etc., followed by a reagent J—R¹, where Jrepresents a halide (chloride, bromide or iodide) or pseudohalide(tosylate, mesylate, triflate, etc.), at an appropriate temperature (0°C. or room temperature, with warming if necessary) in a solvent such astetrahydrofuran, dimethylformamide or dimethylsulfoxide. Alternatively,this reaction is performed using the Mitsunobu conditions (Mitsunobu,Synthesis 1981, pp. 1-28). The compound (II) is treated with an alcoholcompound R¹OH, along with a phosphine (triphenyl, tributyl, etc.) and aphosphine-activating reagent such as diethyl azodicarboxylate.

[0042] Compounds of Formula (II) are, for example, prepared according tothe route shown in Scheme 2.

[0043] A compound of Formula (III) is coupled to an aromatic compound ofFormula (IV), with elimination of the elements of M—K; for compound(III), K represents a halide, pseudohalide (such as mesylate, tosylateor triflate), or thiomethyl, and P represents a protecting group (if theconditions of the reaction warrant protection of the imidazole N—H;otherwise, P can be H). Suitable P groups may include benzyl,4-methoxybenzyl, methoxymethyl, trimethylsilylethoxymethyl,tert-butoxycarbonyl or benzyloxycarbonyl. For compound (IV), Mrepresents groups such as lithium, bromomagnesium, chlorozinc,(dihydroxy)boron, (dialkoxy)boron, trialkylstannyl and the like. Thecoupling reaction may be performed in the presence of an appropriatecatalyst, such as tetrakis(triphenylphosphine)palladium,bis(triphenylphosphine)palladium dichloride,[1,3-bis(diphenylphosphino)propane]nickel dichloride, etc.

[0044] Two particularly useful methods involve the coupling ofchloroheterocycles with in-situ-prepared arylzinc reagents according tothe method of Negishi et al. (J. Org. Chem. 1977, 42, 1821), and thecoupling with arylboronic esters according to the method of Suzuki etal. (Chem. Letters 1989, 1405). Appropriate solvents for reactions ofthis type usually include tetrahydrofuran, diethyl ether,dimethylformamide, or dimethylsulfoxide. Typical temperatures range fromambient up to the boiling point of the solvent. Once coupled, the Pgroup may be removed to afford compound (II). Conditions for the removalof the protecting groups are well known to those familiar to the art oforganic synthesis; e.g. hydrogenation to remove benzyl orbenzyloxycarbonyl, a fluoride source (such as tetrabutylammoniumfluoride) to remove silylethoxymethyl, an acid source (such astrifluoroacetic acid) to remove tert-butoxycarbonyl or 4-methoxybenzyl,etc.

[0045] Compounds of formula (III) can be prepared according to the planshown in Scheme 3.

[0046] A diamine compound of formula (V) (in this case, P is a groupsuch as benzyl, which can be introduced already attached to the nitrogenatom; otherwise, P could represent H initially, and another protectinggroup being introduced in a later step) is used in a cyclocondensationreaction to make the imidazole ring. The conditions used will, ofcourse, depend on the X group chosen, and may include the intermediacyof the compound (VI). A review of imidazole-forming reactions may befound in Comprehensive Heterocyclic Chemistry (Pergamon Press, 1984)vol. 5, pp. 457-498.

[0047] Preparation of compounds of formula (V) wherein both A and B arenitrogen atoms may proceed according to the route of Scheme 4.

[0048] A compound of formula (VII) may be available from commercialsources, particularly for K=chloride. Compounds bearing pseudohalide Kgroups may be available from the corresponding dihydroxy compounds bytreatment with an appropriate activating reagent, such as anorganosulfonic anhydride or sulfonyl chloride.

[0049] Compound (VII) may be converted to (V) by either (i)monoalkylation with a compound P—NH₂, followed by reduction of the nitrogroup; (ii) reduction of the nitro group, to give an amine compound offormula (VIII), followed by monoalkylation with a compound P—NH₂; or(iii) use of a source of ammonia (ammonia gas, ammonium hydroxide, etc.)in either route, followed by protection of the amine group with thegroup P. Pyrimidine chemistry of this type is well represented in theliterature, and is reviewed in Comprehensive Heterocyclic Chemistry,vol. 6. Alkylation of chloropyrimidines with amine compounds can beaccomplished under either acidic (e.g. HCl or acetic) or basic(trialkylamines, potass ium tert-butoxide, etc.) conditions. Nitrogroups in compounds of this type can be reduced to amino groups usingone of any number of conditions, including catalytic hydrogenation, tindichloride, sodium dithionite, zinc metal, iron powder, etc.

[0050] Preparation of compounds of formula (V) wherein either A or Brepresent nitrogen atoms is shown in Scheme 5.

[0051] An hydroxypyridone compound of formula (IX) can be nitrated togive compound (X), employing conditions such as concentrated or fumingnitric acid, optionally in the presence of concentrated sulfuric oracetic acid. The hydroxypyridone can be selectively monoactivated with aK group to give a compound of formula (XI); one method to do thisinvolves treatment of the dicyclohexylamine salt of compound (X) withphosphorus oxychloride to give (XI) wherein K=Cl.

[0052] Alternatively, both the hydroxy and pyridone groups in compound(X) can be activated at the same time, using stronger conditions such asphosphorus oxychloride and heat, or excess toluenesulfonic anhydride, togive compound (XII). Compound (XI) may be converted to the protectedamine compound (XIII) using the same general route discussed above forthe pyrimidines. Selective monoalkylation using compound (XII) is alsopossible, but will probably give mixtures of regioisomeric products(XIV) and (XV). The nitro groups in these compounds can then be reducedas discussed above, to give compounds of formula (V), wherein either Aor B is nitrogen.

[0053] An alternative approach to the method involving introduction ofthe R¹ group at the final step is shown in Scheme 6.

[0054] This is particularly useful in the cases where R¹ represents agroup where alkylation of compound (II) is impractical (e.g. a verybulky R¹ group), but can also be used in a general manner. Here,compounds of formula (XVI) or (XVII) (either amino- or nitro-pyridinesor pyrimidines) are alkylated with an amine reagent R¹—NH₂, under eitheracidic or basic conditions as described above.

[0055] Nitro compound (XVIII) can be converted to amine compound (XIX)by nitro reduction reactions described earlier. Compound (XIX) can becyclized to imidazole compound (XX). As above, this reaction will dependupon the choice of X group. For example, for X=CHR⁹, one can use anorthoester reagent such as R²CH(R⁹)C(OR)₃, with heating in neat solutionor high-boiling solvents, and the optional presence of an acid catalyst(such as hydrochloric or sulfuric acid) (see Montgomery and Temple, J.Org. Chem. 1960, 25, 395). For X=NR¹⁰, the cyclization is performedusing reagents such as an guanidine reagent of the structureR²R¹⁰N—C(═NH)NH₂ or a urea-derived reagent of the structureR²R¹⁰N—C(═NH)D, where D represents a group like OCH₃, SCH₃ or SO₂CH₃.For X=O, the ring is formed using a reagent of the structure (R²O)₄C(with acetic acid catalysis), provided one has access to the reagentwith the R² group of choice (see Brown and Lynn, J. Chem. Soc. PerkinTrans. I 1974, 349). Alternatively, the diamine (XIX) is treated withphosgene, followed by O-alkylation to introduce the R² group (such as areagent like R²—I or R²—Br).

[0056] A similar route can be used for X=S, which would use thiophosgeneor some similar reagent, followed by S-alkylation with the R² group. Thesulfur atom in this compound (and sulfide groups throughout the moleculein general) can be oxidized to either the sulfoxide or sulfone ifdesired by treatment with an appropriate oxidizing agent such aspotassium permanganate, potassium peroxomonosulfate orm-chloroperbenzoic acid. Finally, compound (XX) can be used in an arylcoupling reaction as described above to replace the K group with thedesired aryl group in compound (I).

[0057] Methods of synthesis of compounds R¹—OH, R¹—J and R¹—NH₂ arerelated, in that the alcohol can be used in the synthesis of the othertwo compounds, as is shown in Scheme 7.

[0058] For example, the hydroxy group may be converted to the followingJ groups, using the indicated reagents (this route is not limited tothese J groups): methanesulfonate, using methanesulfonyl chloride oranhydride and an appropriate base; toluenesulfonate, usingtoluenesulfonyl chloride or anhydride and an appropriate base; iodide;using iodine/triphenylphosphine; bromide, using phosphorus tribromide orcarbon tetrabromide/triphenylphosphine; or trifluoromethanesulfonate,using trifluoromethane-sulfonic anhydride and an appropriate base.

[0059] Both compounds R¹—OH and R¹—J are used in the methods portrayedin Scheme 1. Conversion of R¹—J to R¹—N₃ requires the use of an azidesource, such as sodium azide, and a solvent such as dimethylsulfoxide ordimethylformamide, or water and a phase-transfer catalyst (such astetrabutylammonium hydrogen sulfate). Reduction of the azide compoundR¹—N₃ to R¹—NH₂ may be accomplished using reagents such as sodiumborohydride or triphenylphosphine, or hydrogen gas and a catalyst (suchas palladium on carbon). The amine R¹—NH₂ may then be employed in themethods portrayed in Scheme 6.

[0060] In the cases where the compound R¹—OH could be represented by astructure of formula (XXI) (Scheme 8), wherein R^(1a) and R^(1b)represents substructures which, taken together with the carbinol methinegroup, comprise the entire group R¹, this compound may be prepared byaddition to a carbonyl compound.

[0061] This route is particularly useful in the case where R^(1a) orR^(1b) represents a cycloalkyl group, such as cyclopropyl. Anorganometallic reagent (where M′ represents a metallic group, such asLi, CuCN, CuI, MgCl, MgBr, MgI, ZnCl, CrCl, etc.) can be allowed toreact with an aldehyde reagent to prepare the alcohol compound offormula (XXI).

[0062] Alternatively, a ketone of formula (XXII) may be treated with areducing agent, such as sodium borohydride, lithium aluminum hydride,etc., which will also generate the alcohol of formula (XXI). Standardmethods of ketone synthesis may be used where appropriate in thepreparation of compounds for formula (XXII), which will be familiar tothose skilled in the art of organic synthesis.

[0063] An homologous approach may also be employed in the synthesis ofalcohols R¹—OH, involving the ring-opening reaction of cyclic ethercompounds with organometallic reagents (Scheme 9).

[0064] Here, an organometallic reagent R^(1a)—M″ is used, where M″represents metals such as Mg, Zn or Cu. Especially useful is the methoddescribed in Huynh, et al., Tetrahedron Letters 1979, (17), pp.1503-1506, where organomagnesium reagents are allowed to react withcyclic ethers with catalysis provided by copper(I) iodide. Use of anepoxide compound of formula (XXIII) in this manner would result insynthesis of an alcohol compound of formula (XXIV), and use of anoxetane compound of formula (XXV) would generate an alcohol of formula(XXVI). Both compounds (XXIV) and (XXVI) are variants of R¹—OH.

[0065] Synthesis of compound R¹—NH₂ with formula (XXVII) is portrayed inScheme 10.

[0066] A simple reductive amination of ketone (XXII) will produce amine(XXVII). This reaction may be performed using anhydrous ammonia in thepresence of hydrogen and a catalyst.

[0067] Alternatively, addition of an organometallic reagent to a nitrilecompound gives an imine, which may be treated in situ with a reducingagent (such as sodium cyanoborohydride) to give the corresponding amine(XXVII). Finally, a compound of formula (XXVIII), wherein Q is anoptionally-substituted oxygen atom (i.e. an oxime) or nitrogen atom(i.e. a hydrazone), may be allowed to react with an organometallicreagent R^(1b)—M′″. Here, metallic groups M′″ such as MgBr, CuCl orCeCl₂ have been used in additions to oximes or hydrazones. Theintermediate addition products of formula (XXIX) may be subjected toreductive cleavage (using conditions such as sodium/liquid ammonia orcatalytic hydrogenation), which will afford amines (XXVII).

[0068] Amino acids, either naturally-occurring or synthetic, arepotential sources of useful starting materials for the synthesis of thecompounds of this invention. Scheme 11 shows some possible applicationsof this approach.

[0069] Protected amino acids of formula (XXXI) are prepared from theparent compounds of formula (XXX); useful protecting groups (“Prot”)include tert-butoxycarbonyl, benzyloxycarbonyl and triphenylmethyl.Standard texts in peptide chemistry describe this protection. Thecarboxylic acid group may be reduced using reagents such as lithiumborohydride, which gives alcohol (XXXII). The hydroxy group may beconverted to a leaving group “J” as described before. The compound offormula (XXXIII) may be treated with appropriate reagents to produce awide variety of functional groups included in the scope of thisinvention (compound (XXXIV)); displacement of J with cyanide (sodiumcyanide in warm dimethylformamide may be used here) gives a nitrile,displacement of J with a mercaptan (in the presence of a base, such aspotassium carbonate) gives a disulfide, displacement of J with asecondary amine gives a tertiary amine, etc.

[0070] Haloalkoxy-substituted aromatic groups (i.e., as ring D, eitherphenyl or pyridyl, having one or more haloalkoxy groups as substituentson the ring) may be introduced at several positions in the synthesis.For example, a reagent D—M (compound IV) may be prepared, wherein M is ametal suitable for cross-coupling with a heterocyclic compound (formulaIII, see above). In this case, the D group bears the haloalkoxy group,which is prepared according to methods discussed below. Alternatively,the complete molecule of Formula (I) with a phenolic OH substituent onthe D group is treated with appropriate reagents to effect incorporationof the haloalkoxy functionality.

[0071] Phenolic groups are converted to haloalkoxy groups by haloalkylalkylating reagents. For example, treatment of sodium phenolates(available from phenols upon treatment with basic reagents such assodium hydride in appropriate solvents) with reagents such as2,2,2-trifluoroethyl methanesulfonate (according to the method of F.Camps, J. Coll, A. Messeguer and M. A. Pericas, Synthesis 1980, p. 727)or 2,2,2-trifluoroethyl p-toluenesulfonate (according to the method ofD. Preschler, T. Thiele and R. Ruhmann, J. Fluorine Chem. 1996, 79, p.145-148) gives the corresponding aryl group substituted with a2,2,2-trifluoroethoxy group. Many trifluoromethoxy-substituted aromaticreagents are available from commercial sources, which may be used toprepare compounds of the formula type IV by standard organic chemistry.Where the appropriate starting material is not available, phenolic OHgroups are converted into trifluoromethoxy groups by treatment withreagents such as trifluoroacetic acid (according to Grinberg, et al.,Izv. Akad. Nauk SSSR, Ser. Khim. 1997, p. 1505-1508) or carbontetrachloride and antimony trifluoride with catalytic antimonypentachloride (according to Dow Chemical Co., U.S. Pat. No. 4,950,802).

[0072] Trifluoromethoxy aryl compounds are also made by conversion of aphenol to an intermediate group and subsequent fluorination to thedesired product. Examples: are 1) the reaction of dithiocarbonates with1,3-dibromo -5,5-dimethylpyrrolidine-2,4-dione/pyridinium fluoride(according to M. Kuroboshi, K. Suzuki and T. Hiyama, Tetrahedron Lett.1992, 33, p. 4173-4176); 2) the reaction of aryl thiochloroformates withmolybdenum hexafluoride (according to F. Mathey and J. Bensoam,Tetrahedron Lett. 1973); and 3) the reaction of aryl fluoroformates withsulfur tetrafluoride/HF/sodium fluoride (according to W. A. Sheppard, J.Org. Chem. 1964, 29), all which afford trifluoromethoxy aryl compounds.Difluoromethoxy groups are prepared from phenols by treatment withchlorodifluoromethane in the presence of sodium hydroxide (according toS. V. Shelyazhenko, Y. A. Fialkov and L. M. Yagupol'skii, J. Org. Chem.(Russia) 1992, p. 1317-1323). Shelyazhenko et al. also teaches thechlorination of such difluoromethoxy aryl groups to give arylchlorodifluoromethoxy compounds. Other haloalkoxy compounds may beprepared by Mitsunobu-type coupling of phenols with halo-substitutedalcohols (employing reagents like diethyl azodicarboxylate andtriphenylphosphine).

[0073] Also provided herein are compositions comprising the compounds ofthis invention, particularly pharmaceutical compositions comprisingpharmaeutically acceptable carriers and therapeutically effectiveamounts of the compounds provided herein. “Pharmaceutically acceptablecarriers” are media generally accepted in the art for the delivery ofbiologically active agents to mammals, e.g., humans. Such carriers aregenerally formulated according to a number of factors well within thepurview of those of ordinary skill in the art to determine and accountfor. These include, without limitation: the type and nature of theactive agent being formulated; the subject to which the agent-containingcomposition is to be administered; the intended route of administrationof the composition; and, the therapeutic indication being targeted.Pharmaceutically acceptable carriers include both aqueous andnon-aqueous liquid media, as well as a variety of solid and semi-soliddosage forms. Such carriers can include a number of differentingredients and additives in addition to the active agent, suchadditional ingredients being included in the formulation for a varietyof reasons, e.g., stabilization of the active agent, well known to thoseof ordinary skill in the art. Descriptions of suitable pharmaceuticallyacceptable carriers, and factors involved in their selection, are foundin a variety of readily available sources, e.g., Remington'sPharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa.,1985, the contents of which are incorporated herein by reference.

[0074] “Therapeutically effective amounts” of biologically active agentsare amounts effective to lessen, inhibit or prevent diseases anddisorders in mammals, or the symptoms thereof. Such amounts includeoptimal and suboptimal doses, and can be determined in a variety of waysknown to ordinarily skilled artisans, e.g., by administering variousamounts of a particular agent to an animal afflicted with a particularcondition and then determining the effect on the animal. Typically,therapeutically effective amounts of biologically active agents rangefrom about 0.1 mg per kg of a mammal being treated to about 100 mg perkg, although amounts outside this range can also be therapeuticallyeffective under a variety of conditions.

[0075] In particular, therapeutically effective amounts of the compoundsof this invention are amounts effective to antagonize, or lower, levelsof corticotropin releasing factor (CRF) in mammals, thereby alleviatingin the mammals conditions characterized by abnormally high levels of CRFexpression. In this regard, CRF is known to have a broadextrahyopthalamic distribution in the CNS, contributing therein to awide spectrum of autonomic, behavioral and physiological effects (see,e.g., Vale et al., 1983; Koob, 1985; and, De Souza et al., 1985). Forexample, CRF concentrations are significantly increased in thecerebrospinal fluid of patients afflicted with affective disorder ormajor depression (see, e.g., Nemeroff et al., 1984; Banki et al., 1987;France et al., 1988; Arato et al., 1989), and thus, antagonism of CRFshould ameliorate these conditions.

[0076] Moreover, excessive levels of CRF are known to produce anxiogeniceffects in animal models (see, e.g., Britton et al., 1982; Berridge andDunn, 1986 and 1987), and, CRF antagonists are known to produceanxiolytic effects; accordingly, therapeutically effective amounts ofcompounds provided herein are, for example, determined by assessing theanxiolytic effects of varying amounts of the compounds in such animalmodels. Furthermore, clinical data provides evidence that CRF has a rolein psychiatric disorders and neurological diseases including depression,anxiety-related disorders and feeding disorders; a role for CRF has alsobeen postulated in the etiology and pathophysiology of Alzheimer'sdisease, Parkinson's disease, Huntington's disease, progressivesupranuclear palsy and amyotrophic lateral sclerosis as they relate tothe dysfunction of CRF neurons in the central nervous system (see, e.g.,E. B. De Souza, 1988).

[0077] Neurochemical, endocrine and receptor binding studies have alldemonstrated interactions between CRF and benzodiazepine anxiolytics,providing further evidence for the involvement of CRF in thesedisorders. Chlordiazepoxide attenuates the “anxiogenic” effects of CRFin both the conflict test [K. T. Britton et al., Psychopharmacology86:170 (1985); K. T. Britton et al., Psychopharmacology 94:306 (1988)]and in the acoustic startle test [N. R. Swerdlow et al.,Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptorantagonist (Ro15-1788), which was without behavioral activity alone inthe operant conflict test, reversed the effects of CRF in adose-dependent manner while the benzodiazepine inverse agonist (FG7142)enhanced the actions of CRF [K. T. Britton et al., Psychopharmacology94:306 (1988)].

[0078] The contents of the above-cited disclosures are incorporatedherein by reference.

[0079] Accordingly, antagonism of CRF by compounds of this invention isan effective means of treating conditions such as affective disorder,depression and anxiety. Additional treatable conditions include, withoutlimitation: headache, irritable bowel syndrome, post-traumatic stressdisorder, supranuclear palsy, immune suppression, Alzheimer's disease,Huntington's disease, Parkinson's disease, progressive supranuclearpalsy, amyotrophic lateral sclerosis, gastrointestinal diseases,anorexia nervosa or other feeding disorder, drug addiction, drug oralcohol withdrawal symptoms, inflammatory diseases, cardiovascular orheart-related diseases, fertility problems, human immunodeficiency virusinfections, hemorrhagic stress, obesity, infertility, head and spinalcord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosisand hypoglycemia. Therefore, this invention further provides a method oftreating such conditions, said method comprising administering tomammals afflicted with the conditions a dose of a pharmaceuticalcomposition provided herein.

[0080] The following examples describe experimental procedures used toprepare particular compounds provided by this invention and set forth inTables 1 and 2 hereinbelow. However, those of ordinary skill in the artwill readily understand that these examples are not intended to belimiting, and are merely illustrative of the invention as defined in theclaims which follow thereafter.

EXAMPLES Part I

[0081] The following Table I sets forth exemplary compounds providedherein (wherein A and B are each N and ring D is a phenyl ring). Thecompounds are listed in the table sequentially, by example number, alongwith melting point (“m. p.”) data; or, where the compound is listed asan “oil” in the column for “m. p.,” spectral data is provided followingthe table. These compounds were synthesized according to the schemes setforth hereinabove; specific examples of reaction conditions andmaterials by which two of the compounds,6-(2-Chloro-4-trifluoromethoxyphenyl)-9-dicyclopropylmethyl-8-ethylpurine(Example 8) and6-(2-Chloro-4-difluoromethoxyphenyl)-8-ethyl-9-(2-pentyl)purine (Example11), were made are provided. TABLE 1

Ex. No. R^(1a) X R² R³ R^(aryl1) R^(aryl2) R^(aryl3) m.p.^(b)  1 B CH₂CH₃ H Cl CF₃ H oil  2 C CH₂ CH₃ H Cl CF₃ H oil  3 E CH₂ CH₃ H Cl CF₃ Hoil  4 F CH₂ CH₃ H Cl CF₃ H oil  5 K CH₂ CH₃ H Cl CF₃ H 103- 104  6 LCH₂ CH₃ H Cl CF₃ H  88-92  7 V CH₂ CH₃ H Cl CF₃ H oil  8 Y CH₂ CH₃ H ClCF₃ H 119- 120  9 L CH₂ CH₃ H CH₃ CF₃ H 77-78 10 A O CH₃ H CH₃ CF₃ H 99- 100 11 B CH₂ CH₃ H Cl CHF₂ H oil 12 C CH₂ CH₃ H Cl CHF₂ H oil 13 DCH₂ CH₃ H Cl CHF₂ H oil 14 E CH₂ CH₃ H Cl CHF₂ H oil 15 G CH₂ CH₃ H ClCHF₂ H oil 16 I CH₂ CH₃ H Cl CHF₂ H oil 17 J CH₂ CH₃ H Cl CHF₂ H oil 18L CH₂ CH₃ H Cl CHF₂ H  89-90 19 N CH₂ CH₃ H Cl CHF₂ H oil 20 R CH₂ CH₃ HCl CHF₂ H oil 21 V CH₂ CH₃ H Cl CHF₂ H oil 22 W CH₂ CH₃ H Cl CHF₂ H 139-142 23 X CH₂ CH₃ H Cl CHF₂ H oil 24 Y O CH₃ H Cl CHF₂ H 115- 117 25 ZCH₂ CH₃ H Cl CHF₂ H oil 26 AA CH₂ CH₃ H Cl CHF₂ H oil 27 BB CH₂ CH₃ H ClCHF₂ H oil 28 G CH₂ CH₃ H Cl CF₃ H  76-79 29 N O CH₃ H Cl CHF₂ H 110-112 30 CC CH₂ CH₃ H Cl CHF₂ H 121- 122 31 CC O CH₃ H Cl CHF₂ H  90-91 32Y CH₂ CH₃ H Cl CHF₂ H 116- 117 # Q = 1-cyclobutyl-3-methoxy-1-propyl; R= 1-cyclopentyl-1-ethyl; S = 1-cyclopentyl-1-propyl; T =1-cyclopentyl-1-butyl; U = 1-cyclopentyl-3-methoxy-1-propyl; V =?-cyclopropylbenzyl; W = 1-phenyl-2-butyn-1-yl; X =1-cyclopropyl-2-butyn-1-yl; Y = dicyclopropylmethyl; Z = 2-hexyn-4-yl;AA = cyclopentyl; BB = 1-cyclopropyl-2-propyl; CC = dicyclobutylmethyl

[0082] Spectral Data:

Example 1

[0083] TLC R_(F) 0.41 (25:75 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.76 (1H, d, J=8.4 Hz), 7.45-7.44 (1H, m), 7.27(1H, dm, J=8 Hz), 4.61-4.51 (1H, m), 2.98 (2H, dq, J=7.5, 1.6 Hz),2.48-2.35 (1H, m), 2.10-1.98 (1H, m), 1.75 (3H, d, J=7.0 Hz), 1.41 (3H,t, J=7.5 Hz), 1.35-1.22 (2H, m), 0.93 (3H, t, J=7.2 Hz). MS (NH₃-CI):m/e calculated for C₁₉H₂₁ClF₃N₄O: 413.1349, found 413.1344; 416 (8), 415(35), 414 (24), 413 (100).

Example 2

[0084] TLC R_(F) 0.45 (25:75 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.77 (1H, d, J=8.4 Hz), 7.44 (1H, m), 7.27 (1H,dm, J=8 Hz), 4.57-4.49 (1H, m), 2.97 (2H, dq, J=7.7, 1.7 Hz), 2.47-2.36(1H, m), 2.12-2.02 (1H, m), 1.75 (3H, d, J=7.0 Hz), 1.41 (3H, t, J=7.7Hz), 1.33-1.21 (4H, m), 0.86 (3H, t, J=7.3 Hz). MS (NH₃-CI): m/ecalculated for C₂₀H₂₃ClF₃N₄O: 427.1509, found 427.1507; 430 (8), 429(35), 428 (25), 427 (100).

Example 3

[0085] TLC R_(F) 0.44 (25:75 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.95 (1H, s), 7.80 (1H, d, J=8.4 Hz), 7.45-7.44 (1H, m), 7.30(1H, dm, J=8 Hz), 4.23-4.17 (1H, m), 2.97 (2H, q, J=7.6 Hz), 2.54-2.39(2H, m), 2.14-2.00 (2H, m), 1.43 (3H, t, J=7.6 Hz), 0.84 (6H, t, J=7.3Hz). MS (NH₃-CI): m/e calculated for C₁₉H₂₁ClF₃N₄O: 413.1368, found413.1373; 416 (8), 415 (34), 414 (24), 413 (100).

Example 4

[0086] TLC R_(F) 0.48 (25:75 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.95 (1H, s), 7.79 (1H, d, J=8.4 Hz), 7.45-7.43 (1H, m), 7.27(1H, dm, J=8 Hz), 4.35-4.25 (1H, m), 2.96 (2H, q, J=7.4 Hz), 2.42 (2H,br), 2.12-1.93 (2H, m), 1.43 (3H, t, J=7.4 Hz), 1.37-1.22 (2H, m), 0.91(3H, t, J=7.2 Hz), 0.83 (3H, t, J=7.5 Hz). MS (NH₃-CI) m/e calculatedfor C₂₀H₂₃ClF₃N₄O: 427.1514, found 427.1515; 430 (8), 429 (34), 428(25), 427 (100).

Example 5

[0087] see Table 1 for melting point data.

Example 6

[0088] TLC R_(F) 0.50 (25:75 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.80 (1H, d, J=8.4 Hz), 7.45-7.43 (1H, m),7.31-7.27 (1H, dm, J=8 Hz), 3.80-3.73 (1H, m), 2.93 (2H, q, J=7.3 Hz),2.40 (1H, br), 2.25-2.14 (1H, m), 1.95 (1H, br), 1.42 (3H, t, J=7.5 Hz),1.35-1.10 (2H, m), 0.92 (3H, t, J=7.3 Hz), 0.91-0.80 (1H, m), 0.53-0.44(2H, m), 0.24-0.14 (1H, m). MS (NH₃-CI): m/e calculated forC₂₁H₂₃ClF₃N₄O: 439.1519, found 439.1524; 442 (8), 441 (34), 440 (26),439 (100).

Example 7

[0089] TLC R_(F) 0.46 (25:75 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.98 (1H, s), 7.83 (1H, d, J=8.4 Hz), 7.46-7.27 (7H, m), 5.13(1H, d, J=10.7 Hz), 2.88-2.62 (2H, m), 2.15 (1H, br), 1.26 (3H, t, J=7.5Hz), 1.12-1.02 (1H, m), 0.78-0.62 (2H, m), 0.54-0.44 (1H, m). MS(NH₃-CI): m/e calculated for C₂₄H₂₁ClF₃N₄O: 473.1361, found 473.1365;476 (9), 475 (36), 474 (29), 473 (100).

Example 8

[0090] see Table 1 for melting point data.

Example 9

[0091] see Table 1 for melting point data.

Example 10

[0092] see Table 1 for melting point data.

Example 11

[0093] TLC R_(F) 0.14 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.73 (1H, d, J=8.5 Hz), 7.34 (1H, d, J=2.5 Hz),7.18 (1H, dd, J=8.5, 2.5 Hz), 6.57 (1H, t, J=73.2 Hz), 4.60-4.50 (1H,m), 2.97 (2H, dq, J=7.5, 1.7 Hz), 2.47-2.35 (1H, m), 2.10-1.98 (1H, m),1.74 (3H, d, J=6.6 Hz), 1.41 (3H, t, J=7.5 Hz), 1.39-1.22 (2H, m), 0.93(3H, t, J=7.2 Hz). ¹⁹F NMR (300 MHz, CDCl₃): ? −81.6 (2F, d, J=73.2 Hz).MS (AP): m/e calc'd for C₁₉H₂₂ClF₂N₄O: 395.1450, found 395.1446; 395(100).

Example 12

[0094] TLC R_(F) 0.15 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.74 (1H, d, J=8.5 Hz), 7.35 (1H, d, J=2.5 Hz),7.18 (1H, dd, J=8.5, 2.5 Hz), 6.57 (1H, t, J=73.2 Hz), 4.60-4.49 (1H,m), 2.97 (2H, dq, J=7.7, 1.8 Hz), 2.49-2.36 (1H, m), 2.12-2.00 (1H, m),1.75 (3H, t, J=7.0 Hz), 1.41 (3H, t, J=7.5 Hz), 1.40-1.23 (4H, m), 0.86(3H, t, J=7.2 Hz). MS (AP): m/e calc'd for C₂₀H₂₄ClF₂N₄O: 409.1606,found 409.1590; 409 (100).

Example 13

[0095] TLC R_(F) 0.18 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.74 (1H, d, J=8.4 Hz), 7.34 (1H, d, J=2.1 Hz),7.18 (1H, dd, J=8.4, 2.1 Hz), 6.57 (1H, t, J=73.2 Hz), 4.60-4.49 (1H,m), 2.97 (2H, dq, J=7.7, 1.8 Hz), 2.47-2.35 (1H, m), 2.11-1.99 (1H, m),1.74 (3H, d, J=6.6 Hz), 1.41 (3H, t, J=7.7 Hz), 1.37-1.20 (6H, m), 0.84(3H, t, J=7.0 Hz). MS (AP): m/e calc'd for C₂₁H₂₆ClF₂N₄O: 423.1763,found 423.1764; 423 (100).

Example 14

[0096] TLC R_(F) 0.15 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.94 (1H, s), 7.77 (1H, d, J=8.5 Hz), 7.35 (1H, d, J=2.6 Hz),7.19 (1H, dd, J=8.5, 2.6 Hz), 6.57 (1H, t, J=73.0 Hz), 4.21 (1H, br),2.96 (1H, q, J=7.4 Hz), 2.53-2.39 (2H, m), 2.15-2.00 (2H, m), 1.43 (3H,t, J=7.4 Hz), 0.83 (6H, t, J=7.5 Hz). MS (AP): m/e calc'd forC₁₉H₂₂ClF₂N₄O: 395.1450, found 395.1437; 395 (100).

Example 15

[0097] TLC R_(F) 0.22 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl3): Δ 8.95 (1H, s), 7.78 (1H, d, J=8.4 Hz), 7.35 (1H, d, J=2.5 Hz),7.19 (1H, dd, J=8.4, 2.5 Hz), 6.58 (1H, t, J=73.2 Hz), 4.27 (1H, br),2.95 (2H, q, J=7.7 Hz), 2.41 (2H, br), 2.11-1.98 (2H, m), 1.43 (3H, t,J=7.7 Hz), 1.39-1.20 (4H, m), 0.85 (3H, t, J=7.3 Hz), 0.82 (3H, t, J=7.3Hz). MS (AP): m/e calc'd for C₂₁H₂₆ClF₂N₄O: 423.1763, found 423.1758;423 (100).

Example 16

[0098] TLC R_(F) 0.29 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.95 (1H, s), 7.77 (1H, d, J=8.4 Hz), 7.35 (1H, d, J=2.2 Hz),7.19 (1H, dd, J=8.4, 2.2 Hz), 6.57 (1H, t, J=73.2 Hz), 4.38 (1H, br),2.95 (2H, q, J=7.3 Hz), 2.39 (2H, br), 2.05-1.92 (2H, m), 1.43 (3H, t,J=7.3 Hz), 1.38-1.21 (2H, m), 1.19-1.02 (2H, m), 0.91 (6H, t, J=7.3 Hz).MS (AP): m/e calc'd for C₂₁H₂₆ClF₂N₄O: 423.1763, found 423.1752; 423(100).

Example 17

[0099] TLC R_(F) 0.11 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.75 (1H, d, J=8.8 Hz), 7.35 (1H, d, J=2.6 Hz),7.19 (1H, dd, J=8.8, 2.6 Hz), 6.57 (1H, t, J=73.0 Hz), 3.81-3.71 (1H,m), 3.00-2.90 (2H, m), 2.09-1.99 (1H, m), 1. 82 (3H, d, J=7.0 Hz), 1.40(3H, t, J=7.5 Hz), 0.88-0.78 (1H, m), 0.58-0.41 (2H, m), 0.30-0.20 (1H,m). MS (AP): m/e calc'd for C₁₉H₂₀ClF₂N₄O: 393.1293, found 393.1281; 393(100).

Example 18

[0100] see Table 1 for melting point data.

Example 19

[0101] TLC R_(F) 0.26 (30:70 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.95 (1H, s), 7.74 (1H, d, J=8.4 Hz), 7.35 (1H, d, J=2.2 Hz),7.18 (1H, dd, J=8.4, 2.2 Hz), 6.57 (1H, t, J=73.2 Hz), 4.44 (1H, br),3.57 (1H, br), 3.01 (2H, dq, J=7.3, 1.5 Hz), 2.28 (1H, br), 1.98-1.70(4H, m), 1.63 (3H, d, J=7.0 Hz), 1.62-1.50 (1H, m), 1.43 (3H, t, J=7.3Hz). MS (AP): m/e calc'd for C₂₀H₂₂ClF₂N₄O: 407.1450, found 407.1450;407 (100).

Example 20

[0102] TLC R_(F) 0.11 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.95 (1H, s), 7.75 (1H, d, J=8.4 Hz), 7.34 (1H, d, J=2.2 Hz),7.18 (1H, dd, J=8.4, 2.2 Hz), 6.57 (1H, t, J=73.0 Hz), 4.22 (1H, br),3.15 (1H, br), 3.03-2.94 (2H, m), 2.11-2.00 (1H, m), 1.74 (3H, d, J=6.6Hz), 1.72-1.49 (3H, m), 1.42 (3H, t, J=7.5 Hz), 1.38-1.25 (4H, m). MS(AP): m/e calc'd for C₂₁H₂₄ClF₂N₄O: 421.1606, found 421.1603; 421 (100).

Example 21

[0103] TLC R_(F) 0.20 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.98 (1H, s), 7.80 (1H, d, J=8.4 Hz), 7.48-7.27 (6H, m), 7.19(1H, dd, J=8.4, 2.2 Hz), 6.58 (1H, t, J=73.0 Hz), 5.13 (1H, br d, J=10.6Hz), 2.89-2.61 (2H, m), 1.26 (3H, t, J=7.3 Hz), 1.12-1.02 (1H, m),0.78-0.58 (3H, m), 0.38-0.28 (1H, m). MS (AP): m/e calc'd forC₂₄H₂₂ClF₂N₄O: 455.1451, found 455.1448; 455 (100).

Example 22

[0104] TLC R_(F) 0.21 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 9.04 (1H, s), 7.78 (1H, d, J=8.4 Hz), 7.46-7.30 (6H, m), 7.20(1H, dd, J=8.4, 2.2 Hz), 7.19 (1H, d, J=2.6 Hz), 6.58 (1H, t, J=73.0Hz), 2.98 (1H, dq, J=15.9, 7.5 Hz), 2.65 (1H, dq, J=15.9, 7.5 Hz), 2.00(3H, d, J=2.6 Hz), 1.16 (3H, t, J=7.5 Hz). MS (AP): m/e calc'd forC₂₄H₂₀ClF₂N₄O: 453.1293, found 453.1298; 453 (100).

Example 23

[0105] TLC R_(F) 0.16 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.97 (1H, s), 7.75 (1H, d, J=8.4 Hz), 7.35 (1H, d, J=2.2 Hz),7.19 (1H, dd, J=8.4, 2.2 Hz), 6.58 (1H, t, J=73.0 Hz), 5.19 (1H, dq,J=8.2, 2.2 Hz), 3.35-3.07 (2H, m), 1.88 (3H, d, J=2.2 Hz), 1.70-1.59(1H, m), 1.48 (3H, t, J=7.5 Hz), 0.88-0.78 (2H, m), 0.60-0.45 (2H, m).MS (AP): m/e calc'd for C₂₁H₂₀ClF₂N₄O: 417.1294, found 417.1301; 417(100).

Example 24

[0106] see Table 1 for melting point data.

Example 25

[0107] TLC R_(F) 0.13 (20:80 ethyl acetate-hexane). 1H NMR (300 MHz,CDCl₃): Δ 8.99 (1H, s), 7.74 (1H, d, J=8.4 Hz), 7.35 (1H, d, J=2.2 Hz),7.19 (1H, dd, J=8.4, 2.2 Hz), 6.58 (1H, t, J=73.0 Hz), 5.50 (1H, tq,J=7.8, 2.2 Hz), 3.19 (1H, dq, J=15.6, 7.5 Hz), 3.06 (1H, dq, J=15.6, 7.5Hz), 2.35-2.09 (2H, m), 1.88 (3H, d, J=2.2 Hz), 1.46 (3H, t, J=7.5 Hz),1.01 (3H, t, J=7.5 Hz). MS (AP): m/e calc'd for C₂₀H₂₀ClF₂N₄O: 405.1294,found 405.1291; 405 (100).

Example 26

[0108] TLC R_(F) 0.36 (25:75 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.73 (1H, d, J=8.4 Hz), 7.44 (1H, d, J=1.1 Hz),7.28 (1H, dd, J=8.4, 1.1 hz), 4.79 (1H, -pentet, J=8.4 Hz), 3.01 (2H, q,J=7.7 Hz), 2.62-2.50 (2H, m), 2.23-2.07 (2H, m), 1.89-1.77 (2H, m),1.66-1.49 (2H, m), 1.41 (3H, t, J=7.7 Hz). MS (NH₃-CI): m/e calculatedfor C₁₉H₁₉ClF₃N₄O: 411.1205, found 411.1208; 414 (7), 413 (34), 412(24), 411 (100).

Example 27

[0109] TLC R_(F) 0.30 (30:70 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.95 (1H, s), 7.73 (1H, d, J=8.5 Hz), 7.34 (1H, d, J=2.1 Hz),7.19 (1H, dd, J=8.5, 2.1 Hz), 6.57 (1H, t, J=73.3 Hz), 4.65-4.58 (1H,m), 3.02 (2H, q, J=7.6 Hz), 2.48-2.38 (1H, m), 1.85-1.76 (1H, m), 1.80(3H, d, J=7.0 Hz), 1.42 (3H, t, J=7.6 Hz), 0.49-0.41 (2H, m), 0.38-0.26(1H, m), 0.15-0.07 (1H, m), −0.13-0.21 (1H, m). MS (API): m/e 410 (7),409 (35), 408 (22), 407 (100). Analysis calculated for C₂₀H₂₁ClF₂N₄O: C,59.04; H, 5.20; N, 13.77; found: C, 58.76; H, 5.09; N, 13.72.

Example 28

[0110] see Table 1 for melting point data.

Example 29

[0111] see Table 1 for melting point data.

Example 30

[0112] see Table 1 for melting point data.

Example 31

[0113] see Table 1 for melting point data.

Example 32

[0114] see Table 1 for melting point data.

[0115] Synthesis:

[0116] Preparation of6-(2-Chloro-4-trifluoromethoxyphenyl)-9-dicyclopropylmethyl-8-ethylpurine(Example 8)

[0117] Part A. A solution of 4-trifluoromethoxyaniline (12.0 mL, 88.8mmol) and N-chlorosuccinimide (13.04 g, 97.7 mmol) in acetonitrile (90mL) was heated to reflux for 12 h. After cooling, the solution wasfiltered and evaporated, and the residual material was separated bycolumn chromatography (silica gel, 10:90 ethyl acetate-hexane) to affordthe product, 2-chloro-4-trifluoromethoxyaniline, as a liquid. Theproduct was further purified by distillation to afford 18.14 g (85.7mmol, 97%) pure product, b.p. 50-60° C./5 mm Hg (bulb-to-bulb). ¹H NMR(300 MHz, CDCl₃): Δ 7.16 (1H, d, J=2.5 Hz), 6.96 (1H, dd, J=8.8, 2.5Hz), 6.73 (1H, d, J=8.8 Hz), 4.08 (2H, br s). MS (H₂O-GC/MS): m/e 214(27), 213 (17), 212 (100).

[0118] Part B. A solution of the aniline from Part A (17.97 g, 84.9mmol) in concentrated hydrochloric acid (50 mL) was cooled to −5° C.,and treated with a saturated aqueous solution of sodium nitrite (6.45 g,93.5 mmol) After stirring for 30 min., the solution was diluted with 50mL cyclohexane and 50 mL dichloromethane, and the resulting mixture wasstirred vigorously while a saturated aqueous solution of potassiumiodide (28.2 g, 170 mmol) was added dropwise. The resulting solution wasallowed to stir for 12 h, then was partitioned between water anddichloromethane. The organic phase was washed with 1 N aqueous sodiumbisulfite solution and brine. The three aqueous phases wereback-extracted in sequence with dichloromethane, and the organic phaseswere combined, dried over anhydrous magnesium sulfate, filtered andevaporated. The product was purified by distillation to afford theproduct, 3-chloro-4-iodo-trifluoroanisole (21.38 g, 66.3 mmol, 78%).b.p. 60-70° C./l mm Hg (bulb-to-bulb). ¹H NMR (300 MHz, CDCl₃): Δ 7.87(1H, d, J=8.8 Hz), 7.35 (1H, d, J=2.5 Hz), 6.87 (1H, J=ddd, J=8.8 Hz,2.5H, 0.7 Hz). MS (H₂O-GC/MS): m/e 324 (31), 323 (10), 322 (100).

[0119] Part C. A solution of the iodide from Part B (17.5 g, 54.3 mmol)in THF (50 mL) was cooled to −90° C., and treated dropwise with a hexanesolution of n-butyllithium (38.0 mL, 1.6 M, 60.8 mmol). After stirringfor 30 min., the resulting solution was treated by syringe withtriisopropylborate (14.0 mL, 60.6 mmol) and allowed to warm to ambienttemperature with stirring for 10 h. The solution was treated with 6 Nhydrochloric acid and water (20 mL each), and stirred for 1 h. Then, themixture was partitioned between water and ethyl acetate and separated.The aqueous phase was extracted with additional ethyl acetate, and theextracts were combined, dried over magnesium sulfate, filtered andevaporated. The residual material was triturated with hexane andfiltered, and the filtrate allowed to stand to give a second crop ofsolid product, which was 2-chloro-4-trifluoromethoxybenzeneboronic acid(3.95 g, 16.5 mmol, 30%). m.p. 160-162° C. ¹H NMR (300 MHz, CDCl₃): Δ8.00 (1H, d, J=8.1 Hz), 7.24 (1H, d, J=1.1 Hz), 7.19 (1H, dd, J=8.1, 1.1Hz), 5.31 (2H, s). MS (H₂O-GC/MS, as ethylene glycol ester): m/e 267(100).

[0120] Part D. A solution of dicyclopropyl ketone (50 g) in absolutemethanol (150 mL) in an autoclave vessel was charged with W4 Raneynickel (12 g, washed free of water and in methanol slurry) and thenanhydrous ammonia (17 g). The mixture was subjected to 120 atm ofhydrogen at 150-160° C. for 5 hours, then cooled and excess gassespurged. The resulting slurry was filtered through celite, and thefiltrate was distilled to about one-third the original volume(atmospheric pressure, Vigreaux column). The pot solution was cooled to0° C., diluted with 3 volumes diethyl ether, and treated with 4 Nhydrochloric acid solution in anhydrous dioxane until precipitateformation ceased. The solid product (dicyclopropylmethylaminehydrochloride) was collected by filtration, washed with excess diethylether, and dried under vacuum (45.22 g, 306 mmol, 67%). ¹H NMR (300 MHz,methanol-d₄): Δ 1. 94 (1H, t, J=9.3 Hz), 1.11-0.99 (2H, m), 0.75-0.59(4H, m), 0.48-0.37 (4H, m). MS (NH₃-DCI): m/e 114 (5), 113 (100).

[0121] Part E. A solution of 5-amino-4,6-dichloropyrimidine (5.00 g,30.5 mmol) and diisopropylethylamine (12.0 mL, 68.9 mmol) in ethanol(100 mL) was treated with the amine from Part D (3.81 g, 25.8 mmol), andheated to reflux for 72 h. The resulting mixture was cooled and pouredinto water (300 mL), which was extracted with ethyl acetate (2×300 mL).The extracts were washed with brine, combined, dried over sodiumsulfate, filtered and evaporated. The residual oil was separated bycolumn chromatography (30:70 ethyl acetate-hexane), and the desiredproduct, 5-amino-4-chloro-6-dicyclopropylmethylaminopyrimidine, wastriturated with warm ether-hexane, collected by filtration, and driedunder vacuum (3.15 g, 13.2 mmol, 43%). m.p. 137-138° C. TLC R_(F) 0.17(30:70 ethyl acetate-hexane). ¹H NMR (300 MHz, CDCl₃): Δ 8.01 (1H, s),4.95 (1H, br d, J=7.3 Hz), 3.45 (1H, q, J=7.0 Hz), 3.37 (2H, br s),1.06-0.94 (2H, m), 0.59-0.32 (8H, m). MS (NH₃-CI): m/e 243 (1), 242 (5),241 (36), 240 (16), 239 (100).

[0122] Part F. A solution of the diamine from Part E (1.80 g, 7.54 mmol)and 1 drop concentrated hydrochloric acid in triethyl orthopropionate(12 mL) was heated to 100° C. for 6 hours. The excess orthoester wasremoved by distillation (partial vacuum, short-path), and the potresidue solidified to give the product,N-(4-chloro-6-dicyclopropylmethylaminopyrimidin-5-yl)-O-ethyl-propionimidate.¹H NMR (300 MHz, CDCl₃): Δ 8.08 (1H, s), 4.84 (1H, br d, J=8.0 Hz), 4.35(2H, br), 3.45 (1H, q, J=7.7 Hz), 2.14 (2H, q, J=7.3 Hz), 1.41 (3H, t,J=7.1 Hz), 1.08 (3H, t, J=7.7 Hz), 1.03-0.93 (2H, m), 0.58-0.27 (8H, m).MS (NH₃-CI): m/e 327 (1), 326 (7), 325 (36), 324 (21), 323 (100).

[0123] Part G. A solution of the imidate compound prepared in Part Fabove and p-toluenesulfonic acid monohydrate (50 mg) in diphenyl ether(10 mL) was heated to 170° C. for 2 hours. The resulting mixture wascooled and separated by column chromatography (silica gel, hexane toremove diphenyl ether, then 30:70 ethyl acetate-hexane) to afford theproduct, 6-chloro-9-dicyclopropylmethyl-8-ethylpurine, as a solid (1.42g, 5.13 mmol, 68% for both steps F and G). m.p. 99-100° C. TLC R_(F)0.26 (30:70 ethyl acetate-hexane). ¹H NMR (300 MHz, CDCl₃): Δ 8.63 (1H,s), 2.99 (2H, br), 1.92 (1H, br), 1.50 (3H, t, J=7.3 Hz), 0.87-0.78 (2H,m), 0.50-0.39 (4H, m), 0.20-0.10 (4H, m). MS (NH₃-CI): m/e 280 (6), 279(36), 278 (19), 277 (100).

[0124] Part H. A solution of the purine chloride from Part G (870 mg,3.14 =mol), the boronic acid from Part C (980 mg, 4.08 mmol),triphenylphosphine (190 mg, 0.724 mmol) and 2 M aqueous sodium carbonatesolution (4 mL, 8 mmol) in dimethoxyethane (15 mL) was degassed by threesuccessive cycles of vacuum pumping/purging with dry nitrogen. To thismixture was added palladium (II) acetate 40 mg, 0.178 mmol), and themixture was degassed again as described above and heated to reflux for12 h. After cooling, the mixture was poured into water and extractedtwice with ethyl acetate. The extracts were washed in sequence with 1) a15% w/w aqueous solution of 1,3,5-triazine-2,4,6-trithiol trisodiumsalt, and 2) saturated brine, combined, dried over anhydrous sodiumsulfate, filtered and evaporated. The residual material was separated bycolumn chromatography (15:85 ethyl acetate-hexane) to afford the solidtitle product, which was purified further by recrystallization fromether-hexane (first crop 500 mg, 1.14 mmol, 30%). m.p. 119-120° C.(ether-hexane). TLC R_(F) 0.43 (30:70 ethyl acetate-hexane). ¹H NMR (300MHz, CDCl₃): Δ 8.95 (1H, s), 7.80 (1H, d, J=8.4 Hz), 7.46-7.44 (1H, m),7.31-7.25 (1H, m), 3.92 (1H, v br), 2.98 (2H, br), 1.95 (2H, br), 1.44(3H, br t, J=7 Hz), 0.92-0.82 (2H, m), 0.63-0.53 (2H, m), 0.52-0.42 (2H,m), 0.28-0.18 (2H, m). MS (NH₃-CI): m/e 440 (8), 439 (35), 438 (26), 437(100). Analysis calculated for C₂₁H₂₀ClF₃N₄O: C, 57.74; H, 4.60; N,12.83; found: C, 57.80; H, 4.57; N, 12.43.

[0125] Preparation of6-(2-Chloro-4-difluoromethoxyphenyl)-8-ethyl-9-(2-pentyl)purine (Example10)

[0126] Part A. A solution of 5-amino-4,6-dichloropyrimidine (24.6 g, 150mmol), 4-methoxybenzylamine (20.0 mL, 150 mmol) anddiisopropylethylamine (30.0 mL, 172 mmol) in ethanol (200 mL) was heatedto ref lux for 4 days. After cooling, the solution was evaporated andthe residue partitioned between water and ethyl acetate. The organiclayer was washed with more water and brine, and the three aqueous phaseswere back-extracted in sequence with ethyl acetate. The extracts werecombined, dried over sodium sulfate, filtered and evaporated. Theresulting solid was triturated with ether, collected by filtration anddried under vacuum to afford pure product,5-amino-4-chloro-6-(4-methoxybenzylamino)pyrimidine. m.p. 187-188° C.TLC R_(F) 0.11 (30:70 ethyl acetate-hexane). ¹H NMR (300 MHz, CDCl₃): Δ8.12 (1H, s), 7.33 (2H! d, J=9.0 Hz), 6.89 (2H, d, J=9.0 Hz), 5. 01 (1H,br), 4. 61 (2H, d, J=5. 1 Hz), 3. 81 (3H, s), 3.35 (2H, br). MS(NH₃-CI): m/e 268 (4), 267 (31), 266 (15), 265 (100).

[0127] Part B. A solution of the diamine from Part A in triethylorthopropionate (5 eq.) was treated with a catalytic quantity ofconcentrated hydrochloric acid and warmed to 60° C. for 10 h. Volatilecomponents of the mixture were removed by distillation, and theresulting residue was taken up in mesitylene (0.5 H) and treated withp-toluenesulfonic acid monohydrate (0.05 eq.). This solution was heatedto reflux under a Dean-Stark trap, and the trap tube (containing solventand ethanol) was periodically drained f or a period of 1 h. The solutionwas cooled and evaporated, and the residual material was separated bycolumn chrmatography (silica gel, 30:70 ethyl acetate-hexane) to affordthe product, 6-chloro-8-ethyl-9-(4-methoxybenzyl)purine, as a solid,m.p. 101-103° C.

[0128] Part C. A solution of 4- bromo-3-chlorophenol (15.81 g, 76.2mmol) in isopropanol (150 mL) was treated with 20% w/w aqueous sodiumhydroxide solution (150 mL), and heated to refluxwhile-chiorodifluoromethane was bubbled in via a needle. After 2 h, thegas flow was shut off, and the solution was cooled and evaporated. Theresulting mixture was extracted twice with ethyl acetate, and theextracts were washed with water and brine, combined, dried overmagnesium sulfate, filtered and evaporated. The resulting liquid waspurified by elution through a short column of silica gel (5:95 ethylacetate-hexane), and evaporation afforded the product,4-bromo-3-chloro-difluoroanisole (14.1 g, 54.8 mmol, 72%). TLC R_(F)0.49 (5:95 ethyl acetate-hexane). ¹H NMR (300 MHz, CDCl₃): Δ 7.60 (1H,d, J=8.8 Hz), 7.27 (1H, d, J=2.6 Hz), 6.93 (1H, dd, J=3.8, 2.6 Hz), 6.49(1H, t, J=72.9 Hz). MS (H₂O-GC/MS): m/e 259 (22), 239 (100).

[0129] Part D. A solution of the bromide from Part C (14.1 g, 54.8 mmol)and truisopropylborate (13.9 mL, 60.2 mmol) in 60 mL THF was cooled to−78° C. under nitrogen, and a hexane solution of n-butyllithium (37.5mL, 1.6 M, 60.0 mmol) was added slowly dropwise. The mixture was allowedto warm to ambient temperature with stirring over 12 h, then wasquenched by the addition of 20 mL 6 N hydrochloric acid and 20 mL water.The resulting mixture was extracted twice with ethyl acetate, and theextracts were washed with brine, combined, dried over magnesium sulfate,filtered and evaporated. The resulting solid was triturated withcyclohexane, filtered and dried under vacuum to afford the product,2-chloro-4-difluoromethoxybenzeneboronic acid (5.61 g, 25.2 mmol, 46%).m.p. 167-169° C. (cyclohexane). ¹H NMR (300 MHz, CDCl₃): Δ 7. 97 (1H, d,J=8. 4 Hz), 7. 15 (1H, d, J=2. 2 Hz), 7.07 (1H, dd, J=8.4, 2.2 Hz), 6.59(1H, t, J=73.0 Hz), 5.29 (2H, s). MS (H₂O-GC/MS): m/e 249 (100).

[0130] Part E. A solution of the purine chloride from Part B (1.24 g,4.50 mmol), the boronic acid from Part D (1.50 g, 6.75 mmol),triphenylphosphine (238 mg, 0.907 mmol) and 2 M aqueous sodium carbonatesolution (7 mL, 14 mmol) in dimethoxyethane (23 mL) was degassed asdescribed above, then treated with palladium (II) acetate (51 mg, 0.227mmol). The solution was degassed a second time, and then heated toreflux for 12 h. After cooling, the solution was poured into water. Thiswas extracted twice with ethyl acetate, and the extracts were washed insequence with 15% w/w aqueous 1,3,5-triazine-2,4,6-trithiol trisodiumsalt solution and saturated aqueous brine. The extracts were combined,dried over sodium sulfate, filtered and evaporated. The residualmaterial was separated by column chromatography (silica gel, 25:75 ethylacetate-hexane) to afford the product,6-(2-chloro-4-difluoromethoxyphenyl) -8-ethyl-9-(4-methoxybenzyl)purine,as an oil (1.44 g, 3.24 mmol, 72%). TLC R_(F) 0.24 (50:50 ethylacetate-hexane). ¹H NMR (300 MHz, CDCl₃): Δ 9.03 (1H, s), 7.76 (1H, d,J=8.8 Hz), 7.35 (1H, d, J=2.2 Hz), 7.20 (1H, dd, J=8.8, 2.2 Hz), 7.19(2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.8 Hz), 6.57 (1H, t, J=73.0 Hz), 5.44(2H, s), 3.79 (3H, s), 2.89 (2H, q, J=7.7 Hz), 1.32 (3H, t, J=7.7 Hz).MS (AP): m/e 445 (100).

[0131] Part F. A solution of the 4-methoxybenzyl compound from Part E(1.33 g, 2.99 mmol) in trifluoroacetic acid (10 mL) was heated to refluxfor 12 h. The solution was cooled and evaporated, and the residue takenup in saturated aqueous sodium bicarbonate. This mixture was extractedtwice with ethyl acetate, and the extracts were washed with brine,combined, dried over sodium sulfate, filtered and evaporated. Theresidue was separated by column chromatography (silica gel, ethylacetate) to afford the product,6-(2-chloro-4-difluoromethoxyphenyl)-8-ethylpurine, as an oil (940 mg,2.89 mmol, 97%). TLC R_(F) 0.06 (50:50 ethyl acetate-hexane). ¹H NMR(300 MHz, CDCl₃): Δ 10.62 (1H, br s), 9.17 (0.2H, s), 9.01 (0.8H, s),7.74 (1H, d, J=8.4 Hz), 7.37 (0.2H, d, J=2.6 Hz), 7.36 (0.8H, d, J=2.6Hz), 7.21 (1H, dd, J=8.4, 2.6 Hz), 6.62 (0.2H, t, J=72.3 Hz), 6.57(0.8H, t, J=72.9 Hz), 3.07 (2H, q, J=7.3 Hz), 1.52 (3H, t, J=7.3 Hz). MS(AP): m/e 325 (100).

[0132] Part G. A solution of triphenylphosphine in THF was cooled to−30° C., and treated with 1 eq. of diethyl azodicarboxylate. Thissolution was stirred for 30 min., and an aliquot containing 0.36 mmol ofthe reagents was extracted by syringe and delivered to a septum vialcontaining the purine from Part F (0.241 mmol) and 2-pentanol (32 mg,0.36 mmol). The vial was shaken for 10 h, then the contents wereevaporated by a stream of nitrogen and the residue applied to a solidphase extraction cartridge containing 2 g of silica gel 60 (Supelco).The cartridge was eluted with 10:90 ethyl acetate-hexane, and thefractions collected which contained the product were combined andevaporated to afford the title product (35 mg, 0.089 mmol, 37%) as anoil. TLC R_(F) 0.14 (20:80 ethyl acetate-hexane). ¹H NMR (300 MHz,CDCl₃): Δ 8.96 (1H, s), 7.73 (1H, d, J=8.5 Hz), 7.34 (1H, d, J=2.5 Hz),7.18 (1H, dd, J=8.5, 2.5 Hz), 6.57 (1H, t, J=73.2 Hz), 4.60-4.50 (1H,m), 2.97 (2H, dq, J=7.5, 1.7 Hz), 2.47-2.35 (1H, m), 2.10-1.98 (1H, m),1.74 (3H, d, J=6.6 Hz), 1.41 (3H, t, J=7.5 Hz), 1.39-1.22 (2H, m), 0.93(3H, t, J=7.2 Hz). MS (AP): m/e calculated for Cl₉H₂₂ClF₂N₄O: 395.1450,found 395.1444; 395 (100).

Part II

[0133] The following Table 2 sets forth exemplary compounds providedherein (wherein A is N, B is CH and ring D is a phenyl ring); R¹substituents are as set forth in Table 1 above. The compounds are setforth sequentially, by example number, along with melting point (“m.p.”) data (degrees C.); or, where the compound is listed as an “oil” inthe column for “m. p.,” spectral data is provided following the table.The compounds were synthesized according to the schemes set forthhereinabove. TABLE 2

Ex. No. R¹ X R² R³ R^(aryl1) R^(aryl2) R^(aryl3) m.p. 33 A CH₂ CH₃ H ClCF₃ H oil 34 E CH₂ CH₃ H Cl CF₃ H 57-58 35 H CH₂ CH₃ H Cl CF₃ H oil 36 JCH₂ CH₃ H Cl CF₃ H oil 37 K CH₂ CH₃ H Cl CF₃ H oil 38 M CH₂ CH₃ H Cl CF₃H oil 39 Q CH₂ CH₃ H Cl CF₃ H oil 40 H O CH₃ H Cl CF₃ H oil 41 J O CH₃ HCl CF₃ H oil 42 K O CH₃ H Cl CF₃ H oil 43 M O CH₃ H Cl CF₃ H oil 44 ACH₂ CH₃ H CH₃ CF₃ H 70-71 45 K CH₂ CH₃ H CH₃ CF₃ H oil 46 M CH₂ CH₃ HCH₃ CF₃ H oil 47 Q CH₂ CH₃ H CH₃ CF₃ H oil 48 A CH₂ CH₃ H Cl CHF₂ H77-78 49 B CH₂ CH₃ H Cl CHF₂ H oil 50 H CH₂ CH₃ H Cl CHF₂ H oil 51 J CH₂CH₃ H Cl CHF₂ H oil 52 K CH₂ CH₃ H Cl CHF₂ H oil 53 N CH₂ CH₃ H Cl CHF₂H oil 54 A CH₂ CH₃ H CH₃ CHF₂ H oil 55 B CH₂ CH₃ H CH₃ CHF₂ H oil

[0134] Spectral Data:

Example 33

[0135]¹H NMR (300 MHz, CDCl₃): Δ 8.33 (1H, d, J=5.1 Hz), 7.68 (1H, d,J=8.4 Hz), 7.42 (1H, d, J=1.5 Hz), 7.25 (1H, dd,=8.4, 1.5 Hz), 7.22 (1H,d, J=5.1 Hz) 4.54-4.42 (1H, m), 2.96 (2H, q, J=7.5 Hz), 2. 55-2.39 (1H,m), 2.16-2.02 (1H, m), 1.76 (3H, d, J=7.0 Hz), 1.39 (3H, t, J=7.5 Hz),0.86 (3H, t, J=7.5 Hz).

Example 34

[0136] see Table 2 for melting point data.

Example 35

[0137]¹H NMR (300 MHz, CDCl₃): Δ 8.30 (1H, d, J=4.8 Hz), 7.73 (1H, d,J=8.8 Hz), 7.44-7.41 (1H, m), 7.26 (1H, br d, J=8 Hz), 7.23 (1H, d,J=4.8 Hz), 4.48 (1H, br), 3.38-3.29 (1H, m), 3.24 (3H, s), 2.97 (2H, q,J=7.7 Hz), 2. 95 (1H, br), 2. 80 (1H, br), 2. 57 (1H, br), 2.30-2.19(1H, m), 2.14-2.00 ((H, m), 1.40 (3H, t, J=7.7 Hz), 0.84 (3H, t, J=7.3Hz). Analysis calculated for C₂₁H₂₃ClF₃N₃O₂: C, 57.08; H, 5.26; N, 9.52;found: C, 57.20; H, 4.93; N, 9.20.

Example 36

[0138]¹H NMR (300 MHz, CDCl₃): Δ 8.34 (1H, d, J=5.1 Hz), 7.69 (1H, d,J=8.4 Hz), 7.44-7.41 (1H, m), 7.29-7.24 (1H, m), 7.23 (1H, d, J=5.1 Hz),3.87-3.77 (1H, m), 2.95 (2H, dq, J=7.5, 3.1 Hz), 2.10-2.00 (1H, m), 1.82(3H, d, J=7.0 Hz), 1.38 (3H, t, J=7.5 Hz), 0.83-0.73 (1H, m), 0.54-0.39(2H, m), 0.29-0.22 (1H, m). Analysis calculated for C₂₀H₁₉ClF₃N₃O: C,58.61; H, 4.67; N, 10.25; found: C, 58.51; H, 4.55; N, 10.08.

Example 37

[0139]¹H NMR (300 MHz, CDCl₃): Δ 8.32 (1H, d, J=5.1 Hz), 7.72 (1H, d,J=8.5 Hz), 7.43-7.41 (1H, m), 7.29-7.22 (2H, m), 3.58 (1H, br), 2.92(2H, q, J=7.5 Hz), 2.51-2.39 (1H, m), 2.31-2.19 (1H, m), 1.98 (1H, br),1.39 (3H, t, J=7.5 Hz), 0.87 (3H, t, J=7.5 Hz), 0.85-0.75 (1H, m),0.50-0.40 (2H, m), 0.26-0.16 (1H, m). ¹³C NMR (300 MHz, CDCl₃): ? 158.0,149.1, 141.8, 135.3, 134.1, 133.9, 133.3, 133.0, 122.7, 122.1, 119.1,118.5, 77.2, 63.9, 27.1, 22.2, 15.0, 12.7, 11.4, 6.0, 3.7. MS (NH3-CI):m/e 427 (8), 426 (35), 425 (26), 424 (100); Analysis calculated forC₂₁H₂₁ClF₃N₃O: C, 59.51; H, 4.99; N, 9.91; found: C, 59.40; H, 4.91; N,9.69.

Example 38

[0140]¹H NMR (300 MHz, CDCl₃): Δ 8.32 (1H, d, J=5.1 Hz), 7.73 (1H, d,J=8.4 Hz), 7.43-7.26 (2H, m), 7.25 (1H, d, J=5.1 Hz), 4.98-4.82 (1H, m),3.47-3.37 (1H, m), 3.23 (3H, s), 3.01-2.75 (3H, m), 2.55-2.40 (1H, m),1.70-1.55 (2H, m), 1.38 (3H, t, J=7.7 Hz), 0.82-0.72 (1H, m), 0.50-0.40(2H, m), 0.30-0.20 (1H, m).

Example 39

[0141]¹H NMR (300 MHz, CDCl₃): ? 8.29 (1H, d, J=5.1 Hz), 7.74 (1H, d,J=8.8 Hz), 7.42 (1H, narrow m), 7.27-7.20 (2H, m), 4.45 (1H, dt, J=11.0,3.6 Hz), 3.73-3.62 (1H, m), 3.36-3.29 (1H, m), 3.24 (3H, s), 3.00 (2H,q, J=7.5 Hz), 2.86 (1H, dt, J=10.1, 3.1 Hz), 2.75-2.65 (1H, m),2.50-1.50 (7H, m), 1.44 (3H, t, J=7.5 Hz).

Example 40

[0142]¹H NMR (300 MHz, CDCl₃): Δ 8.19 (1H, d, J=5.1 Hz), 7.70 (1H, d,J=8.4 Hz), 7.44-7.41 (1H, m), 7.24 (1H, br d, J=8 Hz), 7.17 (1H, d,J=5.1 Hz), 4.71-4.61 (1H, m), 4.16 (3H, s), 3.38-3.28 (1H, m), 3.20 (3H,s), 3.19-3.11 (1H, m), 2.58-2.47 (1H, m), 2.33-2.09 (2H, m), 1.98-1.87(1H, m), 0.82 (3H, t, J=7.3 Hz). Analysis calculated for C₂₀H₂₁ClF₃N₃O₃:C, 54.12; H, 4.78; N, 9.48; found: C, 53.75; H, 4.80; N, 9.34.

Example 41

[0143]¹H NMR (300 MHz, CDCl₃): Δ 8.18 (1H, d, J=5.1 Hz), 7.69 (1H, d,J=8.4 Hz), 7.44-7.41 (1H, m), 7.24 (1H, br d, J=8 Hz), 7.17 (1H, d,J=5.1 Hz), 4.17 (3H, S), 3.89 (1H, dq, J=10.2, 7.0 Hz), 1.80-1.70 (1H,m), 1.70 (3H, d, J=7.0 Hz), 0.73-0.63 (1H, m), 0.47-0.27 (3H, m).Analysis calculated for C₁₉H₁₇ClF₃N₃O₂: C, 55.42; H, 4.16; N, 10.20;found: C, 55.38; H, 4.02; N, 10.05.

Example 42

[0144]¹H NMR (300 MHz, CDCl₃): Δ 8.17 (1H, d, J=5.1 Hz), 7.71 (1H, d,J=8.8 Hz), 7.44-7.41 (1H, m), 7.24 (1H, dm, J=8 Hz), 7.17 (1H, d, J=5.1Hz), 4.16 (3H, s), 3.64 (1H, dt, J=9.9, 5.9 Hz), 2.39-2.25 (1H, m),2.17-2.05 (1H, m), 1.79-1.66 (1H, m), 0.85 (3H, t, J=7.3 Hz), 0.78-0.68(1H, m), 0.49-0.36 (2H, m), 0.29-0.20 (1H, m). Analysis calculated forC₂₀H₁₉ClF₃N₃O₂: C, 56.41; H, 4.51; N, 9.88; found: C, 56.44; H, 4.35; N,10.18.

Example 43

[0145]¹H NMR (300 MHz, CDCl₃): Δ 8.18 (1H, d, J=5.1 Hz), 7.71 (1H, d,J=8.4 Hz), 7.44-7.41 (1H, m), 7.24 (1H, br d, J=8 Hz), 7.17 (1H, d,J=5.1 Hz), 4.16 (3H, s), 3.95-3.85 (1H, m), 3.45-3.35 (1H, m), 3.25-3.15(1H, m), 3.21 (3H, s), 2.63-2.52 (1H, m), 2.44-2.31 (1H, m), 1.81-1.71(1H, m), 0.78-0.68 (1H, m), 0.50-0.38 (2H, m), 0.35-0.25 (1H, m).

Example 44

[0146] see Table 2 for melting point data.

Example 45

[0147]¹H NMR (300 MHz, CDCl₃): Δ 8.31 (1H, d, J=5.1 Hz), 7.45 (1H, d,J=8.4 Hz), 7.21 (1H, br s), 7.17 (1H, br d, J=8 Hz), 7.04 (1H, d, J=5.1Hz), 3.56 (1H, br), 2.92 (2H, q, J=7.5 Hz), 2.46 (1H, br), 2.32 (3H, s),2.31-2.19 (1H, m), 1.96 (1H, br), 1.39 (3H, t, J=7.5 Hz), 0.86 (3H, t,J=7.5 Hz), 0.85-0.76 (1H, m), 0.50-0.40 (2H, m), 0.25-0.15 (1H, m).

Example 46

[0148]¹H NMR (300 MHz, CDCl₃): Δ 8.30 (1H, d, J=5.1 Hz), 7.46 (1H, d,J=8.0 Hz), 7.18 (1H, br s), 7.15 (1H, br d, J=8 Hz), 7.04 (1H, d, J=5.1Hz), 3.75 (1H, br), 3.44-3.34 (1H, m), 3.23 (3H, s), 3.00-2.75 (4H, m),2.52-2.40 (1H, m), 2.33 (3H, s), 2.18 (1H, br), 1.37 (3H, t, J=7.5 Hz),0.81-0.72 (1H, m), 0.51-0.41 (2H, m), 0.30-0.20 (1H, m).

Example 47

[0149]¹H NMR (300 MHz, CDCl₃): Δ 8.27 (1H, d, J=5.1 Hz), 7.45 (1H, d,J=8.0 Hz), 7.17-7.13 (2H, m), 7.02 (1H, d, J=5.1 Hz), 4.44 (1H, dt,J=11.0, 3.3 Hz), 3.78-3.62 (1H, m), 3.36-3.26 (1H, m), 3.23 (3H, s),2.99 (2H, q, J=7.5 Hz), 2.86 (1H, dt, J=10.2, 2.5 Hz), 2.78-2.65 (1H,m), 2.30 (3H, s), 2.29-2.20 (1H, m), 2.18-2.08 (1H, m), 1.92-1.79 (3H,m), 1.77-1.67 (1H, m), 1.66-1.56 (1H, m), 1.44 (3H, t, J=7.5 Hz).

Example 48

[0150] see Table 2 for melting point data.

Example 49

[0151]¹H NMR (300 MHz, CDCl₃): Δ 8.33 (1H, d, J=4.8 Hz), 7.65 (1H, d,J=8.4 Hz), 7.33 (1H, d, J=2.2 Hz), 7.22 (1H, d, J=4.8 Hz), 7.16 (1H, dd,J=8.4, 2.2 Hz), 6.56 (1H, t, J=73.2 Hz), 4.62-4.54 (1H, m), 2.96 (2H,dq, J=7.5, 1.0 Hz), 2.50-2.38 (1H, m), 2.10-1.98 (1H, m), 1.75 (3H, d,J=7.0 Hz), 1.38 (3H, t, J=7.5 Hz), 1.37-1.27 (1H, m), 1.23-1.13 (1H, m),0.92 (3H, t, J=7.3 Hz).

Example 50

[0152]¹H NMR (300 MHz, CDCl₃): Δ 8.29 (1H, d, J=5.1 Hz), 7.69 (1H, d,J=8.8 Hz), 7.34 (1H, d, J=2.5 Hz), 7.23 (1H, d, J=5.1 Hz), 7.17 (1H, dd,J=8.8, 2.5 Hz), 6.56 (1H, t, J=73.4 Hz), 4.49 (1H, br), 3.38-3.31 (1H,m), 3.24 (3H, s), 2.96 (2H, q, J=7.5 Hz), 2.95-2.75 (2H, br), 2.54 (1H,br), 2.29-2.19 (1H, m), 2.16-2.00 (1H, m), 1.40 (3H, t, J=7.5 Hz), 0.84(3H, t, J=7.3 Hz).

Example 51

[0153]¹H NMR (300 MHz, CDCl₃): Δ 8.33 (1H, d, J=5.1 Hz), 7.66 (1H, d,J=8.4 Hz), 7.34 (1H, d, J=2.6 Hz), 7.23 (1H, d, J=5.1 Hz), 7.16 (1H, dd,J=8.4, 2.6 Hz), 6.56 (1H, t, J=73.2 Hz), 3.83-3.77 (1H, m), 2.94 (2H,dq, J=7.5, 3.3 Hz), 2.09-1.99 (1H, m), 1.82 (3H, d, J=7.0 Hz), 1.37 (3H,t, J=7.5 Hz), 0.81-0.71 (1H, m), 0.53-0.39 (2H, m), 0.30-0.20 (1H, m).

Example 52

[0154]¹H NMR (300 MHz, CDCl₃): Δ 8.32 (1H, d, J=5.1 Hz), 7.70 (1H, d,J=8.4 Hz), 7.34 (1H, d, J=2.2 Hz), 7.24 (1H, d, J=5.1 Hz), 7.17 (1H, dd,J=8.4, 2.2 Hz), 6.57 (1H, t, J=73.2 Hz), 3.58 (1H, br), 2.92 (2H, q,J=7.5 Hz), 2.54-2.39 (1H, m), 2.34-2.19 (1H, m), 1.98 (1H, br), 1.39(3H, t, J=7.5 Hz), 0.87 (3H, t, J=7.5 Hz), 0.86-0.76 (1H, m), 0.52-0.41(2H, m), 0.26-0.16 (1H, m).

Example 53

[0155]¹H NMR (300 MHz, CDCl₃): Δ 8.32 (1H, d, J=5.1 Hz), 7.66 (1H, d,J=8.8 Hz), 7.33 (1H, d, J=2.2 Hz), 7.22 (1H, d, J=5.1 Hz), 7.16 (1H, dd,J=8.8, 2.2 Hz), 6.56 (1H, t, J=73.2 Hz), 4.49 (1H, br), 3.59 (1H, br),2.99 (2H, q, J=7.5 Hz), 2.31-2.21 (1H, m), 1.97-1.69 (4H, m), 1.62 (3H,d, J=7.3 Hz), 1.61-1.51 (1H, m), 1.41 (3H, t, J=7.5 Hz).

Example 54

[0156]¹H NMR (300 MHz, CDCl₃): Δ 8.30 (1H, d, J=5 Hz), 7.41 (1H, d, J=8Hz), 7.10-7.00 (3H, m), 6.55 (1H, t, J=73 Hz), 4.54-4.42 (1H, m), 2.96(2H, q, J=7 Hz), 2.53-2.39 (1H, m), 2.16-2.01 (1H, m), 1.78 (3H, d, J=7Hz), 1.39 (3H, t, J=7 Hz), 0.84 (3H, t, J=7 Hz).

Example 55

[0157]¹H NMR (300 MHz, CDCl₃): Δ 8.30 (1H, d, J=4.8 Hz), 7.40 (1H, d,J=8.4 Hz), 7.10-7.00 (1H, m), 7.02 (1H, d, J=4.8 Hz), 6.55 (1H, t,J=74.1 Hz), 4.65-4.52 (1H, m), 2.94 (2H, dq, J=7.5, 1.2 Hz), 2.48-2.34(1H, m), 2.29 (3H, s), 2.09-1.98 (1H, m), 1.75 (3H, d, J=7.0 Hz), 1.37(3H, t, J=7.5 Hz), 1.36-1.26 (1H, m), 1.22-1.09 (1H, m), 0.91 (3H, t,J=7.3 Hz).

[0158] Synthesis:

Part III

[0159] The following Table 3 sets forth exemplary compounds providedherein (wherein A is CH, B is N and ring D is a phenyl ring); R¹substituents are as set forth in Table 1 above. The compounds are setforth sequentially, by example number, along with melting point (“m.p.”) data (degrees C); or, where the compounds is listed as an “oil” inthe column for “m. p.,” spectral data is provided following the table.The compounds were synthesized according to the schemes set forthhereinabove. TABLE 3

Ex. No. R¹ X R² R³ R^(aryl1) R^(aryl2) R^(aryl3) m.p. 56 B CH₂ CH₃ H ClCHF₂ H oil 57 B CH₂ CH₃ H Cl CF₃ H oil

Example 56

[0160]¹H NMR (CDCl₃): δ 8.43 (d, J=5.9 Hz, 1H), 7.66 (d, J=8.7 Hz, 1H),7.43 (d, J=5.5 Hz, 1H), 7.32 (d, J=2.6 Hz, 1H), 7.15 (doublet ofdoublets, J=2.5 Hz, J=2.2 Hz, 1H), 6.55 (t, J=73.6 Hz, 1H), 4.47 (m,1H), 2.95 (m, 2H), 2.1 (m, 1H), 1.9 (m, 1H), 1.66 (d, J=6.9 Hz, 3H),1.37 (t, J=7.7 Hz, 3H), 1.3 (m, 1H), 1.14 (m, 1H), 0.923 (t, J=7.3 Hz,3H).

Example 57

[0161]¹H-NMR (CDCl₃) δ 0.93 (3H, t, J=7.4 Hz), 1.16 (1H, m), 1.35 (1H,m), 1.38 (3H, t, J=7.5 Hz), 1.67 (3H, d, J=7 Hz), 1.95 (1H, m), 2.11(1H, m), 2.95 (2H, m), 4.48 (1H, m), 7.24 (broad), 7.41 (1H, broad s),7.44 (1H, d, J=5.9 Hz), 7.69 (1H, d, J=8.5 Hz), 8.43 (1H, d, J=5.9 Hz).

1. A compound of formula (I)

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:A is N and B is C—R⁸, D is an aryl ring or a heteroaryl ring, wherein:said aryl ring is selected from phenyl, naphthyl, indanyl and indenyl;said heteroaryl ring is selected from pyridyl, pyrimidyl, triazinyl,furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl,indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl,benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl,2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, the S-oxide of2,3-dihydrobenzothienyl, the S,S-dioxide of 2,3-dihydrobenzothienyl,indolinyl, benzoxazolin-2-one-yl, benzodioxolanyl, and benzodioxanyl;said aryl or heteroaryl ring is substituted by 1-2 C₁₋₄ haloalkoxygroups; and, said aryl or heteroaryl ring is optionally substituted by1-2 moieties selected independently from C₁₋₆ alkyl, C₃₋₆ cycloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, halogen, C₁₋₄ haloalkyl, OH, C₁₋₄ alkoxy,(C₁₋₄ alkoxy)-C₁₋₄ alkoxy, CN, SH, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl,C₁₋₄ alkylsulfonyl, COR¹⁷, CO₂R¹⁷ and NR¹⁷R¹⁹; X is CH—R⁹, N—R¹⁰, O,S(O)_(n) or a bond; n is equal to 0, 2 or 3; R¹ is selected from H,C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₈ cycloalkyl, C₄₋₁₂cycloalkylalkyl or (C₁₋₄ alkoxy)-C₁₋₄ alkyl, each optionally substitutedwith 1 to 3 substituents selected independently from C₁₋₆ alkyl, C₃₋₆cycloalkyl, C₄₋₈ cycloalkyl, C₄₋₈ cycloalkyl comprising a ring-memberoxygen, aryl, heteroaryl, heterocyclyl, halogen, C₁₋₄ haloalkyl, cyano,—OR¹³, —S(O)_(m)R¹⁴, —COR¹³, —CO₂R¹³, —NR₁₅COR¹³, —N(COR¹³)₂,NR¹⁵CONR¹³R¹⁶, —NR¹⁵CO₂R¹⁴, —NR¹³R¹⁶, —CONR¹³R¹⁶ and the cyclic groupsmorpholinyl, 1-piperidinyl, 1-piperazinyl and 1-piperazinyl having an N4substituted with methyl, acetyl and methylsulfonyl; m is equal to 0, 1,or 2; R² is C₁₋₄ alkyl or C₃₋₈ cycloalkyl, each optionally substitutedwith 1-3 substituents selected from hydroxy, halo and C₁₋₄ alkoxy, orwhere X is a bond, R² is optionally cyano; R³ and R⁸ are eachindependently selected from H, C₁₋₄ alkyl, C₃₋₈ cycloalkyl, C₁₋₄alkoxy,C₁₋₄alkylthio, C₁₋₄alkylsulfinyl, C₁₋₄ alkylsulfonyl, amino, C₁₋₄alkylamino, C₂₋₈dialkylamino, phenyl and phenyl substituted by 1-3groups selected from C₁₋₇alkyl, C₃₋₈cycloalkyl, halogen, nitro,C₁₋₄alkoxy, C₁₋₄alkylthio and C₂-₈ dialkylamino; R⁹ and R¹⁰ are eachindependently H, C₁₋₄ alkyl or C₃₋₈cycloalkyl; R¹³ and R¹⁶ are selectedindependently at each occurrence thereof from H, C₁₋₄ alkyl,C₁₋₄haloalkyl, C₂₋₈alkoxyalkyl, C₃₋₆cycloalkyl, C₄₋₁₂cycloalkylalkyl,aryl, (aryl)C₁₋₄alkyl, heteroaryl and (heteroaryl)-C₁₋₄alkyl; R¹⁴ isselected from C₁₋₄alkyl, C₁₋₄haloalkyl, C₂₋₈alkoxyalkyl, C₃₋₆cycloalkyl,C₄₋₁₂cycloalkylalkyl, aryl, (aryl)C₁₋₄ alkyl, heteroaryl and(heteroaryl)C₁₋₄alkyl; R¹⁵ is independently at each occurrence thereofselected from H, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₄₋₁₂cycloalkylalkyl, benzyland benzyl substituted with 1-3 groups chosen from C₁₋₄alkyl, halogen,nitro, C₁₋₄alkoxy, and dimethylamino; and, R¹⁷, R¹⁸ and R¹⁹ are selectedindependently at each occurrence thereof H, C₁₋₆ alkyl, C₃₋₁₀cycloalkyland C₄₋₁₆cycloalkylalkyl.
 2. The compound of claim 1, wherein R⁸ is H.3. The compound of claim 2, wherein D is phenyl.
 4. The compound ofclaim 2, wherein D is 3-pyridyl.
 5. The compound of claim 3 or 4,wherein the phenyl ring or 3-pyridyl ring is substituted with ahaloalkoxy group on the carbon atom of the ring which is furthest awayon the ring from the carbon atom of the ring which is the point ofattachment of the ring to the imidazopyridine ring.
 6. The compound ofclaim 5, wherein the haloalkoxy group is —OCHF₂ or —OCF₃.
 7. Thecompound of claim 3 or 4, wherein the phenyl ring or 3-pyridyl ringcomprises an additional substituent on the carbon atom of the ring whichis adjacent on the ring to the carbon atom of the ring which is thepoint of attachment of the ring to the imidazopyridine ring.
 8. Thecompound of claim 7, wherein the substituent is selected from C₁₋₆alkyl, halogen, C₁₋₄ haloalkyl, C₁₋₄alkoxy, (methoxy)-C₁₋₄alkoxy, CN,C₁₋₄alkylthio, C₁₋₄alkylsulfinyl and C₁₋₄ alkylsulfonyl groups.
 9. Thecompound of claim 8, wherein the substituent is Cl or CH₃.
 10. Thecompound of claim 3 or 4, wherein the carbon atom of the phenyl ring or3-pyridyl ring which is adjacent to the atom that is furthest away onthe ring from the carbon atom of the ring that is the point ofattachment of the ring to the imidazopyridine ring and which is locatedon the phenyl ring or 3-pyridyl ring between the furthest away carbonatom and the point of attachment carbon atom is unsubstituted.
 11. Thecompound of claim 3 or 4, wherein the carbon atom of the phenyl ring or3-pyridyl ring which is adjacent to the atom that is furthest away onthe ring from the carbon atom of the ring that is the point ofattachment of the ring to the imidazopyridine ring and which is locatedon the phenyl ring or 3-pyridyl ring between the furthest away carbonatom and the point of attachment carbon atom is substituted.
 12. Thecompound of claim 11, wherein the substituent is selected fromC₁₋₆alkyl, halogen, C₁₋₄haloalkyl and C₁₋₄ alkoxy.
 13. The compound ofclaim 12, wherein the substituent is CH₃.
 14. The compound of claim 3 or4, wherein the phenyl ring or 3-pyridyl ring is substituted with: (i)—OCHF₂ or —OCF₃ on the carbon atom of the ring which is furthest away onthe ring from the carbon atom of the ring which is the point ofattachment of the ring to the imidazopyridine ring; (ii) Cl or CH₃ onthe carbon atom of the ring which is adjacent on the ring to the carbonatom of the ring which is the point of attachment of the ring to theimidazopyridine ring; and, (iii) CH₃ on the carbon atom of the ringwhich is adjacent to the atom that is furthest away on the ring from thecarbon atom of the ring that is the point of attachment of the ring tothe imidazopyridine ring and which is located on the ring between thefurthest away carbon atom and the point of attachment carbon atom. 15.The compound of claim 3 or 4, wherein R¹ is C₁₋₇alkyl, C₅₋₇cycloalkyl,or C₂₋₇alkynyl, each of which is optionally substituted C₃₋₅ cycloalkyl,C₁₋₂alkoxy, phenyl or phenyl substituted with 1-3 CN, C₁₋₃alkoxy, orC₁₋₃alkyl groups.
 16. The compound of claim 15, wherein R¹ is 2-butyl,2-pentyl, 2-hexyl, 2-heptyl, 3-pentyl, 3-hexyl, 3-heptyl,1-methoxy-3-pentyl, 4-heptyl, 1-cyclopropyl-1-ethyl,1-cyclopropyl-1-propyl, 1-cyclopropyl-1-butyl,1-cyclopropyl-3-methoxy-1-propyl, 1-cyclobutyl -1-ethyl,1-cyclobutyl-1-propyl, 1-cyclobutyl- 1-butyl,1-cyclobutyl-3-methoxy-1-propyl, 1-cyclopentyl-1-ethyl,1-cyclopentyl-1-propyl, 1-cyclopentyl-1-butyl,1-cyclopentyl-3-methoxy-1-propyl, alpha-cyclopropylbenzyl,1-phenyl-2-butyn-1-yl, 1-cyclopropyl-2-butyn-1-yl ordicyclopropylmethyl.
 17. The compound of claim 3 or 4, wherein R² is CH₃or C₂H₅.
 18. The compound of claim 3 or 4, wherein R³ is H or C_(H) ₃.19. The compound of claim 3 or 4, wherein X is O or CH—R⁹ and wherein R⁹is H.
 20. The compound of claim 3 or 4, wherein: R¹ is 2-butyl,2-pentyl, 2-hexyl, 2-heptyl, 3-pentyl, 3-hexyl, 3-heptyl, 1-methoxy-3-pentyl, 4-heptyl, 1-cyclopropyl -1-ethyl, 1-cyclopropyl-1-propyl,1-cyclopropyl-1-butyl, 1-cyclopropyl-3-methoxy-1-propyl,1-cyclobutyl-1-ethyl, 1-cyclobutyl-1-propyl, 1-cyclobutyl-1-butyl,1-cyclobutyl-3-methoxy-1-propyl, 1-cyclopentyl-1-ethyl ,1-cyclopentyl-1-propyl, 1-cyclopentyl-1-butyl,1-cyclopentyl-3-methoxy-1-propyl, alpha-cyclopropylbenzyl,1-phenyl-2-butyn-1-yl, 1-cyclopropyl-2-butyn-1-yl ordicyclopropylmethyl; R² is CH₃ or C₂H₅; R³ is H or CH₃; X is CH₂ or O;and, the phenyl ring or 3-pyridyl ring is substituted with: (i) —OCHF₂or —OCF₃ on the carbon atom of the ring which is furthest away on thering from the carbon atom of the ring which is the point of attachmentof the ring to the imidazopyridine ring; (ii) Cl or CH₃ on the carbonatom of the ring which is adjacent on the ring to the carbon atom of thering which is the point of attachment of the ring to the imidazopyridinering; and, (iii) CH₃ on the carbon atom of the ring which is adjacent tothe atom that is furthest away on the ring from the carbon atom of thering that is the point of attachment of the ring to the imidazopyridinering and which is located on the ring between the furthest away carbonatom and the point of attachment carbon atom.
 21. (cancelled)
 22. Apharmaceutical composition comprising a pharmaceutically acceptablecarrier and a therapeutically effective amount of the compound ofclaim
 1. 23. A method of treating a mammal afflicted with depression,said method comprising administering to the mammal a therapeuticallyeffective amount of the pharmaceutical composition of claim 22.